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Abstract 
 
 
Long-term depression is a long-lasting decrease in signalling between neurons in the 
central nervous system. It can be elicited via a number of mechanisms, including NMDA 
receptors and mGLuR receptors. NMDA-dependent LTD is caused by the endocytosis of 
AMPA receptors in response to stimuli, whereas mGLuR-dependent LTD acts via the 
action of kinases.  Recent studies have demonstrated a novel form of LTD, which is 
dependent on serine protease action.  Molecular changes in protein expression also 
accompany the generation of this new type of LTD, although the exact mechanism has not 
been determined.  The aims of this current study are to determine the mechanism by which 
subtilisin could modulate LTD, and whether this effect was solely dependent on proteolytic 
action, or other factors.  Subtilisin-mediated LTD was elicited in hippocampal slices of 
mice as an experimental model, and each slice was retained at the end of every experiment 
to enable protein levels to be analysed via immunoblotting.  
Initial experiments were carried out to evaluate the relationship between subtilisin activity 
and metalloprotease action, based on previous studies that demonstrated subtilisin 
proteolysis of the synaptic protein VAMP-1, a known target of the metalloprotease tetanus 
toxin.  The putative link between these two proteases was tested by addition of zinc to the 
perfusing solution, which promotes the activity of zinc-based metalloproteases.  Subtilisin 
however was completely unaffected by this change to extracellular levels of zinc.  
Experiments were also conducted in the presence of the metal ion chelators EDTA and 
captopril to determine the contribution of metal ions to subtilisin action.  Addition of the 
general metal chelator EDTA failed to decrease subtilisin action, and the zinc-specific 
chelator captopril likewise did not display inhibitory action against subtilisin.  Attempts 
were also made to produce a direct comparison between the action of subtilisin and tetanus 
toxin, however, preliminary experiments were unsuccessful as the tetanus toxin used in the 
experiment was unable to cause VAMP-1 proteolysis.   
The possibility that subtilisin action was solely dependent on their inherent serine protease 
function was also explored using the general serine protease inhibitor 
phenylmethanesulfonylfluoride (PMSF).  The use of PMSF could provide a better 
indication of the link between LTD and subtilisin proteolysis, and also shed light on the 
order of protein degradation. Perfusion of PMSF-inactivated subtilisin prevented the 
proteolysis of proteins, and also prevented the generation of LTD and abolished the 
proteolytic activity of subtilisin.  These results indicate a close link between the LTD-
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inducing and proteolytic effects of subtilisin, and in conjunction with the metalloprotease 
experiments, suggest a serine protease basis for subtilisin-mediated LTD.   
These results suggested that subtilisin action was not based on metalloprotease degradation 
of VAMP-1 alone, but on a more general proteolytic effect involving other protein targets 
such as the netrin receptor Unc5H3 and the cytoskeletal protein actin. The specific role of 
the Unc5H3 and VAMP-1 proteins in the subtilisin process was studied using protein-
specific antibodies to prevent proteolysis.  Preincubation of hippocampal slices with 
VAMP-1 proteins did not prevent the proteolytic effects of subtilisin, nor could it prevent 
the generation of LTD.  Preincubation of hippocampal slices with VAMP-1 antibody in the 
presence of either the cell permeabiliser triton, or the pore-forming chemical streptolysin 
also had no inhibitory effect on subtilisin action.  Hippocampal slices were also 
preincubated with Unc5H3 antibodies to determine the importance of this protein to the 
activity of subtilisin; however, this did not change the proteolytic or electrophysiological 
effects of subtilisin.  Addition of either triton or streptolysin to the preincubation solution 
containing Unc5H3 antibodies failed to prevent the effects of subtilisin on the hippocampal 
slice, a result identical to those obtained with VAMP-1 antibody preincubations. 
The importance of actin proteolysis in mediating subtilisin action was also assessed by 
addition of the actin stabiliser jasplakinolide to the aCSF used in perfusions to prevent 
actin degradation. Jasplakinolide was unable to prevent the onset of subtilisin-mediated 
LTD or its associated degradation of actin.  
In order to verify whether the effects of subtilisin represented a novel form of LTD, the 
LTD elicited by subtilisin was compared to that of more established methods of eliciting 
LTD, such as the mGluR agonist DHPG.  Slices exposed to DHPG failed to elicit LTD, 
however, the GABA mimetic ethylenediamine (EDA) appeared to be a potent inducer of 
LTD.   EDA produced a significantly smaller LTD effect in comparison to subtilisin, 
which was not accompanied by degradation of any proteins associated with subtilisin 
perfusion.  
It would be of interest to know whether other serine proteases could cause this LTD effect, 
and based on previous studies, it is known that members of the S8A subfamily and the S1A 
subfamily of serine proteases are capable of causing the same effects as subtilisin.  To date 
much work has been performed on subtilisin, and other groups S8A serine proteases such 
as Proteinase-K.  In comparison, very little is known about of the mechanism utilised by 
group S1A serine proteases in causing LTD.  In order to gain a greater understanding of  
The possibility that other serine proteases could generate LTD was also investigated as part 
of this study, with particular emphasis on members of the S8A (to which subtilisin 
belongs) and S1A subfamily of serine proteases, which are biochemically similar to 
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members of the S8A subfamily.   Previous studies have shown that proteinase-K and 
cadeprin, both members of the S8A, as well as α-chymotrypsin, a member of the S1A 
subfamily, can replicate this LTD effect.  By studying the impact of α-chymotrypsin on 
fEPSP and protein degradation, it was hoped that this would provide a much more 
balanced view on the mechanisms behind the LTD-inducing effects of serine proteases.  
Previous experiments with subtilisin had ruled out the action of mGluRs or the role of 
electrically-stimulated LTD as the basis for subtilisin-mediated LTD.  For this study these 
two factors were investigated using α-chymotrypsin in order to discover the different 
mechanisms utilised by these two serine proteases.  Electrically-elicited LTD is known to 
be sensitive to the action of protein phosphatases, and in the light of this knowledge, 
experiments were conducted using the phosphatase inhibitors phenylarsine oxide (PAO) 
and sodium orthovanadate.  Sodium orthovanadate did not affect the progression of α-
chymotrypsin LTD; however, PAO did significantly decrease the magnitude of this type of 
LTD. This suggests a possible role for tyrosine kinase in this process, although more 
experiments would be necessary to provide a definite link as sodium orthovanadate had no 
effect on the action of chymotrypsin.  The involvement of mGLuR in α-chymotrypsin LTD 
was tested using the p38 MAPK inhibitor SB203580.  Perfusion of this chemical did not 
result in a noticeable decrease in α-chymotrypsin activities, and taken together with 
previous experiments in subtilisin, suggests that serine protease-mediated LTD is not 
solely dependent on these two pathways for their neuronal depressive actions. 
The results presented here strongly suggest that LTD caused by serine proteases such as 
subtilisin and α-chymotrypsin do not involve metalloprotease functions.  Instead, LTD is 
closely linked with the proteolysis of a select number of proteins that are cleaved by the 
endogenous proteolytic functions of these serine proteases.  Furthermore, serine protease-
mediated LTD is not simply restricted to subtilisin alone, but can involve other members of 
the S8A subfamily of serine proteases such as α-chymotrypsin.  Information gathered over 
these investigations also suggests the involvement of mechanisms utilised by other forms 
of LTD, but their overall action depends on categorically different mechanisms.  
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Cdc42 Cell division control protein 42 homolog 
Cdk5 cyclin-dependent kinase 5 
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CNS Central nervous system 
C-terminal Carboxyl terminal 
DCC Deleted in Colorectal Cancer 
DHPG Dihydroxylphenylglycine 
DNA Deoxyribonucleic acid 
DNAse Deoxyribonuclease 
ECL Enhanced chemiluminescence 
E.Coli Escherichia Coli 
EDTA Ethylenediaminetetraaceticacid 
ENaC Epithelial Na+ channels 
(f)EPSP (field) Excitatory post-synaptic potential 
F-actin Filamentous actin 
G-actin Globular actin 
GABA γ-amino butyric acid 
Glyn Glycine 
Glu Glutamic acid 
GluN2B Glutamate NMDA receptor subunit 2B 
GluR2 Glutamate receptor 2 
GRIP glutamate receptor interacting protein 
GTPase Guanosinetriphosphatase 
His Histidine 
HIV Human Immunodeficiency Virus 
HtrA HtrA serine peptidase  
Hz Hertz 
IGF Insulin growth factor 
IL-B Interleukin-B 
Ile Isoleucine 
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LexA Lambda excision A 
LDL Low-density lipoprotein 
LFS Low frequency stimulation 
LTD Long term depression 
LTP Long term potentiation 
Lys Lysine 
MAP1B Microtubule-associated protein 1B 
MAPK Microtubule-associated protein kinase 
mGLuR Metabotrophic glutamate receptors 
MMP Matrix metalloprotease 
Na+ Sodium 
NCS Neuronal Ca2+sensor 
NMDA N-methyl-d Aspartate 
NMDAR N-methyl-d Aspartate receptor 
NSCL-1 Neuronal stem ell leukemia 
N-terminal Amino terminal 
P75NTR p75 neurotrophin receptor 
PAO Phenylarsine oxide 
PC2/PC3 Proproteinconvertase 2/3 
PCSK proproteinconvertase subtilisin/kexin 
PD Parkinson’s Disease 
PI3K Phosphoinositide 3-kinase 
PICK1 Protein Interacting with PRKCA 1  
PKA Protein kinase A 
PKC Protein kinase C 
PMSF Phenylmethanesulfonylfluoride 
PRK1 Protein regulatory kinase 1 
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PRss8 Protease, serine, 8 
RhoA/RhoB Rho GTPase A/B 
RHOGEF Rho GTPase exchange factor 
RIPA Radioimmuno precipitation assay 
RNA Ribonucleic acid 
RNAi RNA-interference 
ROCK Rho-associated protein kinase 
SDS Sodium dodecyl sulphate 
SEM Standard Error of the mean 
Ser Serine 
SNAP-25 Synaptosomal-associated protein 25 
SNARE SNAP (soluble NSF Attachment Protein) Receptor 
SOS Save Overboard Sailors 
SO Sodium Orthovanadate 
SP Signal Peptide 
SREBP Sterol response element-binding protein 
TAFI Thrombin-activatable fibrinolysis inhibitor 
TBST Tris-buffered saline Tween 
TeTx Tetanus Toxin 
TIMP/TIMPS Tissue inhibitors of metalloproteases 
TrKB Tyrosine kinase B 
UmuD UV mutagenesis D 
VAMP Vesicle-associated membrane protein 
VASP vasodilator-stimulated phosphoprotein 
VNO Vomeronasal organ 
WASP 2 Wiskott-aldrich syndrome protein homology 2 	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Chapter 1 - Introduction 
 
 
1.1 Protease overview 
 
 
1.1.1 Protease families 
 
Proteases are involved in numerous physiological functions, and act by cleaving the 
peptide bonds within proteins. They exist in almost all types of organisms, and in 
mammalian cells, they have roles in angiogenesis, cell differentiation, matrix remodelling 
and regulation of the immune system.  They are separated into six different families based 
on their catalytic mechanism, consisting of the threonine, aspartate, cysteine, asparagine, 
glutamic acid, metalloprotease and serine protease families.  Proteases within each family 
are further divided into clans based on the structure of their cleavage proteolytic and 
inhibitory sites, which form the basis for their substrate specificity (Rawlings et al., 2005). 
For the purposes of this investigation, only proteases in the serine, cysteine and 
metalloprotease are directly relevant. 
 
 
1.1.2 Cysteine proteases 
 
Cysteine proteases are a family of proteases that utilise a nucleophilic cysteine residue as 
part of a catalytic triad at their active site for proteolysis. Their members are divided into 
three clans: calpains, papains (which include cathepsin) and bleomycin hydrolase, and 
grouped based on their structure (Storer & Ménard, 1994).  The catalytic cysteine residue 
is located at position 25 of the active site of the papain subgroup, which includes 
cathepsins.   
 
1.1.2.1 Cathepsins 
 
In humans 11 cathepsins are known to exist in humans, where they are expressed 
ubiquitously in cells due to their role in cell turnover and apoptosis (Berti & Storer, 1995; 
Turk et al., 2012). 
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Cathepsins are active in the nervous system, where they regulate cell survival during both 
development and normal physiological function.  During neuronal development, cathepsins 
B and L work collectively to prevent neuronal apoptosis in the cerebral cortex and 
cerebellum.  In their absence apoptosis occurs, accompanied by an accumulation of 
lysosomal bodies in neurons and enlargement of axonal processes (Felbor et al., 2002). 
These proteases have also been implicated in several neurological disorders including 
schizophrenia, which alters cathepsin K expression levels; and myoclonus epilepsy, which 
is accompanied by mutations in the cysteine inhibitor cystatin B (Pennacchio et al., 1996; 
Ko et al., 2006).  The action of cathepsin B may also be related to serine proteases as it 
cleaves urokinase-type plasminogen activator precursor at the same site as kallikrein and 
plasmin (Kobayashi et al., 1991). 
 
1.1.2.2 Caspases 
 
Another important group of cysteine proteases are the caspases, which regulate the crucial 
caspase apoptotic pathway in both developing and adult cells.  Members of the caspase 
subgroup are involved in immune system function, such as interleukin-1B-converting 
enzyme, which converts the inflammation mediator protein IL-B precursor to their active, 
mature form (Thornberry et al., 1992).  Caspases also act within mitochondria, where 
members such as caspase 8 can trigger apoptosis by cleaving the proapoptotic Bcl2 family 
member BID (Li et al., 1998). 
 
 
1.1.3 Metalloproteases 
 
Metalloproteases are proteases that utilise metal ions as part of its catalytic apparatus, and 
can be separated into groups based on the specific metal ion within the active site.  They 
perform a wide range of physiological roles, and are involved with angiogenesis, the 
progression of cancer and other disorders.  One well-known group of metalloproteases are 
the zinc metalloprotease family, which utilise zinc ions and are further categorised 
depending on whether they incorporate single or double zinc ions at the core of their 
functional site.  Zinc metalloproteases are subsequently divided into clans based on the 
amino acid sequence at their active site, several of which are well known, such as the "a 
disintegrin and metalloprotease" (ADAM), matrix metalloprotease (MMP) and the tetanus 
toxin (TeTx)/botulinum toxin (BTx) families (Hooper, 1994) 
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1.1.3.1 Endogenous metalloproteases 
 
In humans, endogenous metalloproteases include the ADAM family of metalloproteases, 
which consist of 21 members and regulate the activation of growth factors, receptors and 
many other signalling molecules by removing the ectodomain of the precursor protein 
(Edwards et al., 2008).  In comparison, matrix metalloproteases (MMPs) are most well 
known as modulators of long-term synaptic signalling and in particular, the involvement of 
MMP-9 in long-term potentiation (LTP) is well attested in literature.  MMP-9 is intimately 
involved in the induction of late-phase LTP in hippocampus, where it facilitates actin 
polymerisation by inactivating cofilin through β1-integrin signalling.  Enlargement of 
dendritic spines is also dependent on the function of MMP-9, which have profound 
implications for hippocampal-dependent memory due to the dependence of this type of 
memory on dendritic remodelling (Nagy et al., 2005; Wang et al., 2008).  Other MMPs are 
also involved in hippocampal processes, as evidenced by the effect of MMP inhibitors that 
reduce LTP magnitude and decreased LTD stability, whereas specific inhibition of MMP-9 
had no effect on LTD. (Meighan et al., 2007). 
MMPs also expressed outwith the nervous system, where they have roles in processes such 
as ephrin signalling, where MMPs 1,2,9 and 13 facilitate the release of the active EphrinA1 
monomer by cleaving the membrane-attached Ephrin A1 precursor (Beauchamp et al., 
2012).  Members of both the ADAM and MMP metalloprotease families are noted for their 
involvement in the formation of proteolytic machinery underlying the progression of 
Alzheimer’s disease.  They are also known to actively target adhesion molecules such as 
N-cadherin on both pre- and postsynaptic membranes, which cause an attenuation of 
synaptic transmission by reducing the number of synaptic proteins available (Restituito et 
al., 2011). 
 
1.1.3.2 Clostridial metalloproteases 
 
Other metalloproteases, such as the tetanus/botulinum family of metalloproteases, are also 
known to have significant effects on the synapse.  The tetanus and botulinum toxin groups 
encompass a number of neurotoxins with potent inhibitory effects on synaptic signalling.  
This is caused by their selective cleavage of synaptic proteins that prevent the formation of 
the exocytotic machinery essential for vesicle release.  Seven botulinum toxins known to 
exist, and are denoted as types A, B, C, D, E, F and G, which together target a wide range 
of synaptic proteins.  Botulinum toxin types A and E can cause paralysis by cleaving 
SNAP-25, a membrane-bound component of the exocytotic SNARE assembly.  Another 
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membrane-SNARE protein, syntaxin, is the target of botulinum toxin C proteolysis, and is 
triggered in response to stimuli-induced Ca2+ influx (Binz et al., 1994; Binz T. et al., 
1994; Mochida et al., 1995).  In comparison, types B, D, F and G cleave a set of proteins 
on the vesicle membrane known as the vesicle-associated membrane proteins (VAMP) or 
synaptobrevin.  The proteolytic site of each subtype varies however, with type G cleaving 
an ala-ala bond, type F at a Glyn-Lys bond and type D cleaving the following Lys-Ile 
bond.  Botulinum type B has the distinction of sharing the same cleavage site as tetanus 
toxin when targeting the VAMP protein, with both cleaving the sole Gln-Phe bond in this 
protein (Schiavo et al., 1994a; Schiavo et al., 1994b; Yamasaki et al., 1994b). Tetanus 
toxin proteolysis is dependent on the presence of their light chains, as targeted expression 
of this TeTx domain alone is sufficient to cause VAMP-2 cleavage and loss of Ca2+ evoked 
transmitter release (Gaisano et al., 1994). 
 
1.1.3.3 Inhibition of metalloproteases 
 
Metalloproteases can be inhibited by several different mechanisms, which inactivate their 
active site via allosteric changes, or disrupt their metalloprotease mechanism by removing 
the metal ion essential for proteolysis.  Examples of inhibitors include the endogenous 
family of “Tissue inhibitors of metalloproteases” (TIMPs), consisting of four members 
which act against both ADAMs and MMPs.  
TIMPs are involved in the progression of cancer, and the presence of TIMP 1 & 2 in 
hepatocellular cancer cells is associated with poor disease prognosis, whereas TIMP 3 is 
located in the extracellular matrix, where it can determine the spread of cancerous cells by 
acting as a regulator of angiogenesis (Pavloff et al., 1992; Altadilla et al., 2009). TIMPs 
are also involved in the progression of other disorders, such as Sorsby’s fundus dystrophy, 
which is caused by a mutation in TIMP-3 leading to dysfunctional regulation of 
angiogenesis (Anand-Apte et al., 1997). 
Metalloproteases can also be effectively inhibited by metal ion chelators, which remove 
the catalytic metal ion required for proteolysis and causing the active site to become inert.  
One example is captopril, an inhibitor for angiotensin converting enzyme involved in the 
conversion of angiotensin I to angiotensin II.  It inhibits angiogenesis by restricting the 
movement of endothelial cells, and also possesses anti-tumour properties (Volpert et al., 
1996; Smith & Vane, 2003).  Captopril is also a capable inhibitor of gelatinous A/MMP 2 
activity, and can restrict the growth of lung tumours and metastases (Prontera et al., 1999).  
Other metal chelators include EDTA, which has been demonstrated to be a very potent 
inhibitor of zinc proteases such as TeTx and BTx.  At a concentration of 1mM, EDTA was 
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able to inactivate BTx N/D light chain domains responsible for botulinum toxin toxicity 
(Yamasaki et al., 1994a). 
 
 
1.1.4 Serine proteases  
 
Serine proteases constitute the largest protease family in existence, and are involved in 
food processing, cell apoptosis, epidermal homeostasis and neuronal signalling.  They are 
characterised by their use of a serine residue as part of the catalytic mechanism, which is 
usually accompanied by histidine and aspartate residues forming a catalytic triad.  Some 
serine proteases exhibit atypical catalytic triads that utilise residues other than histidine or 
aspartate, but are still considered part of the serine protease family.  One such example is 
aspartyl dipeptidase, in which the aspartate residue is replaced by a glutamate residue and 
is not inhibited by the general serine protease inhibitor PMSF (Conlin et al., 1994).  Other 
examples include the Ser/His/His triad utilised by the cytomegalovirus of the Herpes virus 
and the catalytic mechanism of sedolisin proteases that rely on a Ser/Glu/Asp triad.  In 
addition to these variations of the serine protease triad, some serine proteases utilise a 
serine dyad at their active site, an example of which is one comprised of serine and lysine 
residues.  Examples of serine proteases using this dyad active site can be found in E.Coli 
proteases, such as the Lon protease, type I peptidases and the C-terminal peptidases (Ekici 
et al., 2008). 
 
1.1.4.1 Structure and mechanism 
 
The key catalytic process of a typical serine protease is dependent on a catalytic triad of 
Asp-His-Ser residues, and its efficiency can be modified by both endogenous and 
exogenous factors affecting the active site.  The active site of subtilisin BPN’ is maintained 
partly through the presence a hydrogen bond between the histidine and serine residues of 
the catalytic triad.  A network of hydrogen bonds attached to the catalytic aspartic acid 
residue also contribute to the stability of the active site, with a hydrogen bond establishing 
a connection between the aspartic acid and histidine residues of the triad (Wright et al., 
1969; Kuhn et al., 1998).  Amino acids surround the catalytic triad also determine the rate 
of proteolysis, with the replacement of Ile at position 31 (adjacent to the catalytic Asp 
residue) with leucine resulting in a 2 to 6-fold increase in enzyme efficiency (Takagi et al., 
1988).  Additional regulation in some serine proteases such as subtilisin BPN’ is provided 
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by metal ion binding sites.  In subtilisin BPN’ this consists of 2 cation-binding sites, the 
first being a site specific for calcium, the second site capable of binding both monovalent 
and divalent metals with both sites working in unison to provide greater stability for the 
active site (Alexander et al., 2001).   Other examples of serine proteases requiring divalent 
metal ions include the intracellular subtilisins of gram-positive bacteria, which can be 
inactivated by addition of chelating agents that disrupt both protease structure and lowers 
their catalytic rate (Gamble et al., 2012). 
 
A major step in subtilisin-mediated proteolysis is the formation of a tetrahedral 
intermediate between the protease and the substrate, which facilitates hydrolysis.  The 
structure of this intermediate is established and maintained by an oxyanion hole, which is 
supported by two hydrogen bonds between the active site residues Ser221 and Asn155.  
The oxyanion hole also ensures the release of the carbonyl oxygen during the transition 
from the tetrahedral intermediate into an acyl-enzyme.  An additional stabilizing factor 
during this stage is the presence of a hydrogen bond donated to the target peptide by the 
enzyme residue Asn155.  Replacement of this residue by leucine prevents this bond from 
being formed, and results in a reduction of the catalytic rate of subtilisin (Robertus et al., 
1972; Bryan et al., 1986; Bryan P. et al., 1986).  The catalytic rate is also determined by 
the presence of the serine and histidine residues at the active, as loss or replacement of 
either residue causes a major decrease in the proteolytic rate.  Concurrent loss of both 
residues results in the most significant decrease in catalysis (Perona & Craik, 2008).  
Temperature is also a major determinant of serine protease activity, which acts to decrease 
catalytic activity.  This is evident at higher temperatures, as serine proteases that are active 
at this temperature lack intramolecular interactions, rendering them less stable.  For this 
study subtilisin was chosen, as it is a bacterial protease with optimal function at 
physiological pH and temperatures, and is therefore suitable for use with in-vitro 
preparations (Tiberti & Papaleo, 2011). 
 
1.1.4.2 Regulation of serine proteases 
 
Regulation of serine protease action is crucial to normal biological function due to their 
involvement in many physiological processes. Subtilisin expression is regulated by 
signaling via inhibitory molecules and autoproteolysis, which is dependent on the autolytic 
and conformational stability of the enzyme (Wells & Powers, 1986).  Changes to the 
extracellular environment can also be a factor in the suppression several subtilisin-like 
proteases.  For example, fasting decreases the level of proprotein convertase 
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subtilisin/kexin type 9 (PCSK9) whilst simultaneously increasing cholesterol synthesis, 
with both regulated by the sterol response element-binding protein (SREBP) 2 (Browning 
& Horton, 2010).  A further regulatory mechanism exists in some serine proteases 
involving the formation of a complex between the protease and other proteins in a process 
that increases the removal rate of the serine protease.  An example can be found in the 
removal of subtilisin A from blood, which forms a complex with α-macroglobulin and 
accelerates the process. (Mitsudo et al., 2003). 
 
1.1.4.3 Inhibition of Serine Proteases 
 
Serine proteases are inhibited by a wide range of both synthetic and biological compounds, 
reflecting the large number of proteases present in this family.  Amongst biological 
inhibitors, serpins are distinguished as one of the earliest serine protease inhibitors to be 
discovered, and is also one of the most extensively studied.  Serpins are a superfamily of 
proteins that mainly inhibit serine proteases belonging to the chymotrypsin subfamily, and 
regulate activities such as blood clotting via anti-thrombin, or neurological processes via 
neuroserpin.  Serpins are also found in the immune system, where they inhibit endogenous 
enzymes responsible for apoptosis, as well as bacterial proteases such as subtilisin. In the 
central nervous system, neuroserpin acts as the main regulator for tissue plasminogen, a 
serine protease with a broad specificity of action involving processes such as 
neuritogenesis.  The neuroserpin-plasminogen interaction is also involved in synaptic 
plasticity, and also affect learning and memory processes (Miranda & Lomas, 2006).  
 
Likewise, serine protease inhibitors also affect normal physiological function by directly 
antagonizing the activities of serine proteases and can also determine cell susceptibility to 
disease.  They can prevent cellular damage by endogenous proteases, such as neutrophil-
mediated endothelial cell damage.  The effects of neutrophils are partly mediated through 
the release of elastase and other serine proteases, and are inhibited by urinary trypsin 
inhibitors.  These inhibitors are able to inhibit both the extracellular release of elastase by 
neutrophils as well as decreasing their production and secretion (Nakatani et al., 2001).  
Serine protease inhibitors are also capable of preventing some autoimmune diseases, such 
as Netherton syndrome.  This disease is caused by mutations in the Spink5 gene which 
encodes a serine protease inhibitor effective against a range of serine proteases such as 
subtilisin A and trypsin (Mitsudo et al., 2003).  Removal of this serine protease inhibitor 
also has an adverse impact on the severity of acne rosacea, a disorder caused by an 
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epidermal serine proteases known as the which is caused by stratum corneum tryptic 
enzyme (Yamasaki et al., 2007). 
In addition, invasion of host cells by pathogenic organisms is also severely restricted by 
the presence serine protease inhibitors, due to their reliance on serine proteases to facilitate 
cell penetration.  This is demonstrated by the activity of toxoplasma gondii in the presence 
of two irreversible serine protease inhibitors, which prevents cellular penetration by the 
parasite in a does-dependent manner (Conseil et al., 1999).  
 
1.1.4.4 Regulation of the cytoskeleton by serine proteases  
 
In addition to adhesion molecules, serine proteases are also capable of targeting other 
elements of the cytoskeletal structure.  A serine protease known as alkaline serine protease 
exists in the muscle cells of lobsters, where they degrade troponin-C and myosin and help 
protein turnover within the contractile apparatus (Mykles, 1989).  Similar proteases also 
exist in fish as myofibril-bound serine proteases, although in addition to degrading myosin, 
actin, tropomyosin and α-actinin are also targets for proteolysis (Cao et al., 2000).  
Examples of mammalian serine proteases that target cytoskeletal proteins also exist, such 
as the trypsin-like serine proteases found within intestinal smooth muscle cells of rats.  
These act as regulators of enzyme catabolism and inactivate native enzymes (Beynon & 
Kay, 1978).  The subtilisin-like proprotein convertase PACE4 is also known to be a 
regulator of myosin light chain expression, and is a factor controlling myogenic 
differentiation via the IGF-II pathway (Yuasa et al., 2009).  
 
1.1.4.5 Serine proteases and regulation of Hemostasis  
 
Serine proteases are also intimately involved in haemostasis, with notable roles in platelet 
formation and control of blood pressure.  PCSK-9 is a regulator of epithelial Na+ channels 
(ENaC) and can reduce their surface and total cellular expression.  This protease induces a 
change in intracellular trafficking of ENaC subunits by directing more subunits to the 
proteasomal compartment without impacting on channel endocytosis or cell surface 
degradation (Sharotri et al., 2012).  A serine protease, thrombin, is produced as the final 
protease of the blood coagulation cascade and as such, it has a crucial role in formation of 
blood clots by acting on a number of different targets.  Amongst these targets are the 
metalloprotease TAFI, platelet factor XIII and fibrinogen, which undergoes proteolytic 
activation to produce fibrin.  These three proteins are essential to the formation of a stable 
blood clot.  Thrombin also acts as the ligand for protease-activated receptor 1 and 4, which 
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activate platelets in a process accelerated by the cofactor glycoprotein Ibα (Ramakrishnan 
et al., 2001; Huntington, 2005).   
 
1.1.4.6 Serine Proteases and the Immune System 
 
Serine proteases form a crucial part of the immune response in mammals, where they have 
a role in initiating various immune pathways such as the complement system, mediation of 
the inflammatory response and the elimination of foreign bodies.   
 
1.1.4.6.1 Activators of the Complement Pathway 
 
Members of the serine protease family can be found in the complement system, such as the 
serine protease complement factor D, which unlike most serine proteases does not require 
proteolytic activation in order to function.  Instead, it is activated by the substrate, 
complement factor B, a serine protease which represents an important regulatory step for t 
alternative complement pathway activation (Volanakis & Narayana, 2008).  The 
complement system can also be initiated via the lectin pathway, with activation through 
either lectinsficolin or mannose-binding lectin (MBL).  Both processes involve two MBL-
associated serine proteases that are activated in response to lectin signalling and possess 
proteolytic activity against the complement proteins C2, C3 and C4 (Matsushita et al.) 
 
1.1.4.6.2 Mediators of Innate Immune Response 
 
In addition to their role in initiating immunological pathways, some serine proteases can 
also act directly on invading pathogens, such as neutrophil elastase and granzymes found 
within white blood cells. 
Granzymes are a group of proteases stored within the lytic granules of cytotoxic T cells 
and natural killer cells, and function as initiators of cell death by utilising the pore-forming 
protein perforin to trigger cell apoptosis.  The role of each member of the granzyme family 
varies and in humans 5 members are known to exist, denoted as granzymes A, B, H, K and 
M (Zhang et al., 2001). 
Granzyme A activates a DNAse which cause nicks in single-stranded DNA, a feature that 
characterizes the granzyme A-driven alternative apoptotic pathway (Fan et al., 2003).  In 
addition, granzyme A cleaves laminin proteins A, B and C, which are key elements in 
maintaining the integrity of the nuclear envelope.  Laminin B is also a target for the related 
granzyme B, although this occurs at a much lower rate, and the protease is completely 
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ineffective against laminin A and C (Zhang et al., 2001). Granzyme K, which is located on 
the same chromosome as granzyme A, has similar properties with the latter and act on the 
same SET complex as granzyme A.  However, expression of granzyme K is lower than 
granzyme A in cytotoxic cells, but both share partial functional redundancy (Zhao et al., 
2007).  Granzyme H is known for its antiviral properties, which can be traced to their 
proteolytic action against the adenovirus DNA-binding protein, an essential component 
necessary for viral DNA replication.  This granzyme also has a secondary role as an 
activator of granzyme B by cleaving the inhibitory 100K assembly protein (Andrade et al., 
2007).  In comparison to these, granzyme M is mainly expressed in natural killer cells, but 
is also capable of causing DNA damage in a similar manner to granzyme B by inactivating 
the inhibitor for caspase-activated DNAse.  An additional target of this granzyme is the 
structural protein α-tubulin, which cause a disorganization of the microtubule network and 
thereby increasing the susceptibility of the cell to apoptosis (Lu et al., 2006; Bovenschen et 
al., 2008).  
Neutrophil elastase is found within neutrophils, where they co-localise with proteinase 3 
and cathepsin G.  They belong to the chymotrypsin subfamily of serine proteases, and can 
mediate inflammation by upregulating interleukin-8 through toll-like receptor 4 signalling.  
Neutrophil elastases also possess anti-bacterial properties, and are actively involved in 
processing bacteria for destruction within phagosomes.  They restrict the spread of these 
bacteria by cleaving their virulence factors, lowering both the spread and survival rate of 
the bacteria (Weinrauch et al., 2001; Devaney et al., 2003).  This neutrophil serine 
protease also promotes blood coagulation in conjunction with the endogenous cathepsin G, 
although these effects are not systemic, but localized to the thrombus.  This mechanism is 
utilized by the immune system to control bacterial spread during infection, by restricting 
their presence to a limited number of microvessels (Massberg et al., 2010).  During 
infection serine proteases can also direct the migration of immune cells to the infection site 
by activating the chemoattractant ligand chemerin, which binds to receptors found on the 
surface of dendritic cells and macrophages (Zabel et al., 2005). 
 
1.1.4.7 Serine Proteases and Diseases 
 
Serine proteases are commonly found in disease-causing organisms, where they have roles 
such as assisting cell penetration, facilitating the release infective spores or help regulate 
the pathogenic maturation process.  The activities of viral and bacterial serine proteases are 
clinically important, as they enable the survival of well-known pathogenic organisms such 
as the HIV virus and E.Coli.  In addition, mutations to endogenous serine proteases in the 
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body can also increase susceptibility to pathogenic invasion of the body, and underlie a 
number of neurological disorders. 
 
1.1.4.7.1 Serine Proteases and Pathogenic Disease 
 
Pathogenic organisms such as viruses are highly dependent on serine proteases for multiple 
stages in their life cycle.  The viral serine protease VP4 plays an essential role in 
processing both avian and fish birnavirus through the use of a serine-lysine catalytic dyad 
(Lejal et al., 2000).  Another example is the hepatitis C virus, which undergoes processing 
by the NS3 serine protease prior to activation and release.  This process is dependent on an 
induced-fit stabilisation of the catalytic His-Asp hydrogen bond by the substrate, a 
catalytic step common to many viral proteases (Tomei et al., 1993; Barbato et al., 2000).  
Furthermore, serine proteases are involved in the activation of HIV envelope proteins by 
furin, a protease which works in conjunction with proprotein convertase 7 to cleave HIV 
glycoprotein 160 (Hallenberger et al., 1997).  
Serine proteases are also expressed in E.Coli, where they are perform crucial roles to 
enable the normal function of this bacterium.  These include signal peptidase (SP), which 
removes the N-terminal signal peptide of proteins that have been translocated across the 
membrane; and the UmuD protease, which is involved in the cellular SOS response to 
DNA damage.  Both proteases utilise the same unusual serine-lysine dyad catalytic 
mechanism, and share the same arrangement of residues within their active site.  
Activation of UmuD leads to the inactivation of another serine protease, LexA, which 
allows SOS genes to become activated (Paetzel & Strynadka, 1999; Luo et al., 2001).  
Other notable serine proteases in E.Coli include Lon protease, which shares the same 
catalytic dyad mechanism as SP and UmuD.  It regulates the degradation of short-lived 
regulatory proteins, and also assists in the removal of abnormal or defective proteins 
(Botos et al., 2003).  E.Coli also express the heat shock-inducible protein HtrA, which has 
serine protease activity and is homologous to the mammalian HtrA2 protein.  It promotes 
cell apoptosis by suppressing the activity of inhibitors against apoptotic proteins.  This 
allows the activation of caspase protease family members, in particular the initiator caspase 
3 that triggers the apoptotic pathway (Verhagen et al., 2002). 
 
1.1.4.7.2 Serine Proteases in Neurological Illness 
 
Serine proteases are intimately involved in many physiological processes, and can also be 
found in the nervous system.  Defects in either expression or function of these proteases 
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underlie several neurological diseases, including Alzheimer’s disease (AD), Parkinson’s 
disease (PD) and multiple sclerosis.  As an example, the expression of the apoptotic HtrA2 
protease is related to the onset of both Alzheimer’s and Parkinson’s disease, as a disruption 
to their expression increases susceptibility of striatal neurons to degradation.  This is also 
supported by animal models of the disease, in which mice treated with HtrA2 display 
symptoms characteristic of the onset of Parkinson’s disease.  A mutation within the HtrA2 
gene can also be found in many patient’s suffering from Parkinson’s disease, and this 
compromised mitochondrial function and increased the likelihood of apoptosis (Martins et 
al., 2004; Strauss et al., 2005).  This protease is also linked to amyloid beta activity, a 
protein that constitutes a major component of amyloid plaques found in the neural tissue of 
patients suffering from Alzheimer’s disease.  Intracellular amyloid beta induces neuronal 
apoptosis via an interaction with HtrA2, and has a potential role in modulating the 
expression of amyloid processing protein (Park et al., 2004).  Other serine proteases 
affected by AD and PD includes neurosin, which is localized to senile plaques in 
Alzheimer’s disease and to lewy bodies in Parkinson’s disease.  In both diseases they are 
severely downregulated in the affected brain regions of patients and are expressed at a 
lower concentration in the CSF of patients with AD (Ogawa et al., 2000; Mitsui S et al., 
2006; Mitsui et al., 2006).  Neurosin is also associated with the degradation of myelin 
proteins such as myelin basic protein and myelin-associated protein, and remyelination of 
oligodendrocytes after central nervous system insult.  This is further supported by a 
correlation between neurosin and myelin expression levels in a mouse model of multiple 
sclerosis, with demyelination decreasing and remyelination increasing neurosin expression 
(Terayama et al., 2005; Bando et al., 2006). 
 
1.1.4.8 Serine Proteases and the Nervous System 
 
Serine proteases also perform important physiological functions in the nervous system.  A 
well-known CNS serine protease is neuropsin, which modulates the turnover of adhesion 
molecules.  Through this mechanism, it regulates the synaptic morphology of neurons and 
is involved with both the early stage of LTP generation and LTD.  Both forms of 
neuropsin-mediated synaptic plasticity are present postsynaptically, in a manner similar to 
electrically induced synaptic changes.  The action of this protease at a macromolecular 
level also impacts on physiological function, as inhibition of neuropsin attenuates both the 
generation of LTP and memory formation in mice (Tamura et al., 2005).  Neuropsin is 
highly expressed in the hippocampus, where it acts as a regulator of LTP and is associated 
with increased levels of the LTP indicator protein zif268.  Its expression is elevated in 
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response to stimulation, and is one of contributing factors for hippocampal kindling (Chen 
et al., 1995) The effects of neuropsin are partly mediated through the degradation of 
fibronectin and collagen, which can disrupt the extracellular environment and affect the 
stability of neuronal connections (Rajapakse et al., 2005).  In hippocampal Schaeffer 
collateral axons, neuropsin selectively cleaves the synaptic adhesion molecule L1 
associated with the development of spatial memory.  Neuropsin-dependent LTP relies 
solely on its proteolytic activity proteins of the extracellular matrix and has no direct effect 
on NMDA receptors.  This is significant as all other forms of LTP are characterised by an 
NMDA-dependent increase in calcium levels (Komai S et al., 2000; Komai et al., 2000; 
Matsumoto-Miyai et al., 2003). 
 
1.1.4.9 Subtypes of Serine Proteases 
 
Within each group of serine proteases, members are further classified into distinct clans, 
and several clans have been particularly well characterised and extensively studied.  This 
includes type II transmembrane protease, tissue kallikrein-related proteases, chymotrypsin 
and subtilisin groups.  Trypsin and chymotrypsin members are two of the most intensively 
studied members as these were amongst the first serine proteases to be discovered.  
 
1.1.4.9.1 Chymotrypsin subfamily 
 
The trypsin clan of serine proteases are distinguished by an active site containing a His-
Asp-Ser catalytic triad, and regulate a number of biological functions such as digestion and 
synaptic plasticity.  They are further subdivided into subfamilies, the most prominent of 
which are the type II transmembrane proteases, tissue kallikrein-related peptidases, trypsin 
and chymotrypsin. 
 
1.1.4.9.1.1 Type II Transmembrane Proteases  
 
These membrane-bound serine proteases are found in all vertebrates, where they interact 
directly with extracellular signalling cues and neighbouring cells (Kitamoto et al., 1995; 
Hooper et al., 2001) Their main role is to process other digestive proteases, although they 
also have roles in the regulating cardiac function, auditory function and epithelial 
homeostasis.  An example of an epithelial serine protease is matriptase, which regulates 
prostatin and controls the initiation of a zymogen cascade crucial to epithelial 
differentiation (Westler et al., 2002; Szabo & Bugge, 2008).  Other members of this clan, 
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such as CAP1/PRss8, are responsible for maintaining the integrity of the fully formed 
epithelial barrier.  Mutations of this serine protease can result in a loss of occludin and 
disrupt the function of tight junctions (Leyvraz et al., 2005). 
 
1.1.4.9.1.2 Tissue Kallikreins 
 
These proteases were initially investigated as regulators of blood pressure through 
bradykinin receptors.  Subsequent discovery of kallikrein-related peptidases also 
demonstrated that this group of serine proteases contribute to epidermal cell desquamation 
and may also act as possible tumour cell markers (Leeb-Lundberg et al., 2005; Lundwall & 
Brattsand, 2008).  
Notable members of the kallikrein-related peptidase family include kallikrein related 
protease 8 (neuropsin) which has a major role in regulating brain plasticity, and kallikrein-
like protease 6 (neurosin), which is a risk factor for Alzheimer’s disease (Mitsui et al., 
2006). 
 
1.1.4.9.1.3 Trypsins 
 
Trypsins are well known for their involvement in the digestive process, where they are 
initially synthesised as inactive trypsinogen molecules.  Proteolytic cleavage of this 
precursor activates the protease by changing the position of active site residues to form a 
more ordered arrangement.  Due to this important physiological role of trypsin, aberrant 
expression can cause digestive tract disorders such as hereditary pancreatitis, which occurs 
due to a mutation in trypsinogen.  Trypsin also promotes pathological tumour cell growth 
by activating MMPs, and some members of the trypsin family possess metalloprotease 
elements are sensitive to changes in metal ion concentrations.  One such example is the 
trypsin-like protease NS3 proteinase, which possesses a zinc-binding domain, supporting 
the possibility that other serine proteases may not solely rely on serine protease action, but 
can incorporate mechanisms of other protease families such as metalloproteases (Khosravi-
Far et al., 1995; Love et al., 1996; Kukor et al., 2002). 
 
1.1.4.9.1.4 Chymotrypsins 
 
Chymotrypsins are secreted by pancreatic cells in a manner similar to trypsin, but are 
separated and distinguished as a different clan of serine proteases due to variations in 
peptide specificity.  Both types of serine proteases share a high degree of structural 
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homology, and trypsin can acquire chymotrypsin-like properties by a combination of S1 
site replacement and addition of chymotrypsin surface loops.  Trypsin modified in such a 
manner utilises extended loops in a similar way to chymotrypsin proteolysis, which 
improves substrate binding.  This change converts the normal trypsin specificity for basic 
side-chains to a preference for hydrophobic side-chains characteristic of chymotrypsin 
action (Hedstrom et al., 1992).  The mechanism of catalysis of both chymotrypsin and 
trypsin are typical of the serine protease family, involving the formation of an enzyme-
substrate complex acting as a tetrahedral intermediate during proteolysis (Bender & Kezdy, 
1964). 
 
1.1.4.9.2 Subtilisins 
 
The subtilisin family of serine proteases encompass a number of physiologically important 
members.  Of particular importance are the serine proteases belonging to the proprotein 
convertase subfamily, and the subtilisin/subtilisin-like proteases.   
 
1.1.4.9.2.1 Proprotein convertases 
 
The proprotein convertase family of subtilisin proteases is involved with a wide range of 
cellular activities, including regulation of plasma low-density lipoprotein (LDL) levels.  
This process is regulated by proprotein convertase subtilisin/kexin type 9 (PCSK9), which 
selectively directs the transport of LDL receptors to lysosomes by interacting with amyloid 
precursor proteins.  These associations are mediated through apolipoprotein B, which 
prevent autophagic degradation of LDL and increasing the amount available for the 
vesicular LDL formation (Sun et al., 2012; DeVay et al., 2013; Kosenko et al., 2013).  
Insulin is also an endocrine target of the subtilisin-like proprotein convertases, with 
members furin, PCSK2 and PCSK3 responsible for proteolytic activation of proinsulin in 
islet β cells (Smeekens et al., 1992). 
 
1.1.4.9.2.2 Subtilisin and Subtilisin-like Proteases  
 
The subtilisin subfamily is a group of well-known serine proteases widely used in 
commercial applications and as a research tool for selective studies on protein 
modification.  They were named after the bacteria, bacilis subtilis, from which these serine 
proteases were initially extracted.  Well-known members include subtilisin BPN’ and 
subtilisin Carlsberg (subtilisin A), and there are over 100 subtilisin-like proteases, known 
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as subtilases, which share similar active site sequences with established subtilisins (Siezen 
& Leunissen, 1997).  Subtilisin and subtilisin-like proteases are synthesised as precursor 
proteins consisting of a regulatory signal peptide sequence for secretion connected to the 
active enzyme domain via an amino acid sequence.  This signal peptide directs the initial 
protease localisation to the cell membrane, undergoing subsequent autolytic cleavage to 
release the mature enzyme.  In the absence of autocatalytic proteolysis, the activation 
process can be triggered using other subtilisins (Power et al., 1986; Ikemura et al., 1987).  
Activation of subtilisin BPN’ involves dimerization of two precursor subtilisin molecules, 
which provide mutual assistance to activate each other (Hu et al., 1996).   The structure of 
mature subtilisin enzymes consists of a single polypeptide chain folded into three parts 
linked by hydrogen bonds, with the active site at its core (Wright et al., 1969). 
 
 
1.2 Long-term depression 
 
The heterosynaptic form of long-term depression was first characterised in the 1980s, 
where it was discovered that conjunctive stimulation of climbing fibres could elicit a long-
lasting decrease in synaptic signal at parallel fibre-Purkinje cell synapses (Ito & Kano, 
1982).  This effect had previously been proposed to explain the findings of (Lynch et al., 
1977), which suggested that LTP would be accompanied by a concurrent decrease in 
synaptic signalling in neighbouring cells.  Subsequent experiments also demonstrated the 
existence of homosynaptic LTD, which could be triggered by repetitively stimulating at a 
frequency of 1-3 Hz (Dudek & Bear, 1992).  This represented one of the first experiments 
related to LTD, and subsequent studies have shown the existence of LTD paradigms in 
other regions of the brain, such as the hippocampus.  LTD generated in the hippocampus 
has been extensively studied due to its relation to both the formation and storage of 
memory. 
 
 
1.2.1 LTD and LTP 
 
Long-term depression (LTD) and long-term potentiation (LTP) represent two opposing 
types of long lasting alterations to nervous system signalling.  Long-term depression 
describes a process by which a stimulus elicits a sustained decrease in the size of an 
evoked potential, whereas long-term potentiation has the opposite effect of causing a long-
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lasting increase in potential size.  The relationship between these effects is most notably 
demonstrated during the generation of heterosynaptic LTD, and can be interchangeable 
under certain conditions.  Heterosynaptic LTD can be generated in untetanised 
hippocampal CA1 neurons in response to the expression stimulation-induced LTP in 
neighbouring cells.  This process is dependent on the stimulation-induced release of ATP 
by astrocytes, which spatially sharpens the initial LTP effect (Chen et al., 2013). 
The neuronal expression of either LTD or LTP is regulated by changes to the basal levels 
of intracellular calcium, with raised levels promoting LTD, and lower levels promoting the 
formation of LTP.  Both processes involve AMPA receptors, but their expression levels are 
either increased or decreased reflecting the opposing effects of LTP and LTD (Beattie et 
al., 2000; Xiao et al., 2001). 
These two synaptic processes can be regulated by growth factors, such as brain-derived 
neurotrophic factor (BDNF), which promotes the generation of LTP by activating the 
tyrosine kinase B (TrKB) receptor.  Blockading these receptors using inhibitors prevents 
LTP and instead facilitates a switch from LTP to LTD (Montalbano et al., 2013).  
Curiously, the BDNF precursor pro-BDNF has the opposite effect to active BDNF, and 
promotes the expression of LTD.  This is partly explained by pro-BDNF targeting the p75 
neurotrophin receptors (p75NTR), in comparison to BDNF, which targets TrKB receptors.  
Regulation of these two processes by BDNF and pro-BDNF supports the involvement of 
growth factors in long-term modulation of synaptic signalling (Woo et al., 2005).  Types of 
LTD are categorised based on the mechanism used to elicit these effects, with the most 
well-known being NMDAR or mGluR-mediated LTD. 
 
 
1.2.2 NMDA receptor-dependent LTD 
 
LTD elicited by n-methyl-D-aspartate (NMDA) receptors was first discovered as a 
contributing factor to homosynaptic LTD.  Subsequent studies indicated that this type of 
LTD could also be triggered by low frequency stimulation (LFS).  NMDA-dependent LTD 
involves activation of L-type voltage-gated calcium channels, independent of an increase 
in intracellular calcium levels.  The mechanism by which NMDA receptors trigger LTD is 
however dependent on a clathrin-based endocytosis of AMPA receptors, a process that 
occurs after an influx of calcium.  This is regulated by the calcium sensing protein 
hippocalcin that binds to a subunit of the AP2 adaptor complex, a protein acting as a link 
between clathrin and the proteins to be endocytosed (Palmer et al., 2005).  This type of 
	   37	  
AMPAR-dependent LTD is stabilised by interaction between the AMPAR-binding protein 
(ABP) and glutamate receptor interacting protein (GRIP), which is bound to AMPA 
receptors during LTD.  Failure of this association destabilizes the LTD effect, an event that 
can be mediated through the PICK 1 calcium sensor.  The PICK 1 protein also regulates 
actin turnover at the synaptic site by binding F-actin and promoting the depolymerisation 
of actin fibers, thereby modifying neuronal morphology (Rocca et al., 2008).  The need for 
F-actin turnover in NMDAR-dependent LTD was also demonstrated by studies where the 
addition of either the actin stabilizer phalloidin, or a cofilin inhibitory peptide prevented 
NMDA-mediated LTD.  This study also found that changes to actin were regulated by 
calcium through the calcium-dependent serine-tyrosine phosphatase, calcineurin (Morishita 
et al., 2005).  Additionally, NMDAR-LTD is involved in the lateral transport of these 
receptors, a process regulated by actin and sensitive to the action of actin stabilizers such 
as Jasplakinolide, which prevents actin depolymerisation (Ireland & Abraham, 2008) 
Other cytoskeletal proteins are also associated with LTD, but mostly through indirect 
mechanisms by disrupting the cell structure.  Silencing the microtubule-associated protein 
1B changes synaptic plasticity and impairs LTD generation.  This was partly due to the 
targeting of TIam1, an activator of Rac1 GTPase, which has a downstream effect on actin 
(Rio et al., 2004).  A number of protein kinases, such as Cdk5 (cyclin-dependent kinase 5), 
are also involved in the progression of NMDA-dependent LTD.  Cdk5 activity is linked 
with that of the nuclear activator p35, and decreasing its expression impairs the generation 
of both LTD and LTP.  This in turn can lead to deficiencies in spatial learning and memory 
(Ohshima et al., 2005).  Glycogen synthase kinase 3 is also a contributor to the induction 
of LTD, and its expression is further enhanced by LTD via protein phosphatase 1 upon the 
generation of LTD.  Conversely, inhibition of this kinase is also able to inhibit NMDA-
dependent LTD (Peineau et al., 2007). 
The different subunits of the AMPA receptors are also important to the progression of 
NMDAR-LTD, with the GluR1 subunit being a particularly important component.  This 
AMPA subunit is normally constitutively phosphorylated by protein kinase A under 
physiological conditions, however during LTD it undergoes targeted dephosphorylation 
(Sandkühler J et al., 1997; Lee et al., 1998; Chamberlain et al., 2013). 
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1.2.3 mGluR-dependent LTD 
 
LTD can also be elicited by metabotropic glutamate receptors (mGluRs), and differ from 
NMDAR-dependent LTD in several aspects.  In the hippocampal CA1 region, they can be 
triggered through the action of both mGluR1 and mGluR5.  In the cerebellum and perihinal 
cortex, the mechanism for mGLuR-dependent LTD also involves several kinases.  
Cerebellar mGluR-dependent LTD requires activation of protein kinase C (PKC), as 
demonstrated by a loss of LTD induction in the presence of PKC inhibitors, and the LTD-
mimicking effect of the PKC agonist phorbol-12, 13-diacetate.  In the cortex, induction of 
mGluR-LTD involves a complex formed from the neuronal Ca2+sensor (NCS) protein 
NCS-1 and PICK 1, proteins that detect changes to the intracellular levels of calcium (Jo et 
al., 2008).  Experiments using hippocampal slice preparations have also demonstrated the 
necessity of p38 MAP kinase and protein tyrosine phosphatase activation during the 
induction of synaptically-induced mGluR-LTD (Moult et al., 2008).  In addition to kinase, 
mGLuR-mediated LTD in the mature synapses of the adult brain is accompanied by an 
increase in protein synthesis.  In contrast, mGluR-mediated LTD in the developing nervous 
system is not associated with any form of protein synthesis, but cause a large decrease in 
presynaptic function that is absent from the mature synapses.  This data indicates within 
the same type of LTD, different individual mechanisms may be employed under different 
environmental conditions (Nosyreva & Huber, 2005).  At GABAergic synapses, mGluR-
dependent LTD cause a decrease in GABA, a process regulated via endocannabinoid 
signalling (Chevaleyre & Castillo, 2003). 
 
 
1.2.4 Other forms of LTD 
 
Other forms of LTD are less well-characterised, but several are known to share similarities 
in mechanism with either NMDAR-dependent or mGLuR-dependent LTD. High frequency 
stimulation paradigms, previously associated with the formation of LTP alone, are now 
known to cause of several types of LTD in a number of brain regions.  Patterned high 
frequency stimulation can elicit a type of LTD dependent on AMPA receptor endocytosis, 
whilst being independent of NMDA receptor signalling.  Instead, it requires co-activation 
of both GABAA and muscarinic acetylcholine receptors that help maintain low levels of 
postsynaptic depolarisation, a factor which facilitates LTD induction (Zhua et al., 2013).  
High frequency stimulation is also the basis for long-term depression in kainate receptors, 
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which relieves slow hyperpolarisation in hippocampal mossy fibre synapses.  It is 
dependent on the activation of adenosine A2A receptors, a process also involved in 
NMDA-dependent LTP; however, kainate-dependent LTD do not involve NMDA receptor 
signalling (Chamberlain et al., 2013). 
In addition, the endocrine signalling molecule insulin is also capable of generating LTD.  
This form of LTD is dependent on a concurrent rise in intracellular Ca2+ and the activation 
of protein kinases including phosphate kinase C and phosphatidylinositol 3-kinase (PI3K).  
It is however independent of either NMDA or mGLuR input, as demonstrated through the 
use of kynurenic acid, an NMDA receptor blocker, and MCPG, a broad-spectrum 
metabotropic glutamate receptor antagonist.  Both compounds failed to prevent the 
induction of insulin-LTD, which is mechanistically separate from LTD generated by low 
frequency stimulation.  An interesting feature of this type of LTD is the existence of 
regional differences in the mechanism used to elicit LTD.  In hippocampal neurons, the 
effects of insulin-LTD are mediated through a clathrin-dependent endocytosis of the 
GluR2 AMPA receptor subunit present on the postsynaptic membrane, a process shared 
with LFS-induced LTD.  In the neurons of the ventral tegmental region however, insulin 
induces LTD in excitatory synapses by inhibiting the release of presynaptic glutamate.  
This is regulated through endocannabinoid signaling, requiring the activation of a receptor 
tyrosine kinase (Schnabel et al., 1999; Labouèbe et al., 2013). 
 
 
1.2.5 Serine protease-dependent LTD: A novel form of LTD 
 
A recent study discovered a novel form of LTD, which could be elicited by group S8A 
serine proteases such as subtilisin.  The S8A group of serine proteases encompasses a 
number of proteins, including subtilisin A, proteinase K, cadeprin and α-chymotrypsin, 
which are all capable of eliciting LTD (MacGregor et al., 2007).  Initial studies suggested 
that this type of LTD was dependent on the proteolytic action of the serine protease, as 
LTD induction was sensitive to the action of protease inhibitors.  Subsequent studies 
support the model of a proteolytic basis for subtilisin-mediated LTD, as this long-lasting 
decrease in synaptic signalling was accompanied by a selective degradation of actin, 
VAMP-1 and Unc5H3 proteins.  This type of LTD was not NMDA or mGluR-dependent, 
although it shares some similarities in mechanism with other forms of LTD, such as the 
need for protein synthesis during the establishment of LTD, a process also present in 
electrically-elicited LTD. Subtilisin-mediated LTD is also sensitive to mGluR antagonists, 
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indicating a possible indirect role for mGluRs in this type of LTD.  Studies have also found 
that subtilisin-mediated LTD involves proteasome mechanisms, although activation of 
caspases alone is not the sole cause of LTD (Forrest et al., 2013). 
Further evidence of the role of subtilisin in generating LTD was provided by behavioural 
studies in mice exposed to this protease.  Injection of subtilisin into the dorsal 
hippocampus immediately after an inhibitory avoidance test caused noticeable deficits in 
memory formation in experimental mice.  This impairment was dose-dependent, with 
effects being most prominent at higher levels of subtilisin infusion.  These memory 
impairments reflect the role of other more established forms of LTD, such as NMDA-LTD, 
in the regulation of memory formation (Kornisiuk et al., 2011). 
 
 
1.2.6 Roles of LTD 
 
Physiological roles for LTD have been difficult to ascertain with absolute certainty due to 
inherent difficulties of eliciting this effect in vivo, as well as the lack of LTD-specific 
inhibitors.  However, over the decades mounting evidence has suggested that LTD is 
crucial to a number of neuronal processes, and in particular, the formation of memory in 
several brain regions. 
 
1.2.6.1 Memory and Learning in the Hippocampus 
 
The hippocampal region of the brain has long been thought of as a region heavily involved 
in the formation of new memories, and the existence of within the neurons of the CA1 
neurons have been linked to the memory process.  This is supported by evidence from 
numerous studies in which different aspects of the LTD process were inhibited, leading to 
disruptions in both morphology and functionality of neuronal structures.  An investigation 
involving the inhibition of the serine/threonine protein phosphatase 2A, a protein necessary 
for LTD in the forebrain, demonstrated a decrease in NMDAR-dependent LTD.  This 
decrease reduced the abilities of mice when tested in both water maze tests and T maze 
tests for place recognition (Nicholls et al., 2008). Impairment of dopaminergic 
neurotransmission by inhibiting the dopaminergic transport protein also caused a decrease 
in the size of the hippocampal LTD at CA1-CA3 synaptic junctions.  In addition, 
performance in the Morris water maze test was also reduced by an inhibition of the 
dopamine transporter, which links the effects of LTD to elements of behavioural-related 
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learning and memory (Morice et al., 2007).  Other functions of the hippocampus, such as 
novelty recognition, are also linked to the expression of LTD.  LTD is facilitated by 
exploration of a novel environment containing either familiar or new objects, with both 
stimuli triggering effects via dopamine D1/5 receptors and 5-hydroxytryptamine 4 (5-HT4) 
receptors (Kemp & Manahan-Vaughan, 2004; Lemon & Manahan-Vaughan, 2006).  These 
studies provide evidence of LTD involvement in hippocampal processes and in particular, 
with regards to learning and memory, that can have behavioural implications. 
 
1.2.6.2 Stress-induced LTD and memory processes 
 
Impairments in spatial memory retrieval within the hippocampus can be attributed to the 
induction of LTD.  LFS-LTD is facilitated by the release of corticosterone, which is 
dependent on glucocorticosteroid receptor activation and protein synthesis.  Antagonists of 
these processes are therefore capable of blocking the induction of LFS-LTD (Xu et al., 
1998).  Corticosterone can also elicit mGluR dependent LTD in the hippocampus, as 
demonstrated by the formation of DHPG-dependent LTD in hippocampal slices of rats 
subjected to acute stress that caused an elevation of corticosterone levels.  In contrast, 
hippocampal slices from control rats which were not subject to stress, and the resulting 
spike in corticosterone, did not respond to DHPG (Chaouloff et al., 2007).  NMDA-
dependent LTD is similarly capable of causing memory impairments, and in particular, the 
GluN2B subunit is known to be the basis for NMDAR-LTD modulated disruption of 
memory retrieval.  Addition of a GluN2B-selective antagonist promoted memory 
following acute stress, but produced no effect on controls, highlighting their crucial role in 
stress-induced memory impairment.  General inhibitors of NMDA-dependent LTD is also 
capable of alleviating stress-induced memory impairments, and these investigations 
indicate that hippocampal LTD alone is capable of triggering memory impairments (Wong 
et al., 2007). 
 
 
1.3 Protein markers 
 
 
Over the course of this study, the expression levels of several proteins were measured as 
part of the experiments performed.  These encompass a wide range of proteins which are 
either relevant directly or indirectly to the function of the nervous system. 
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1.3.1 Netrins 
 
Netrins are a group of signalling molecules that are expressed in several regions of the 
central nervous system.  They act as regulatory factors direct the proper migration of 
neuronal cells, and provide either chemoattractive or chemorepulsive cues depending on 
the target receptor. 
The balance between these two opposing netrin effects is crucial to the normal 
development of the nervous system, as demonstrated in animals with disrupted netrin-1 
signalling.  The loss of netrin can lead to abnormal axonal projections and in the 
hippocampus cause the failure of commissural axons to cross the midline.  In turn, this 
causes a disorganisation of the neurons travelling to the ipsilateral septum, and the ectopic 
termination of netrin-1 mutant neurons (Barallobre et al., 2000) 
 
1.3.1.1 Netrins in chemoattraction 
 
In the cerebellum, netrin-1 is released by cells of the lateral ganglionic eminence, acting as 
a chemoattractant signal to guide the migration of corticofugal neurons to the ganglionic 
eminence (Métin et al., 1997).  Netrin also attracts the neurons of the ventral midbrain, 
promoting dopaminergic outgrowth to this region and is one of several factors directing 
thalamorcortical axon projection to the internal capsule.  Loss of these signalling cues 
cause disorganised axon projections through the ventral midbrain and a general 
misguidance of these neurons (Braisted et al., 2000; Lin et al., 2005).  Netrin signalling 
can be transformed from a chemoattractant signal to a chemorepulsive one by external 
factors.  An example can be found in Xenopus neurons, where the response to netrin is 
Ca2+-dependent.  Blockading Ca2+ entry switches cellular response to netrin, from a 
chemoattractive cue to a chemorepulsive signal (Hong et al., 2000). 
 
1.3.1.2 Netrin in chemorepulsion 
 
In the striatal ventricular zone, netrin-1 is expressed as a chemorepulsive signal that drives 
the migration of subventricular neurons into the developing striatum (Hamasaki et al., 
2001).  Netrin-1 is also responsible for directing the termination of dentate gyrus/hilus 
neurons in the CA3 region of the hippocampus, and inhibition of these signals has 
implications for memory processes (Steup et al., 2000).  Axon projections of spinal 
commissural neurons are also guided by chemorepulsive cues from netrin signalling.  In 
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their absence, these neurons are unable to project medially and instead continue ventrally 
where they invade the motor column (Serafini et al., 1996). 
 
1.3.1.3 Mechanism of Action of Netrins 
 
Netrin signalling is regulated by adenosine receptor A2β, and by laminin-1, both of which 
regulate netrin via cAMP-1 expression.  One mechanism of netrin action involves 
regulating elements of the cytoskeleton within neurons.  An example is the 
phosphorylation of the microtubule-associated protein 1B, which is phosphorylated by 
glycogen synthase and cyclin-dependent kinases in response to netrin signalling (Höpker et 
al., 1999; Corset et al., 2000; Rio et al., 2004).  Netrin is also able to regulate actin 
turnover via the Unc5H receptors, which cause an upregulation of actin polymerisation via 
Rho GTPases (Dent et al., 2004). 
 
1.3.1.4 Netrin Receptors 
 
Netrin receptors are separated into two different groups: Deleted in Colorectal Cancer 
(DCC), which mediates chemoattraction in response to netrin; and the Unc5H family of 
receptors, which mediate chemorepulsion in response to netrin.  These are often 
colocalised to the same neuronal pathways, but are generally expressed in different 
regions.  Both types of receptors can be found in Schwann cells after spinal cord injury, 
where DCC is preferentially expressed in the injury site and the surrounding unmyelinated 
region, whilst Unc5H receptors are more abundant in the intact nerves (Webber et al., 
2011).  In some instances both receptors are colocalised together at the same sites, as is the 
case in retinal ganglion cells, where both are downregulated in response to axotomy of 
dopamine-containing neurons (Ellezam et al., 2001; Flores et al., 2009).  Developmentally, 
the expression of these two receptors is also linked in the spinal cord, where both receptors 
are expressed predominantly at different stages of development.  During development, 
DCC receptors constitute the largest portion of netrin receptors being expressed in these 
neurons.  In contrast, Unc5H receptors are the predominant form of netrin receptors in the 
adult, indicating a change in the role of netrin over this time period (Manitt et al., 2004). 
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1.3.1.4.1 Deleted in Colorectal Cancer (DCC) 
 
DCC is responsible for mediating the chemoattractant effects of netrin, and are found 
invarious neuronal processes.  Expression of DCC in the locus coeruleus during 
development is responsible for directing neuronal migration from the dorsal rhombomere 
to the dorsolateral pontine tegmentum.  In the forebrain, DCC guides the migration of 
luteinizing hormone-releasing hormone neurons from the vomeronasal organ (VNO) to the 
forebrain.  Although both DCC and Unc5H3 are expressed in these cells, only DCC 
mutations causes abnormal neuronal migration, indicating a more important role for netrin 
chemoattraction in this process (Schwarting et al., 2001; Schwarting et al., 2004; Shi et al., 
2008).  
DCC-mediated netrin chemoattraction also involves the BHLH transcription factors 
NSCL-1 and NSCL-2 as part of neuronal guidance during the formation of the 
precerebellar nuclei.   Reducing the levels of these transcription factors induces an 
upregulation of Unc5H3 and a subsequent change to netrin chemorepulsion.  Both effects 
act to halt neuronal migration and cause ectopic accumulation of these cells (Schmid et al., 
2007). 
 
1.3.1.4.2 Unc5H Receptors 
 
The Unc5H family of receptors consists of four members: Unc5H1, Unc5H2 Unc5H3 and 
Unc5H4, and are known as dependence receptors due to the presence of death domains 
which can trigger apoptosis.  These apoptotic effects are usually prevented by netrin, 
which cause the multimerization of Unc5H receptors.  The chemorepulsive response 
mediated through Unc5H receptors however requires a dimerization of Unc5H and DCC 
receptor cytoplasmic domains (Hong et al., 1999).   All members of the Unc5H receptor 
family mediate netrin chemorepulsion, although variations between members exist both in 
their expression and their response to netrin binding.   These differences are further 
explored below, with particular emphasis on Unc5H1 and Unc5H3, which are of most 
relevance to this study. 
 
1.3.1.4.2.1 Unc5H1 
 
The Unc5H1 receptor expression can be found in neurons extending both dorsally and 
ventrally in the mouse hindbrain during development.  They also regulate the dorsal 
projection of branchiomotor neurons, and are downregulated during initial acquisition of 
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trace memory in mice, encouraging axonal extension and formation of new nerve terminals 
(Barrett & Guthrie, 2001; Donahue et al., 2002; Murray et al., 2010).  In the spinal cord, 
Unc5H1 has proapoptotic roles unrelated to netrin signalling, and is also the mediator 
through which netrin chemorepulsion is effected (Williams et al., 2006).  Unc5H1 
expression is regulated by the Pax6 transcription factor, c-kinase 1 and protein kinase C, 
which forms a complex with Unc5H1 receptors to promote their endocytosis.  The 
formation of such a complex can prevent growth cone collapse in response to netrin 
signalling, indicating the major role of these proteins in modulating neuronal migration and 
synaptic formation (Williams et al., 2003; Numayama-Tsuruta et al., 2010).  
 
1.3.1.4.2.2 Unc5H3 
 
In contrast to Unc5H1, which has a major role in regulating apoptosis, Unc5H3 is mostly 
utilised as a chemorepulsive receptor for netrin.  Unc5H3 receptor expression is necessary 
for delineating the rostral cerebellar boundary during development.  Mutations of this 
receptor can cause migrating neuroprogenitor cells to ignore chemorepulsive netrin cues, 
resulting in the ectopic expression of granule cells.  As the position of granule cells are 
responsible for directing the subsequent migration of Purkinje cells, this also leads to 
ectopic Purkinje cell expression, leading to an overall reduction in the anatomical size of 
the cerebellum.  These changes also decrease foliation of the cerebellum, producing motor 
function deficits in mice.  Mutations in the gene encoding Unc5H3 receptors also cause 
ataxia and hyperactivity in experimental mice models (Przyborski et al., 1998; Goldowitz 
et al., 2000; Choi et al., 2003).  Migration of cerebellar interneurons in the first few 
postnatal weeks is guided by netrin-1 signalling through Unc5H3 receptors at short 
distances, without the involvement of DCC receptors.  Migration within the corticospinal 
tract is also directed by Unc5H3 receptors.  These neuronal movements can be abolished 
by mutations to the Unc5H3 receptor, causing ectopic migration and reducing the number 
of decussating neurons at the hindbrain-spinal cord junction (Finger et al., 2002; Guijarro 
et al., 2006).  In dorsal root ganglia, neuronal migration is regulated by netrin-1 signalling 
through the Unc5H3 receptors expressed in proprioceptive neurons (Guana & Condic, 
2003; Masuda et al., 2008). 
Both Unc5H3 and Unc5H1 are implicated in the dorsal migration of spinal accessory 
motor neurons away from the ventral midline region.  In this process Unc5H3 signaling 
has a more prominent role as the loss of Unc5H3 alone can prevent cell migration, whereas 
loss of Unc5H1 did not interrupt the migration of these neurons (Dillon et al., 2007).  The 
apoptotic role of Unc5H3 is also highlighted in colorectal cancer cells, which express 
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lowered levels of this receptor.  This corresponds to a decreased level of apoptosis, which 
enhances the spread of these tumour cells (Bernet et al., 2007). 
 
1.3.2 GTPases 
 
Guanine nucleotide binding proteins are a family of enzymes that act by cycling between 
guanosine-diphosphate bound and guanosine-triphosphate bound states, and are commonly 
known as Guanosine triphosphatases (GTPases).  They are involved in cellular activities 
such as intracellular vesicle transport, cytoskeletal organisation, cell morphogenesis and 
protein kinase cascades.  The Ras GTPase superfamily is one of the most well known 
GTPase families, and consists of five groups: Rho/Rac, Ras, ARF, Ran and Rab GTPases.  
Members of the Rho GTPases in particular are of most interest to this current study 
(Wennerberg et al., 2005). 
 
1.3.2.1 Rho GTPases 
Rho GTPases constitute a major element in the regulation of the actin cytoskeleton and 
focal adhesions in cells, and are responsible for the organization of actin filaments, 
specifically the formation of lamellipodia and filopodia (Nobes & Hall, 1999).  They are 
regulated by the guanine nucleotide exchange factors (GEFs), which catalyse the exchange 
of GDP to GTP and thereby activating the GTPase.  Conversely, GTPase activating 
proteins (GAPS) promote their intrinsic GTPase activity, leading to hydrolytic inactivation 
(Moon & Zheng, 2003; Rossman et al., 2005).  Rho GTPases are separated into different 
groups depending on their overall structure, the most well known members being Cdc42, 
RhoA and RhoB.  In the context of the current study, RhoA and RhoB levels were 
measured due to their role as regulators of actin, a protein severely affected by the 
perfusion of subtilisin and other serine proteases used over the course of this study. 
 
1.3.2.1.1 RhoA GTPase 
 
A major role of RhoA is the regulation of the actin cytoskeleton via ROCK kinase, a 
process underlying many activities of RhoA such as the loss of cell adherence in response 
to Ras activation in cell cultures.  This is due to either a disruption of acto-cytoskeletal 
components by RhoA, causing cell integrity to become compromised (Khosravi-Far et al., 
1995).  RhoA downregulates nuclear migration of precerebellar neurons towards cells 
expressing netrin by signalling through ROCK, although high levels of netrin-1 are capable 
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of inhibiting ROCK action an negating the effects of RhoA.  This process is caused by the 
maintenance of cAMP levels via a netrin-dependent mechanism, leading to increased 
intracellular levels of DCC receptors (Causeret et al., 2004; Moore et al., 2008; Li et al., 
2013).  
RhoA is also involved in the reduction of growth cone size in response to Semaphorin3A 
signalling, by decreasing the availability of f-actin patches necessary for growth cone 
elongation.  As a result, actin monomers are formed into intra-axonal F-actin bundles that 
interact with myosin II to cause axonal contraction.  Semaphorin 4D is also capable of 
causing growth cone collapse via RhoA activation and utilises receptor tyrosine kinase 
ErB-2 as an intermediate.  This actin-myosin response to RhoA expression is also utilised 
by BDNF to abolish chemoattractant signalling by Cdc42 (Swiercz et al., 2004; Gallo, 
2006). 
RhoA also assists in axonal guidance by stabilising the region behind the growth cone and 
preventing the formation of lamellipodia in this area.  This restricts growth cone turning by 
suppressing most protrusions, allowing it to migrate towards a chemoattractive signal 
(Loudon et al., 2006). 
 
1.3.2.1.2 RhoB GTPase 
 
The gene encoding RhoB is one of a group of rapidly inducible genes activated in response 
to stimulation or retroviral protein-tyrosine kinases (Jähner & Hunter, 1991).  It is a known 
inducer of cell apoptosis, and has potent inhibitory effects on cell transformation and 
human tumor growth.  RhoB is a target for the tumor suppressing farnesyltranferase 
inhibitors, which act via RhoB to inhibit cell growth (Du et al., 1999).  RhoB itself 
possesses anti-tumour properties as a trigger for apoptosis, and restricting the activation of 
Akt kinases by insulin growth factor 1 (Chen et al., 2000).  Conversely, inhibition of RhoB 
via PI3K and Akt kinases represents a crucial step in Ras-mediated oncogenesis (Jiang et 
al., 2004). 
RhoB is also an important regulator of intracellular transport, and is responsible for 
directing movement of RhoB-containing endosomes to the cell membrane (Sandilands et 
al., 2004).  RhoB also regulates the localization of serine/threonine kinase PRK1 to 
endosomes and the intracellular trafficking of Cdc42 (Mellor et al., 1998).  RhoB also 
regulates the recruitment of Rac GTPase, allowing changes to the actin cytoskeleton at 
both central and peripheral sites in preparation for cell migration (Huang et al., 2011). 
Recently, RhoB was found to mediate long-term synaptic changes.  Its expression is 
associated with the induction of early-LTP, and by acting through cofilin, operates as a 
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modulator of spine and dendritic morphology (McNair et al., 2010). 
 
 
1.3.3 Actin 
 
Actin are cellular proteins that are organised into filaments providing mechanical support 
to cells and form the primary mechanism for cell motility.  They are responsible for 
transport of vesicles within cells, and assist in the formation of cell-cell junctions necessary 
for the integrity of multicellular organisms (Pollard & Cooper, 2009).  Three different 
isoforms of actin exist in vertebrates: α, β and ϒ, which are differentiated by changes to the 
N-terminus.  Actin belongs to superfamily of sugar kinases, and fold into two major A/B 
domains (Bork et al., 1992).  
In cells actin either exist as individual G-actin monomers, or are joined together as F-actin 
filaments.  F-actin formation and extension involve addition of ATP-bound G-actin 
monomers to the positive, or barbed end of the filament.  Conversely, decreases in filament 
length involve the dissociation of ADP-bound G-actin monomers from the negative, or 
pointed end through the inherent catalytic ATPase mechanism of F-actin.  Actin 
dissociation from the filament is also aided by weakening the bonds binding ADP-actin to 
the actin filament at the pointed end.  The relative balance between the rate of these two 
activities regulates the overall filament length (Dominguez & Holmes, 2011).  F-actin is 
essential to the formation and regular function of the cell cytoskeleton, and consists of two 
G-actin actin chains formed into a left-handed helix.  Extension and contraction of actin 
filament length are regulated by the activities of nucleation factors at either end of the 
filament.  Known regulatory factors for actin include cofilin, DNase I, cordon-bleu and 
profilin.  Cofilin and the actin binding protein DNAse I cooperatively bind actin in the 
cytoplasm and are colocalised with actin in vivo.  Cofilin is expressed in both the 
cytoplasm and the periphery, where it promotes actin depolymerisation, cell protrusions 
and drives cell migration.  In contrast, DNase I expression is limited to the cytoplasm 
(Chhabra et al., 2002).  
Polymerisation of actin is promoted by profilin, which has a high affinity for G-actin 
monomers that are bound to its C-terminal via an α-helix.  Profilin forms a complex that 
sequesters actin monomers, and stabilises them via a catalytic exchange of actin-bound 
ADP for ATP in a process that increases the ability of the actin monomer to become 
polymerised.  Profilin activity is more potent at the pointed end of actin filaments and are 
highly expressed in dynamic cells where there is a need for constant actin turnover, and is 
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expressed at lower levels in more mature, stable cells (Schluter et al., 1997).  Cordon-bleu 
is another promoter of actin filament length, and act by increasing the assembly of cross-
linked actin monomers at the barbed end of actin.  It binds actin via three WASP 2 
domains (wiskott-aldrich syndrome protein homology 2) and has a key role in increasing 
neurite outgrowth and branching.  Inhibition or loss of cordon-bleu can result in an 
attenuation of dendritic growth (Ahuja et al., 2007). 
Actin filaments, in conjunction with myosin, form part of the acto-myosin mechanism 
underpinning cell contraction in smooth and striatal muscle cells (Hanson & Lowy, 1963; 
Graceffa & Dominguez, 2003).  Actin-myosin interactions involve a strong association 
between the DNase-binding loop on actin and the head of myosin, which is stabilised by 
loops present in both actin and parts of the myosin head (Lorenz & Holmes, 2010).   
 
1.3.3.1 Actin in cell migration and elongation 
 
Cell migration depends on two processes regulating the actin cytoskeleton at the leading 
edge.  Lamellipodium is transient and is present at the extreme front of the leading edge, 
where it promotes growth cone protrusion and retraction.  Further back towards the cell 
soma, acto-myosin filaments form the lamella that drives the main migratory process 
(Ponti et al., 2004).  Actin involvement in these migratory processes are regulated by 
growth factors such as platelet-derived growth factor (PDGF), which acts via integrin-
linked kinases and P38 MAPK signalling to promote migration.  PDGF activation of Rho 
GTPases represents another form of actin regulation, as Rho GTPase trigger P21-activated 
kinase phosphorylation of LIM-kinase via P21-activated kinase.  This leads to the 
phosphorylation of cofilin, which is subsequently activated (Edwards et al., 1999; 
Esfandiarei et al., 2010).  Lamellipodia in migrating cells also contain nascent adhesions, 
where actin binds to the cytoplasmic domains of the integrin adhesion receptors to 
establish these projections (Choi et al., 2009). 
Lamellipodia activity is concurrent with the action of the finger-like cytoplasmic filopodia 
projections responsible for guiding the growth cone.  Filopodia arise from lamellipodia in a 
process controlled by members of the WASP family of proteins, and the direction of these 
projections take are partly dependent on the action of Src family kinases, which regulate 
filopodial motility (Biyasheva et al., 2003; Robles et al., 2005).  Filopodial extension and 
lateral movement depends on a balance between retrograde flow and polymerisation of 
actin bundles at an angle to the leading edge (Mallavarapu & Mitchison, 1999; Oldenbourg 
et al., 2000).  In the dendritic network, members of the Arp family of proteins regulate 
actin dynamics by controlling lamellipodia reorganistation. VASP (vasodilator-stimulated 
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phosphoprotein) molecules also support these activities by preventing the capping of the 
actin filament at the barbed end and promoting actin filament clustering, which are 
subsequently stabilised by cross-linkage proteins such as fascin.  The importance of these 
cross-linking proteins is underlined by the use of RNA interference on fascin expression, 
which results in a decrease in filopodia density and a disruption of their morphology.  
Conversely, overexpression of fascin promotes extension of existing filopodia and the 
development of new filopodia (Svitkina et al., 2003; Vignjevic et al., 2006; Applewhite et 
al., 2007). 
The extent of lamellipodia and filopodia growth is dependent on the ratio of G-actin to F-
actin within the growth cone, with a higher ratio promoting protrusion (Lee et al., 2013).  
Filopodia are also important clinically as the driving force behind the invasive behaviour 
of cancer cells, which utilise actin bundles in conjunction with trafficking proteins such as 
dynamin to invade and degrade the extracellular matrix (Li et al., 2010). 
 
1.3.3.2 The Actin Cytoskeleton 
 
Another important component of the actin cytoskeleton is the stress fibres, which are found 
as either dorsal or ventral fibres, or as unattached transverse arcs.  Dorsal stress fibers 
connect to a substrate at one end via focal adhesion points and are assembled by formin-
dependent actin polymerisation.  In comparison, transverse arcs are unconnected at either 
end, and are formed by annealing the end of myosin and actin bundles from lamellipodia.  
However, both types of fibres are capable of becoming ventral fibres and binding focal 
adhesion points at either end (Hotulainen & Lappalainen, 2006).  Interactions between 
focal adhesion points, dorsal and ventral stress fibres are regulated by talin, vinulin and 
paxilin, with paxilin expression in particular being elevated prior to actin filament 
assembly at the focal adhesions (Barry & Critchley, 1994).  This dynamic actin assembly is 
assisted by cortactin, which binds actin and the Arp2/3 complex to act as a link between 
cadherin adhesions and the actin cytoskeleton.  Inhibition of cortactin blocks Arp2/3-
dependent actin assembly and the association of actin with cadherin, in addition to 
attenuating cell growth (Weaver et al., 2002; Helwani et al., 2004). 
Actin forms a complex with the cadherin tail and β-catenin in a process requiring the 
presence of both actin cables and myosin II, which is regulated by α-catenin and vinulin.  
As cell elongation proceeds, cadherin adhesions are formed sequentially along actin fibres, 
with fully developed adhesion points found mainly in the lamellipodia.  Actin is necessary 
for the establishment of cadherin adhesions, and as the cell moves cadherin adhesion points 
are degraded, causing actin depolymerisation (Kobielak & Fuchs, 2004; Lambert et al., 
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2007).  Cadherin adhesions are also involved in Ca2+ -driven filopodia penetration of 
neighbouring cells, which is the first stage in the establishment of cell-cell junctions.  
These are established by the binding of cadherin to the cytoplasmic end of filopodia, 
concurrently with the binding of desmosomes to the opposite end in target cells.  The 
process is completed by the reorganisation of actin reorganisation into punctae, a stage 
crucial to ensuring the complete sealing of the intracellular space (Vasioukhin et al., 2000).  
At apical junctions, adhesion proteins such as cadherin associate with both actin and other 
cytoplasmic proteins such as Rac GTPase, which may improve the efficiency of binding.    
The integrity of tight junctions are also susceptible to actin depolymerisation, which causes 
the endocytosis of occludin, a plasma membrane protein integral to the function of tight 
junctions (Shen & Turner, 2005; Miyoshi & Takai, 2008).  
Actin cytoskeletal changes are accompanied by a simultaneous increase in protein 
biosynthesis, driven by transcription factors activated by actin polymerisation.  By acting 
through several signalling cascade this ultimately leads to the activation of nuclear 
transcription factors and an increase in protein expression (Olson & Nordheim, 2010).  
 
1.3.3.3 Actin and the endocytotic pathway 
 
F-actin also takes part in clathrin-mediated endocytosis, where it is involved with multiple 
stages of the clathrin processes, such as their separation and cell surface mobility.  
Inhibition of actin by either latrunculin A or Jasplakinolide, which both stabilise actin, 
almost completely inhibits clathrin-related processes (Yarar et al., 2005). 
Actin filaments also drive the cell membrane invagination preceding the formation of 
clathrin-coated endocytotic vesicles.  A model of this process involves the polymerisation 
of actin filaments around the endocytotic site, pushing the invaginated membrane inwards 
to form a separate vesicle (Galletta et al., 2010). 
 
 
1.3.4 Synaptic proteins 
 
Synaptic transmission in the nervous system is dependent on exocytotic release of 
neurotransmitters in response to stimuli.  The following steps are observed in this process: 
synthesis of the neurotransmitter in the Golgi apparatus, followed by vesicular transport to 
the synaptic site, where they are sequestered by synaptic proteins in preparation for release.  
In response to stimulation, voltage-gated calcium channels open, elevating intracellular 
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Ca2+ levels and triggering the fusion of vesicles with the cell membrane at the synapse and 
release their cargo of neurotransmitters.  The release mechanism involves a number of 
proteins, which are collectively known as SNARES (Soluble NSF Attachment Protein 
receptor).  The main proteins belonging to this complex are the synaptobrevins/vesicle-
associated membrane proteins (VAMPs), synaptotagmin, SNAP-25, synaptophysin and 
syntaxin.  A disruption to the expression of these proteins is the major cause of many 
pathological processes, such as botulism, caused by the cleavage of VAMPs by clostridial 
toxins.  As part of this study, the expression levels of several members of the SNARES 
family were measured.  Synaptobrevin/VAMP-1 is a protein highly susceptible to subtilisin 
cleavage as shown in previous studies, and is therefore a good marker for changes to 
subtilisin action.  Synaptotagmin and synaptophysin both act as synaptic protein controls 
for VAMP, and are known be more resilient in resisting subtilisin proteolysis based on 
previous studies. 
 
1.3.4.1 Synaptotagmin 
 
Within the SNARE complex, synaptotagmin selectively binds calcium under physiological 
conditions, and is responsible for the intracellular response to the calcium influx as a result 
of stimuli.  The essential role of synaptotagmin was demonstrated in a knockout mouse 
model lacking this protein, which displayed severe disruptions to synaptic transmission and 
caused the death of homozygous knockout mice within 48 hours of birth (Geppert et al., 
1994).  In a similar manner, point mutations in synaptotagmin that decrease Ca2+ affinity 
lowers the rate of vesicle release in response to calcium influx (Yoshihara & Littleton, 
2002).  Synaptotagmin promotes vesicle fusion by binding VAMP in a Ca2+-dependent 
manner; however, it is also associated with SNAP-25 and syntaxin in a Ca2+ independent 
manner (Stein et al., 2007). 
In addition to promoting the exocytosis of vesicles, synaptotagmin is also involved with 
the endocytosis of spent vesicles from the membrane after neurotransmitter release. A 
mutation in this protein depleted the amount of synaptic vesicles available for 
neurotransmitter release by reducing vesicle reuptake, but had no impact on the transport 
of newly synthesized vesicles to the synaptic site.  As membrane fusion proteins are 
recycled for reuse after neurotransmitter release, inhibition of the endocytotic process 
decreases the availability of these proteins and prevents the replenishment of synaptic 
vesicles (Deák et al., 2004).  The effectiveness of the synaptotagmin response to Ca2+ is 
also dependent on the composition of the synaptotagmin heterodimers.  Some members of 
the synaptotagmin family such as synaptotagmin IV possess a very low affinity to calcium 
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in comparison to synaptotagmin I, and can therefore reduce the overall rate of calcium 
binding at synapses (Littleton et al., 1999).   In addition to their roles in endocytosis and 
exocytosis, synaptotagmin also assists in the recycling process of internalized receptors.  
Synaptotagmin III is responsible for the formation and delivery of endosomes containing 
internalized receptors to the pericentriolar endocytic recycling compartment.   However, an 
inhibition of this protein results in a peripheral accumulation of these vesicles, in contrast 
to their movement under normal physiological conditions (Grimberg et al., 2003).  
 
1.3.4.2 Syntaxins 
 
Syntaxin links the calcium-sensing function of synaptotagmin to the SNARE vesicle fusion 
apparatus.  Syntaxins, SNAP-25 and synaptobrevin form the complex responsible for 
vesicle docking, determining the state of the vesicle prior to fusion.  This complex is also 
necessary for vesicle fusion to take place, and the loss of syntaxin precludes the formation 
of a stable SNARE complex (O'Connor et al., 1997; Walter et al., 2010). Syntaxin, and the 
associated SNAP-25 protein, are both recycled after vesicle fusion and are expressed 
widely in synaptic vesicles (Walch-Solimena et al., 1995). 
 
1.3.4.3 Synaptosomal-Associated Protein 25 (SNAP-25) 
 
SNAP-25 (Synaptosomal-Associated Protein 25) is a target-membrane SNARE, and is 
essential for evoked release at neuromuscular junctions and nervous system synapses.  
They are expressed in the neurons of the mossy fibre region and the dentate gyrus of the 
hippocampus, and can be found in axonal growth cones during development (Oyler et al., 
1989; Osen-Sand et al., 1993). 
It is also capable of forming complexes with other SNARE proteins such as the 
synaptobrevins/VAMPs and syntaxin.  SNAP-25 acts as a stabilizing factor for a α-SNAP 
sensitive complex between VAMP and syntaxin.  In their absence, SNAP-25 is able to 
interact with synaptotagmin, linking the elements of the SNARE complex with calcium-
sensing proteins (McMahon & Südhof, 1995; Schiavo et al., 1997; Schiavo G. et al., 
1997).  
Loss of SNAP-25 also affects synaptic recycling in a similar manner to synaptotagmin, by 
reducing the readily releasable vesicle pool and abolishing the fast Ca2+-mediated response 
(Zhang et al., 2002). 
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1.3.4.4 Synaptophysin 
 
Synaptophysin is a member of the SNARE protein group often associated with VAMP, and 
consists of two members, synaptophysin and synaptoporin (synaptophysin II).  Both are 
often co-expressed at nerve terminals, and are colocalised within the same vesicles.  
However, synaptoporin expression is largely restricted to a few selective neuronal 
populations, whereas synaptophysin expression can be found in most nerve terminals 
(Fykse et al., 1993). 
The synaptophysin protein spans the cell membrane 4 times, with both the amino and 
carboxyl terminals residing in the cytoplasmic domain.  Differences in the structure of 
synaptophysin between species are due to changes in the intravesicular loops.   The 
cytoplasmic domain however, which contains the Ca2+ binding site, is highly conserved 
between species (Rehm et al., 1986; Johnston et al., 1989).  
During postnatal murine brain development, a 80-fold increase in synaptophysin was 
observed in the cerebellum, correlating with a period of synaptogenesis (Knaus et al., 
1986).  This relationship between synaptophysin and synaptogenesis is clearly visible 
during the development of the rat hippocampal dentate gyrus.  Changes to synaptophysin 
expression corresponded to periods of denervation and renervation in this region, and 
increasing the expression of synaptophysin corresponded to an increase in the size of the 
inner molecular layer.  This suggests that synaptophysin expression can be used as an 
indication of terminal formation or loss within the region (Masliah et al., 1991). 
Synaptophysin expression is also activity-dependent, as cell-cell contact triggers their 
expression in newly formed puncta, whereas in quiescent cells the expression of these 
proteins is more dispersed (Chhabra et al., 2002). 
 
Synaptophysin also interacts with VAMP proteins, a process that only occurs in the adult 
nervous system, as embryonic VAMP is unable to bind the synaptophysin equivalent in the 
embryo (Becher et al., 1999).  Synaptophysin regulates VAMP transport to the synaptic 
vesicles in a dose-dependent manner, specifically the movement of the VAMP-2 isoform, 
as the VAMP-1 isoform is unaffected by changes to synaptophysin expression. This 
targeting mechanism involves the formation of a heterodimer complex between the 
cytoplasmic domains of both synaptophysin and VAMP-2, which can be further promoted 
by inhibiting the formation of the VAMP-syntaxin-SNAP 25 complex (Edelmann et al., 
1995; Washbourne et al., 1995; Pennuto et al., 2003; Bonanomi et al., 2007).  
Synaptophysin is also a regulator of activity-dependent synapse formation, as 
demonstrated by differences in synaptic formation between cells carrying wild-type and 
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mutated forms of synaptophysin (Tarsa & Goda, 2002).  
Expression of synaptophysin is also clinically relevant due to their role in synaptic 
signaling.  Mice possessing mutated synaptophysin show a reduced capability for object 
novelty recognition and have spatial learning deficiencies. Synaptophysin expression is 
also reduced in Alzheimer’s disease, where patients display a 50% reduction in the 
expression of this protein in the parietal, temporal and midfrontal cortex (Masliah et al., 
1989; Schmitt et al., 2009).  
 
1.3.4.5 VAMP 
 
The synaptobrevin/VAMP (vesicle-associated membrane protein) family of proteins 
consist of 10 members in humans, involved in either exocytosis or endocytosis within cells 
of the nervous system and the neuroendocrine system.  
The structure of VAMP-1 consists of three separate domains: a proline-rich domain, an 
internal domain and a hydrophobic carboxyl-terminal that anchors the protein to the 
membrane (Trimble et al., 1988).  In the central nervous system, VAMP proteins are 
associated with both synaptic vesicles and the presynaptic plasma membrane, remaining on 
the membrane of the cytoplasmic domain throughout the vesicle fusion process 
(Taubenblatt et al., 1999).  The most well-known members of the VAMP family, VAMP-1 
and VAMP-2, are expressed in the rat central nervous system, but their distribution varies 
according to location.  VAMP-2 is widely distributed and strongly expressed in many 
major neuronal nuclei and is found in regions including the autonomic motor nuclei, the 
sensory nuclei and the supraoptic nuclei.  In contrast, VAMP-1 expression is present in 
more specialised areas such as the nerve terminals of thalamic neurons or the zona incerta 
of the subthalamic nuclei.  Both members of VAMP are highly expressed in the locus 
coeruleus, where they are colocalised with synaptophysin (Trimble, 1993; Raptis et al., 
2005).  
 
The synaptobrevin/VAMP proteins can also be found in non-neural tissue, such as the 
kidneys, spleen or adrenal glands, although variations exist in the type of VAMP proteins 
expressed by each individual tissue.  VAMP-2 is expressed in rat pancreatic islets, where it 
is involved in the release of secretory granules containing insulin and microvesicles 
containing GABA (Regazzi et al., 1995; Rossetto et al., 1996).  VAMP protein 
homologues are also associated with exocytosis and reuptake of GluT4-containing small 
vesicles in rat adipocyte cells, which are released in response to insulin signalling (Cain et 
al., 1992).  
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Multimerisation of the VAMP protein leads neurotransmitter release, and this process can 
be triggered via several mechanisms.  Multimerisation can be induced by phosphorylation 
of VAMP proteins by endogenous kinases, such as the calmodulin-dependent protein 
kinase II and casein kinase II.  Both phosphorylate residues within the cytoplasmic region 
of VAMP whilst the protein is localised within synaptic vesicles (Nielander et al., 1995).  
Application of stimuli can also promote the multimerisation of VAMP and synaptophysin, 
increasing the proportion of these proteins from 10% to 25% of the total protein expression 
in synaptosomes via a kinase-independent mechanism (Khvotchev & Südhof, 2004).  In 
addition to synaptophysin complexes, VAMP also forms complexes with syntaxin and 
SNAP-25, a process which precedes their anterograde axonal transport to nerve endings.  
These interactions are dependent on the involvement of the VAMP N-terminal, and can be 
blocked by mutations in this region which prevent subsequent vesicle priming (Shiff & 
Morel, 1997; Walter et al., 2010).    
This complex also has an important association with the Ras GTPase Rab3A, which is 
necessary for exocytosis in a variety of tissues.  Genetic knockout models of VAMP also 
demonstrate a delay in fast endocytosis after stimulation, a process used for synaptic 
vesicle recovery.  This demonstrates the role of VAMP in replenishing the rapid-release 
pool of vesicles at the synaptic site (Horikawa et al., 1993; Deák et al., 2004).  VAMP 
action occurs downstream of vesicle docking, as their absence does not prevent vesicle 
targeting and docking in response to stimuli.  Likewise, spontaneous transmitter release is 
unaffected by the loss of VAMP (Broadie et al., 1995). 
 
In the spinal cord, both VAMP-1 and VAMP-2 are widely expressed, VAMP-1 most 
prominently in the nerve terminals of the ventral horn, and VAMP-2 found mainly in the 
dorsal horns.  In general VAMP-1 is localised to motor neurones, whereas VAMP type 2 is 
localised in adrenergic and sensory neurones (Li et al., 1996).  The axonal expression in 
response to nerve damage differs between VAMP-1 and VAMP-2, with VAMP-1 being 
less severely affected and possessing a faster recovery period than VAMP-2.  There were 
however no differences to the expression of VAMP-1 or VAMP-2 within the cell soma 
after injury (Jacobsson et al., 1998). 
 
Synaptic proteins also perform crucial roles in the human immune system by facilitating 
the release of neutrophil granules.  The exocytotic release of these granules is dependent 
on the presence of complexes formed by different VAMP isoforms.  Release of both 
neutrophil-specific and tertiary granules are mediated through complexes containing 
VAMP-1 and VAMP-2 and SNARE proteins, whereas the release of axurophilic granules 
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involves formation of a complex containing VAMP-1 and VAMP-7.  Both sets of VAMP 
complexes interact with the plasma membrane by an association with syntaxin (Mollinedo 
et al., 2006). 
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1.4 Aims of this project 
 
Based on previous studies, it is known that subtilisin-mediated LTD involves the selective 
degradation of proteins, although as a relatively new type of LTD, very little is known of 
its mechanism. The purpose of these investigations was therefore to determine if subtilisin-
mediated LTD was dependent proteolytic action alone, and if mechanisms from other types 
of proteases, such as metalloproteases, were involved.  A secondary aim was to determine 
the relative importance of the proteins most susceptible to subtilisin action to the resultant 
LTD effect.  Finally, the action of subtilisin was compared to those of other types of LTD 
in order to verify that this was a novel type of LTD.  Subtilisin action was also compared 
to those of another serine protease, to determine whether these effects were restricted to 
subtilisin alone, or could be replicated by other members of the serine protease family. 
 
1) Potential metalloprotease mechanisms were investigated by altering extracellular 
conditions to either enhance or inhibit the action of metalloproteases. 
 
2) The importance of proteolytic activity to the generation of LTD by subtilisin was 
investigated by selectively inhibiting serine protease activity. 
 
3) The importance of the proteins most susceptible to subtilisin action was investigated by 
targeted blockade using protein-specific antibodies, and for actin, through the use of a 
polymerising agent. 
 
4) Subtilisin-mediated LTD was also compared to other common types of LTD to establish 
whether this type of LTD was a novel form of LTD.  
 
5) The ability of other serine proteases to generate effects similar to subtilisin was 
evaluated by comparing the action of another serine protease, namely α-chymotrypsin, 
with subtilisin. 
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Chapter 2 - Methods 
 
 
2.1 Hippocampal slice preparation 
 
Hippocampal slices were prepared from young adult male mice (ICR strain), weighing 
between 25-35g.  Mice were anaesthetised using an intraperitoneal injection of 25% 
urethane, at a dosage of 1ml/100g.  After a short period, limb and corneal reflexes were 
checked to determine the effectiveness of anaesthesia.  Upon the cessation of these 
reflexes, the mouse was killed by cervical dislocation.  The brain was rapidly removed and 
placed into ice-cold, oxygenated aCSF containing (mM): KH2PO4 (2.2); KCl (2.0); 
NaHCO3 (25); NaCl (115); CaCl2 (2.5); MgSO4 (1.2); glucose (10); distilled water.  The 
hemispheres were separated, and the hippocampus dissected from each side.  The 
hippocampi were then sliced transversely using a McIlwain tissue chopper to produce 
slices with a thickness of 450µm. Slices were transferred to a petri dish containing cold, 
oxygenated aCSF, for separation into individual slices. The volume of aCSF within the 
dish was then reduced by removal via a syringe to obtain an optimal level that allowed 
oxygen diffusion into the slices whilst ensuring they would be sufficiently immersed. The 
slices were then placed in a closed incubation chamber continuously gassed with 95% 
O2/5% CO2, at room temperature. 
 
 
2.2 In-Vitro Electrophysiological Recordings 
 
Slices were kept in the incubation chamber for at least 1 hour prior to recording to allow 
acclimatization and recovery after dissection. Individual slices were retrieved and placed 
on a wire mesh within a 1ml recording chamber, and held in place using small silver bars 
placed over the top of the slice. Oxygenated (95% O2/5% CO2) aCSF was continuously 
perfused over the slice at a rate of 3-4ml/min. The temperature of the aCSF was maintained 
between 28 and 30°C using a water bath. Stimuli were delivered via a concentric, bipolar 
stimulating electrode, positioned manually using micromanipulators on the stratum 
radiatum in the CA2 region to elicit orthodromic-evoked responses. Stimuli were produced 
using a NeuroLog period generator (NL303) and delay-width (NL403), and delivered using 
a NeuroLog stimulus isolator (NL800) to ensure signal fidelity.  The stimulus was 
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delivered at 330µs square wave pulses at a frequency of 0.1Hz through the bipolar 
electrode.  
 
Recording electrodes were made using borosilicate glass capillaries, pulled to a fine tip of 
1µm using a Kopf vertical pipette puller.  Under a microscope, the tip was then broken to a 
diameter of around 2-8µM to lower the electrical resistance of the electrode, and 
subsequently filled with 4mM NaCl with a fine needle. The micropipette was then attached 
onto micromanipulators, and an Ag/AgCl wire electrode, connected to a headstage, was 
inserted into the top end of the micropipette prior to use.  The other end of this electrode 
was connected to a NeuroLog pre-amplifier (NL104), and the evoked response was filtered 
using Neurolog filters (NL125) as well as a noise canceller (Hum Bug, Quest Scientific).  
This response was visualised using a Gould Oscilloscope 1602, and the signal was 
captured using Cambridge Electronic Design microplus1401 interface onto the computer-
based Signal software. Population spikes were recorded by placing the recording electrode 
on the CA1 pyramidal cell layer; for field excitatory post-synaptic potentials (EPSPs), the 
electrode was place in the stratum radiatum to record at the synapse junction of CA3 and 
CA1 pyramidal neurons. (Figure 1.1)  A sampling frequency of 10000Hz was used to 
capture waveforms over the course of the experiment, with stimuli delivered every second 
during the setup of the experiment, and at 10-second intervals during the course of the 
experiment.  The strength of the stimulus was adjusted using a Neurolog pulse buffer 
(NL510) to produce a maximum response from the slices; the population spike size being 
defined by the difference between the positive and negative peak potentials, and the fEPSP 
size defined as the difference between the negative peak potential and the recovering 
baseline.  For all experiments, after attaining maximal response, the stimuli was reduced to 
a submaximal response of around 70% prior to the start of recordings to allow for changes 
in potential size in response drugs perfused over the course of the experiment.   For each 
experiment, a stable baseline was maintained 10 minutes prior to the start to allow an 
accurate measure of the action of drugs. Percentage values are derived from the average of 
10 points prior to addition of the drug. Data from all experiments were analysed and 
normalised using GraphPad Prism software, with baseline percentage value derived from 
averaging the 10 points prior to addition of the drug. 
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Figure 1.1 Diagram of acute in-vitro mouse hippocampal slice, and locations of 
stimulating/recording electrodes. 
 
General locations for electrode placement are shown above.  Stimulating electrodes were 
placed within the CA2 region of the hippocampal slice, and recording electrodes in the 
pyramidal layer (for population spikes) or the stratum radiatum (for fEPSPs).  Diagram 
locations: comm. = commissural; sc. = Schaeffer collaterals; ent. = Entorhinal cortex; mf. 
= mossy fibres.  
 
 
2.3 Bradford Assay 
After electrophysiology was completed, slices were removed from the recording chamber 
and placed into Eppendorf tubes kept on dry ice, and subsequently stored at -80°C until 
further use. Proteins were subsequently extracted from these hippocampal slices for 
western blotting.  110µl of RIPA buffer (composition: 50mM Tris; 150mM NaCl; 1% 
Igepoal; 0.5% TritonX 100; 0.1% sodium dodecyl sulphate [SDS]; complete Mini EDTA-
free protease inhibitor cocktail tablet {composition: aprotinin; bestatin; calpain inhibitor I; 
calpain inhibitor II; chymostatin; E-64; leupeptin; α2-macroglobulin; petabloc SC; 
pepstatin; PMSF; TLCK-HCL; trypsin inhibitor (chicken, egg white); trypsin inhibitor 
Orthodromic	  Stimulus	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(soybean)}) was added to the Eppendorf tubes and the mixture of solution and slice tissue 
was homogenized with a pestle until no visible debris was left. The tubes were then placed 
in a centrifuge and spun at 13,000 rpm at 4 degrees Celsius for 5 minutes to remove cell 
debris. Eppendorfs were carefully removed from the centrifuge, and the clear supernatant 
carefully pipetted into a new Eppendorf tube, taking care not to disturb the pellet at the 
bottom of the original tube. During this process samples and solutions were kept on ice to 
minimize protein degradation. 
A Bradford Assay was used to measure protein concentration in each sample by comparing 
the samples to a set standard. The standard concentration curve for this assay was prepared 
using 0, 0.25, 0.5, 1.0, 1.5 and 2.0µg/ml Bovine Serum Albumin, using a stock solution of 
2mg/100ml.  Samples for the assay were prepared by adding 4µl sample to 396µl distilled 
water in an Eppendorf tube.  Biorad reagent was mixed with distilled water at a 1:1 
dilution, and 200µl was added to each sample and standard solution and mixed thoroughly 
using a vortex.  200µl from each solution was pipetted into a 96-well plate in duplicates, 
and measured using fluorometry at 595nm on a plate reader, with values analyzed using 
Revelation Link software.  Once the protein concentration in each sample was established, 
proteins were normalized using the lowest protein value, by adding distilled water to reach 
an optimal protein concentration of 12-15µg protein per gel lane. 
 
 
2.4 Western blotting 
 
After normalisation, samples for the western blots were prepared by mixing 65% sample 
(32.5µl), 25% 4x sample buffer (12.5µl) and 5% 10x reducing agent (5µl) in Eppendorf 
tubes.  The solution in the tubes were then mixed thoroughly using a vortex before being 
placed into a water bath and heated to 70°C for 10 minutes, prior to gel loading. A mixture 
of NuPage MOPS running buffer (50ml) and distilled water (950ml) was prepared, 200µl 
of which was set aside in a conical flask and 0.5ml NuPage antioxidant added to this 
solution.  NuPage 4-12% Bis-tris gel cassettes was removed from packaging, and rinsed 
with distilled water. The comb was carefully removed to prevent damage to the loading 
wells, and rinsed three times with NuPage buffer from the conical flask.   After the last 
rinse, the buffer was left in the wells before being placed in a gel tank for electrophoresis, 
with the wells on the inside of the central reservoir. The remaining buffer in the conical 
flask, containing antioxidant, was poured into the central reservoir. The rest of the buffer 
was added to the outside this reservoir to keep the gel cool and prevent it from drying out. 
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Each gel was loaded with10µl Amersham Full-Range Rainbow Molecular Weight Marker 
(RPN800V), and 15µl of prepared samples (for 15-lane gels) or 20µl prepared samples (for 
10 or 12-lane gels) into individual wells. The gels were then run for 1 hour and 20 minutes, 
at 150V, 240 mA. PVDF membranes and transfer buffer were prepared in the interim.  
Transfer buffer with prepared with the following composition: 50ml NuPageTransfer 
buffer, 200ml methanol (100ml for one gel), 750ml distilled water and 1ml antioxidant. 
These were thoroughly mixed before setting aside 200ml of buffer for the central reservoir.  
The remaining solution was used to soak the filter paper, PVDF membrane, transfer case 
and sponges for the transfer process.  Prior to soaking in transfer buffer, PVDF membranes 
were soaked in methanol for one minute to allow the membrane to interact with the 
transfer buffer. Sponges were flattened using a small roller, to ensure they were fully 
saturated in transfer buffer, before 2 were placed into the case.  Once electrophoresis was 
completed, the gel cassettes were removed from the tank, and placed on a flat surface.  The 
gel cassettes were then cracked around the edges, and the top removed carefully to prevent 
damage to the gel.  Pre-soaked filter paper was placed on top of the gel, which was then 
turned over, and the gel carefully separated from the other side of the cassette. The PVDF 
membrane was then placed onto the exposed side with another soaked filter paper on top of 
the membrane.  The filter papers were checked to ensure no bubbles could affect the 
protein transfer, before being placed onto the sponge stack in the case. Another gel was set 
up in the same manner as the first, with 3 sponges separating the two gel sets. A final 2 
sponges were placed on top of the second gel set before the case cover was added, with all 
sponges checked for bubbles prior to placement.  The complete case was then secured in 
the running tank.  Transfer buffer from the flask was poured into the central reservoir in 
the case, up to 1cm from the top of the case, to prevent the membrane from drying out.  
Distilled water was added to the rest of the running tank to keep the case cool during the 
transfer process.  The transfer was run for 1 hour 10 minutes at 30V, 450mA.  After the 
protein transfer was completed, the membrane was separated from the gel, and rinsed 
several times with distilled water. They were then immersed in ponceau solution over 5 
minutes to determine whether the transfer was successful.  The membrane was then rinsed 
with distilled water, before being checked for the presence of protein bands.  The 
membrane was then immersed in 0.1 NaOH for 10-30 seconds to remove the ponceau 
solution from the membrane.  The membranes were again rinsed with distilled water before 
being stored in TBST.  TBST was made by mixing 100ml TBS stock solution (comprising 
48.4g TRIS and 160g NaCl in 2l distilled water, pH adjusted to 7.6 using 50% HCl, before 
addition of 0.5ml Tween), and topped up to 1l with 900ml distilled water. Membranes 
were subsequently blocked by immersion in a milk-TBST solution (5g milk powder in 
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100ml TBST) for one hour on a shaker.  They were then cut to separate protein bands in 
order to allow individual primary antibody incubation. Both primary and secondary 
antibodies were prepared in the milk-TBST solution.  Primary antibodies were left in at 
4°C on a shaker, before being washed in TBST for three 15-minute intervals.  The blots 
were then incubated using the relevant secondary antibody for 1 hour at room temperature, 
on a shaker. 
The following antibodies were used over the course of these experiments.  Unc5H1 (Gt) at 
1:1,000 dilution; Unc5H3 (Gt) at 1:1,000 (for EDTA experiments only) and 1:500 dilution; 
RhoA (Mse) at 1:1,000 dilution; RhoB (Mse) at 1:1,000 dilution; actin (Gt) at 1:10,000 
dilution; Synaptotagmin (Mse) at 1:10,000 dilution; Synaptophysin at 1:10,000 dilution 
and VAMP-1 (Gt) at 1:10,000 dilution.  Secondary antibodies used were Donkey anti-goat 
and Goat anti-mouse, both at a 1:5,000 dilution.  
After the secondary incubation was completed, membranes were again washed in TBST 
for three 15-minute intervals, before being rinsed in water.  They were then placed on a flat 
surface on a plastic folder, and developing ECL solution was added to the membranes.  
The membranes were then covered for 5 minutes to allow the ECL solution to react with 
the secondary antibodies, before being placed into the developing cassette.  Any excess 
ECL was blotted off using tissue, before being placed into the developing cassette. 
The cassette was then taken into a dark room, and a developing film was placed into the 
cassette for an initial exposure period of 1 second.  This film was then developed, and 
based on the intensity of the band signal, other film exposures were taken to provide an 
optimum band for analysis.  These films were then scanned, and analysed using ImageJ 
software developed by National Institutes of Health.  A box encompassing the whole band 
was selected, and three background measurements were made prior to measuring the 
protein bands in order to take into account any background changes in intensity.  
Measurements were taken in triplicate, and the average of the three measurements was 
taken for comparison in each band. These were then analysed by carrying out either t-tests 
or two-way ANOVAs using GraphPad Prism software.  The protein band of each marker 
was determined by comparing their expected location with the protein ladder, as 
demonstrated in Figure 1.2.  
 
Results were graphed using excel and Sigmaplot, with each data point represented as mean 
± SEM. 
 
All chemicals involved in electrophysiological recordings including aCSF chemicals, 
subtilisin and chymotrypsin were sourced from Sigma Aldrich.  For immunblotting, gel 
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Synaptophysin 
packs, running buffers and transfer buffers were obtained from Life Technologies.  
Ponceau solution was obtained from Sigma, ECL solutions from Millipore and Biorad 
solution (for protein assays) from Bio-Rad Laboratories.  Antibodies for immunoblotting 
were obtained from the following companies: Santa Cruz (Actin, Unc5H1, Unc5H3, 
RhoA, RhoB goat-anti-mouse, donkey-anti-goat), Millipore (Synaptophysin), R & D 
Systems (VAMP-1, Synaptotagmin).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Relative size of protein markers 
 
The above diagram indicates the expected size of each protein marker, when compared 
with the protein ladder on the immunoblot. 
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Chapter 3 - Contribution of protease 
mechanisms to subtilisin-mediated LTD  	  
3.1 Metalloprotease mechanisms 
 
3.1.1 Introduction 
 
Based on previous studies, it is known that subtilisin targets a number of proteins, 
including the synaptic protein VAMP-1 (Forrest et al., 2011).  The synaptic proteins 
comprising the SNARE complex, which include the VAMP proteins, are also established 
targets of the clostridial metalloproteases TeTx and BTx.  These neurotoxins are zinc-
dependent metalloproteases, and are therefore susceptible to extracellular changes to metal 
ion concentrations.  This attribute has been demonstrated in multiple studies in which the 
actions of these metalloproteases have either been enhanced by addition of metal ions, or 
attenuated using metal chelators (Yamasaki et al., 1994a).  Since both subtilisin and the 
clostridial metalloproteases target VAMP-1, experiments were conducted to evaluate 
possible contributions of metalloprotease mechanisms to the activities of subtilisin.  
 
 
3.1.2 Results 
 
3.1.2.1 Extracellular zinc ions do not potentiate subtilisin action 
 
In order to examine whether subtilisin was dependent on metalloprotease action, an 
experimental protocol was developed in which subtilisin was exposed to exogenously 
applied zinc ions. Addition of zinc to the perfusate is known to cause a significant increase 
in TeTx activity, and a similar response with subtilisin would suggest that subtilisin acts 
via a similar mechanism.  To test this hypothesis, the following protocol was used: a 
fEPSP with amplitude of 0.5-1mV was established for 10 minutes to allow a stable 
baseline to be measured.  An aCSF solution supplemented with 50µM zinc was then 
perfused over the slice in the recording chamber for 10 minutes, to establish if the addition 
of zinc alone had any impact on the fEPSP size.  If no change to potential size was 
observed after this period, aCSF containing 4µM subtilisin was perfused onto the slice over 
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a period of 10 minutes, followed by a 40-minute recovery period in aCSF supplemented 
with zinc. Control experiments involved perfusion of normal aCSF throughout this period, 
with the exception of the 10 minutes in which subtilisin was applied to the slice.  Addition 
of zinc did not significantly change the decrease in fEPSP subsequent to subtilisin 
perfusion (P = 0.7767, Figure 3.1a).  No significant changes were observed in protein 
expression as measured by immunoblotting between slices exposed to subtilisin in aCSF, 
or in aCSF supplemented with zinc (P > 0.05, Figure 3.1b) for all proteins.  	  
3.1.2.2 The metal ion chelator EDTA does not inhibit subtilisin activity 	  
The action of metalloproteases can also be attenuated through the use of chelators that 
remove the catalytic metal ion at the active site.  One chelator commonly used to inhibit 
metalloproteases is ethylenediaminetetraacetic acid, or EDTA.  Previous studies have 
suggested that this chelator can act as an effective inhibitor against the metalloprotease 
action of both BTx and TeTx (Tetx and BTx B).  If EDTA had a similar inhibitory effect 
on subtilisin, this could indicate a role for metal ions in the action subtilisin. To test this 
hypothesis, a protocol similar to previous experiments with zinc was adopted.  After the 
formation of a stable fEPSP baseline of 0.5-1.0 mV was obtained over 10 minutes, aCSF 
supplemented with 20µM EDTA was applied to the slice over a period of 10 minutes, 
again to check for any differences in fEPSP size.  Following this period the slice was 
perfused with 4µM subtilisin dissolved in aCSF, before a 40-minute recovery period was 
observed.  In control experiments normal aCSF was perfused throughout, with the 
exception of 10 minutes during which subtilisin was applied to the slice.  Addition of 
EDTA did not significantly change the decrease in fEPSP subsequent to subtilisin 
perfusion (Figure 3.2a).  No significant changes were observed in the expression of most 
proteins measured via immunoblotting (Figure 3.2b).  Expression of VAMP-1 however did 
differ significantly between slices perfused with EDTA + aCSF and slices perfused with 
aCSF alone.   N = 4 for both treatment groups.  
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Figure 3.1a Effect of aCSF supplemented with zinc on hippocampal fEPSP size after 
subtilisin perfusion. 
The subtilisin-mediated decrease in fEPSP size was not affected by addition of aCSF 
supplemented with 50µM zinc to aCSF (27.07 ± 2.22%, N=4) when compared to controls 
(31.92 ± 7.03%, N=4) (Students t-test, P = 0.6585).  Arrows a, b and c indicate time points 
at which traces were taken. 	  	  	  	  	  
Subtilisin 
 
 
 
 
 
Zinc-aCSF 
+ subtilisin 
 
 
 
aCSF 
prior to  
addition 
of zinc	  
a b c 
a b c 
Subtilisin	  
	   69	  
Effect of zinc perfusion of subtilisin-related protein degradation
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Figure 3.1b Effect of 50µM zinc on protein degradation in response to subtilisin. 
 
No significant changes in protein expression were observed across all markers between 
slices treated with zinc and with aCSF alone. (P > 0.05, N =4) 
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Figure 3.2a Effect of aCSF supplemented with EDTA on hippocampal fEPSP size 
after subtilisin perfusion. 
The subtilisin-mediated decrease in fEPSP size was not affected by addition of aCSF 
supplemented with 20µM EDTA to aCSF (34.96 ± 11.85, N=4) when compared to controls 
(31.06 ± 3.823, N=4) (Students t-test, P = 0.3132).  Arrows a, b and c indicate time points 
at which traces were taken. 	  	  	  Subtilisin	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Figure 3.2b Effect of 20µM EDTA on protein degradation in response to subtilisin. 
No significant changes in protein expression were observed across all markers between 
slices treated with EDTA and with aCSF alone. (P > 0.05, N =4), with the exception of 
VAMP-1, which was extremely significant (P < 0.0001). 
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3.1.2.3 Captopril is ineffective as an inhibitor of subtilisin 	  
Captopril is an ACE inhibitor that can be used as an effective chelator of zinc 
metalloproteases.  Unlike EDTA however, it is specific for zinc endopeptidases such as the 
clostridial toxins (Schiavo et al., 1993).  The protocol used during this experiment was 
identical to the one used for both EDTA and zinc, however, in this experiment aCSF was 
supplemented with 100µM captopril.  Baseline levels in normal aCSF were established 
over a 10-minute period, followed by another 10-minute slice exposure to aCSF containing 
captopril. This was followed by 10 minutes of subtilisin perfusion, before a 40-minute 
washout/recovery period in aCSF containing captopril.  
No significant changes (Figure 3.3a, P = 0.515) were observed in the progression of 
subtilisin-mediated LTD between hippocampal slice treated with captopril (63.98 ± 
20.84%, N=3) and slices perfused with normal aCSF (39.39 ± 27.47%, N=3). No 
significant changes were observed in protein expression as measured by immunoblotting 
between slices exposed to subtilisin in the presence of zinc (Figure 3.3b, P > 0.05) for all 
proteins.  	  	  
3.1.2.4 Comparison of Subtilisin and Tetanus Toxin effects 	  
The clearest indication of whether subtilisin action was a result of metalloprotease activity 
would be to compare the action of subtilisin alongside a metalloprotease.  To this end, an 
experiment was planned for comparing the effects of tetanus toxin with subtilisin.  
Preliminary experiments were carried out to measure the effects of TeTx on hippocampal 
slice recordings, which demonstrated no difference between the two groups (Figure 3.4, P 
= 0.549).  Immunoblotting of these hippocampal slices however indicated no change in the 
expression of any proteins, including VAMP-1, the target for tetanus toxin (data not 
shown). 	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Figure 3.3a Effect of aCSF supplemented with captopril on hippocampal fEPSP size 
after subtilisin perfusion. 
The subtilisin-mediated decrease in fEPSP size was not affected by addition of aCSF 
supplemented with 100µM captopril to aCSF (39.39 ± 27.47, N=3) when compared to 
controls (63.98 ± 20.84, N=3) (Students t-test, P =).  Arrows a, b and c indicate time points 
at which traces were taken. 
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Figure 3.3b Effect of 100µM captopril perfusion on protein degradation in response 
to subtilisin. 
No significant changes were observed between slices perfused with aCSF + captopril and 
slices perfused with aCSF alone.  N =3 for both treatment groups. 
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Figure 3.4 Comparison of hippocampal fEPSP response between a 15-minute 
exposure to TeTx and a 15-minute stoppage period in aCSF.  
 
No differences were observed in the end fEPSP size between slices exposed to 2µM TeTx 
over a period of 15 minutes, and slices left in normal aCSF over this period.  Slices 
exposed to TeTx (118.22 ± 5.57, N=7), slice exposed to normal aCSF (104.97 ± 20.78, 
N=7), P = (), no significant. Arrows a, b and c indicate time points at which traces were 
taken. 
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3.1.3 Discussion 
	  
These experiments were conducted as a result of the similar pattern of VAMP cleavage by 
both subtilisin and tetanus toxin.  This suggested two possibilities; firstly, that subtilisin 
and tetanus toxin could share a metalloprotease mechanism.  Another possibility was that 
subtilisin action depended on the activation of a metalloprotease possessing similar 
properties to tetanus toxin, which could explain the degradation of VAMP-1 by both 
proteases.  However, none of the previous literature regarding clostridial toxins has 
demonstrated that they are capable of generating long-term depression.  Similarly, all 
previous studies regarding subtilisin-mediated LTD have been focused on its 
characteristics as a serine protease and have not examined the possibility of a role for 
metalloproteases.  If subtilisin action was dependent on the action of metalloproteases, this 
would represent a new function for the metalloprotease family.  Initial experiments were 
based on the assumption that subtilisin possessed a zinc-dependent mechanism, as VAMP-
1 was similarly targeted by tetanus toxin, a zinc-dependent metalloprotease (Yamasaki et 
al., 1994a).  Tetanus toxin is known to be sensitive to the application of chelators such as 
EDTA, and the exogenous application of zinc ions (Simpson et al., 1993) However, the 
addition of zinc ions did not increase the potency of subtilisin, as would be expected of a 
zinc dependent metalloprotease.  Furthermore, addition of the zinc-metalloprotease 
inhibitor captopril to aCSF failed to inhibit subtilisin, further supporting the view that zinc 
did not have an important role in subtilisin action.  Experiments were also carried out to 
determine whether subtilisin could utilise, or possess, general metalloprotease functions 
involving other metal ions.  As a general chelator of metal ions, EDTA represents an 
effective inhibitor of many metalloproteases.   However, application of EDTA did not have 
a significant effect on subtilisin-mediated LTD and proteolysis, unlike their effects on 
metalloproteases such as botulinum toxins (Yamasaki et al., 1994b), therefore discounting 
the influence of metal ions in subtilisin action.  The failure of tetanus toxin to cause 
VAMP-1 degradation, as demonstrated by immunoblotting, prevented a definitive 
comparison between the mechanisms of subtilisin and an established metalloprotease. 
Further optimisation of the application of tetanus toxin would be necessary to rectify this 
anomaly. However, based on negative results of all other experiments regarding the role of 
metalloproteases in subtilisin action, it would appear likely that metalloprotease 
mechanisms do not contribute to subtilisin action.  
There were several limitations to the experimental protocol, would could have an impact 
on the results presented here.  The addition of zinc could lead to a disruption of the ionic 
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balance within the cell; however, electrophysiological data did not demonstrate a 
noticeable impact in potential when zinc-supplemented aCSF was applied.  The use of zinc 
at a concentration of 50µM might also be too low to generate a measurable change in 
potential due to the action of buffering agents within the aCSF.  Furthermore, the use of 
20µM of EDTA may be insufficient to buffer endogenous zinc, as previous experiments 
were conducted with EDTA at millimolar concentrations (Schiavo et al., 1993).  In 
addition, the presence of other metal ions found within the aCSF could also affect the 
efficiency of these chelators in binding zinc.	  
	  
	  
3.2 - Serine protease mechanisms 
 
3.2.1 Introduction 	  
Previous studies have demonstrated the existence of a potential link between the LTD 
effect caused by subtilisin, and selective degradation of proteins presumably based on its 
status as a serine protease.  However, to date the relationship between these two processes 
is unclear, and it is not known whether perfusion of subtilisin was capable of eliciting LTD 
outwith its serine protease action.  In order to obtain a better understanding of this 
relationship, experiments were conducted using the general serine protease inhibitor 
phenylmethylsulfonyl fluoride (PMSF).  PMSF possesses inhibitory action against a range 
of serine proteases, including the chymotrypsin subfamily that shares a similar catalytic 
active site as subtilisin (MacGregor et al., 2007).  Initial experiments were conducted using 
PMSF at a concentration of 200µM; a second experiment was also conducted using a much 
lower PMSF concentration of 5µM. 
 	  
3.2.2 Results 	  
3.2.2.1 Effect of 200µM PMSF on subtilisin-mediated activities 	  
The first experiment was conducted by preparing a solution containing 200µM PMSF and 
4µM subtilisin dissolved in aCSF.  This solution was gassed with a mixture of 95% O2 and 
5% CO2 over a period of 30 minutes to allow interactions to take place between the 
protease inhibitor and subtilisin molecules.  In this intervening period, a fEPSP with an 
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amplitude of 0.5-1mV was again elicited in a hippocampal slice, and maintained over a 
period of 10 minutes to allow formation of a stable baseline.  The PMSF-subtilisin 
perfusate was then perfused over the slice for a 10-minute period, followed by a 40-minute 
recovery period in which the slice was perfused with normal aCSF.  In control slices, 
subtilisin dissolved in aCSF was perfused in place of a PMSF-subtilisin solution over a 10-
minute exposure period.  Normal aCSF was perfused throughout the whole experiment, 
except for a 10-minute period in which aCSF supplemented with either subtilisin alone or 
PMSF + subtilisin was perfused over the slice.  Perfusion of hippocampal slices with 
PMSF + subtilisin caused a major attenuation of subtilisin activity in comparison to 
perfusion with subtilisin alone, with the difference being statistically significant (P 
=<0.0001, N=4, Figure 3.5a).  Furthermore, results from immunoblotting between the two 
treatment groups reflected the differences found in electrophysiological recordings (P < 
0.05 for all proteins, N =4, Figure 3.5b).  A small depressive effect in fEPSP size was also 
observed immediately after perfusion of the PMSF-subtilisin solution began, and although 
the potential recovered during the washout period, this could unexpected effect could have 
an impact on the results obtained.  	  	  
3.2.2.2 Effect of 5µM PMSF on subtilisin-mediated activities 	  
In order to determine whether the decrease in fEPSP size was due to an interaction of 
PMSF with subtilisin, or due to a high PMSF concentration, experiments were conducted 
with a lower concentration of 5µM PMSF.  A secondary aim of these experiments was to 
determine whether the degradation of a specific protein could underlie the generation of 
LTD.  By comparing the effects of PMSF at two different concentrations, it could be 
possible to determine the protein responsible for the LTD effect.  The protocol used for this 
experiment was the similar to the one used for testing 200µM PMSF, but with the use of a 
5µM concentration of PMSF.  Normal aCSF was again perfused throughout the whole 
experiment, with the notable exception of a 10-minute period in which the mixture of 
PMSF and subtilisin, dissolved in aCSF, was perfused. 
At a concentration of 5µM, PMSF was able to completely block the onset of LTD in 
response to subtilisin perfusion (P < 0.0001, N = 6, Figure 3.6a), and preventing the 
degradation of proteins (P < 0.05 for all protein markers, N = 6, Figure 3.6b) 	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Figure 3.5a Effect of co-perfusion of 200µM PMSF on fEPSP response to 4µM 
subtilisin perfusion. 
Slices were treated with either 4µM subtilisin alone or a mixture of 200µM PMSF and 
4µM subtilisin.  Pretreatment of subtilisin with PMSF significantly attenuated the fEPSP 
response to subtilisin (102.16 ± 3.63%, N = 4) in comparison to subtilisin alone (alone 
32.95 ± 1.55%, N = 4) (P<0.0001).  Of note was the initial decrease in PMSF-treated 
slices, reached a maximum value of 59.78 ± 3.38% (N =4) baseline. Arrows a, b and c 
indicate time points at which traces were taken. 	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Figure 3.5b Effect of co-perfusing 200µM PMSF on protein degradation response to 
4µM subtilisin. 
Significant differences between the two treatments were observed in all protein markers: 
Unc5H1, RhoB (P<0.05, *), Unc5H3, SynT and VAMP-1 (P<0.001, **); RhoA, Actin 
(P<0.0001, ***).  N = 4 for both subtilisin and PMSF + subtilisin. 
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Figure 3.6a Effect of co-perfusion of 5µM PMSF the on fEPSP response to 4µM 
subtilisin perfusion 
Pretreatment of subtilisin with PMSF significantly attenuated the fEPSP response to 
subtilisin (93.51 ± 3.8%, N = 6) in comparison to subtilisin alone (25.2 ± 3.63%, N = 6) (P 
< 0.0001). Arrows a, b and c denote time points at which traces were taken as shown 
below. 	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Effect of perfusing PMSF on subtilisin-related protein degradation
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Figure 3.6b Effect of co-perfusing 5µM PMSF on protein degradation response to 
4µM subtilisin 
Significant differences between the two treatments were observed in all protein markers: 
SynT, RhoB (P<0.05,*), Unc5H3, Unc5H1 and RhoA (P<0.001, **); VAMP-1, Actin 
(P<0.0001, ***).  N = 11 for both subtilisin and PMSF + subtilisin.	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3.2.3 Discussion 	  
Based on the negative results of experiments regarding the contribution of metalloprotease 
mechanisms to the action of subtilisin, it was suggested that subtilisin-mediated LTD was 
instead dependent on their endogenous serine protease mechanism. In order to confirm this 
theory, the serine protease action of subtilisin was inhibited through the use of the general 
serine protease inhibitor PMSF. An additional aim was to confirm whether the proteolysis 
of proteins in response to subtilisin perfusion was related to the generation of LTD.  Using 
two concentrations of PMSF, the possibility of a sequential breakdown of proteins was also 
explored, which could result in the identification of the precise mechanism of subtilisin 
action.  However, both concentrations of PMSF produced a similar inhibition LTD 
generation usually found after perfusion of subtilisin.  PMSF at both these concentrations 
were also equally effective in preventing protein degradation in response to subtilisin.  
These results reinforce the view that subtilisin action is based solely on its serine protease 
function, in agreement with a previous study demonstrating the effectiveness of PMSF as 
an inhibitor of subtilisin and related serine proteases (MacGregor et al., 2007).  These 
experiments did not however provide any new data on its mechanism of action.   Further 
experiments into the role of serine protease mechanisms could be conducted using lower 
concentrations of PMSF, as subtilisin is completely inhibited by 5µM PMSF.  At a 
concentration of 200µM, PMSF also generated an initial decrease in potential size, which 
could be the result of an inhibition of endogenous serine proteases. Reducing the 
concentration of PMSF to 5µM abolished this effect. A more specific serine protease 
inhibitor, such as eglin (McPhalen et al., 1985) could be more efficient in determining the 
susceptibility of individual proteins to subtilisin degradation, therefore highlighting any 
potential proteolytic cascades in response to the induction and onset of LTD. 	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Chapter 4 – Investigations into the role of specific 
protein targets in subtilisin-mediated LTD. 
 
 
4.1 Importance of VAMP-1 proteins to the action of 
subtilisin 
 
4.1.1 Introduction 	  
The action of proteases can be effectively inhibited by preventing interfering with the 
binding of the substrate to the active site. This can be effected through a change in the 
structure of the active site by substituting key residues at this site, or by altering the 
recognition site on the substrate via methylation or phosphorylation.   
The shape of the substrate recognition site can also be changed using antibodies targeted to 
this site, and is known to be effective in preventing the action of proteases against 
substrates.  An example of this method is the use of antibodies against malarial merozoites, 
which prevent the activation of a key surface protein by proteolytic processing (Blackman 
et al., 1994).   Of particular interest is a study that demonstrated that antibodies against 
VAMP proteins could prevent its degradation by tetanus toxin (Poulain et al., 1993) It is 
therefore plausible that antibodies could also prevent the degradation of VAMP-1 by 
subtilisin.  The use of antibodies would also allow an evaluation into whether structural 
changes to these proteins themselves could trigger LTD.   
For the purposes of this investigation, protein-specific antibodies against Unc5H3 and 
VAMP-1 were used, as these were the proteins most affected by the action of subtilisin.  
The following protocol was used for all antibody experiments; with minor changes 
between each separate set of experiments.  After a 1-hour recovery period following 
dissection, hippocampal slices were separated into two groups into petri dishes, each 
containing approximately the same number of slices.  One dish was set aside as a control, 
and slices within were exposed to aCSF alone throughout the incubation period.  Slices in 
the second dish was incubated in an aCSF solution containing a set concentration of either 
VAMP-1 or Unc5H3 antibodies, and both control and antibody dishes were subsequently 
left in the incubation chamber gassed with a mixture of 95% O2 and 5% CO2 for 20 
minutes at room temperature.  At the end of this period, aCSF in both dishes was removed 
via a syringe, and the slices were carefully washed 3 times with fresh, oxygenated aCSF.  
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After these washes were completed, normal aCSF was added to both dishes and slices 
placed back into the incubation chamber for a recovery period of 30 minutes prior to use.  
For experiments involving triton, slices were exposed to a more concentrated antibody 
solution for an initial period of 5 minutes, before aCSF containing the 0.01% triton was 
added to produce the desired antibody concentration, and left to incubate for a further 15 
minutes.   Thereafter they were washed 3 times as before, and left to incubate for 30 
minutes at room temperature prior to use.  Experiments with streptolysin involved 
incubation of slices with 500ng streptolysin over a period of 5 minutes, before the addition 
of antibody-containing aCSF for the remaining 15-minute period of incubation.  
Subsequent washes and recovery incubation period was identical to the other experiments. 	  	  
4.1.2 Results 	  
4.1.2.1 Effect of 1:5000 VAMP-1 antibody preincubation on subtilisin 
 
VAMP-1 antibodies were initially applied to hippocampal slices at a concentration of 
1:5000. A solution containing this concentration of antibodies was prepared by addition of 
0.4µl antibody to 20ml of aCSF, a volume that represents the total volume of the petri dish.  
Preincubation of hippocampal slices with VAMP-1 antibodies at this concentration did not 
result in any significant changes (P > 0.05, N = 4, Figure 4.1a) to the extent of subtilisin-
mediated fEPSP depression.  This result was also mirrored by the findings from 
immunoblotting, which demonstrated no change (P> 0.05 for all markers, apart from 
Unc5H1 (P =0.0063), N = 4, Figure 4.1b) in the levels protein expression, including the 
levels of VAMP-1. 
 
4.1.2.2  Effect of hippocampal slice preincubation with 0.01% triton and 1:5000 VAMP-1 
antibody on the effects of subtilisin 
 
As the use of 1:5000 VAMP-1 antibodies failed to cause any changes to either fEPSP 
response or protein expression levels, it was possible that this was due to the inability of 
the antibodies to penetrate the cells within the hippocampal slice.  In an effort to eliminate 
this variable, the permeabilising agent triton was be used to facilitate antibody entry into 
the cells.  A 5ml aCSF solution containing 0.4µl VAMP-1 antibody was prepared and 
incubated with the hippocampal slices over a period of 5 minutes.  A 15ml aCSF solution 
	   86	  
containing 2µl triton was prepared, and subsequently added to the slices to yield a total 
triton concentration of 0.01% and incubated for a further 15 minutes.  Preincubation of 
hippocampal slices in with the mixture of 0.01% triton and 1:5000 VAMP-1 antibodies did 
not cause any significant changes to the size of the LTD effect in response to subtilisin 
perfusion (P > 0.05, N = 4, Figure 4.2a).  Likewise, no significant differences were 
observed in the pattern of protein degradation between slices preincubated with the triton-
VAMP-1 solution, and those preincubated in aCSF alone (P > 0.05, N =3, Figure 4.2b). 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   87	  
0.5m
V 
5ms 
a b c 
0.5m
V 5ms 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
Figure 4.1a Effect of preincubating hippocampal slices with VAMP-1 antibodies on 
fEPSP response to subtilisin perfusion. 
 
Preincubation with VAMP-1 antibodies did not change the fEPSP response to subtilisin 
(29.99 ± 3.45%, N=3) when compared with slices incubated in aCSF alone (28.51 ± 
2.21%, N=4)(P = 0.0968). Arrows a, b & c indicate time points at which sample fEPSPs 
were taken, as shown below. 	  	  	  	  	  	   Subtilisin	  	  	  	  	  	  	  	   VAMP-­‐1	  	  	   antibody	  	   preincubation	  	  	   +	  subtilisin	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Effect of 1:5000 VAMP-1 antibody preincubation of hippocampal 
slices on subtilisin-related protein degradation
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Figure	   4.1b	   Effect	   of	   preincubating	   hippocampal	   slices	   with	   1:5000	   VAMP-­‐1	  
antibodies	  on	  protein	  expression	  in	  response	  to	  subtilisin.	  
There was a very significant difference in protein expression for Unc5H1 (P = 0.0063, **) 
between the two groups; all other proteins were not significantly different.  N = 3 for both 
antibody preincubation and untreated groups. 
Control for 
VAMP-1 
Antibody 
preincubation	   Control 
Subtilisin 
+ VAMP-1 
antibody 
preincubation 
Subtilisin 
+ aCSF 
**	  
	   89	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure 
4.2a Effect of preincubating hippocampal slices with 0.01% triton and 1:5000 VAMP-
1 antibodies on fEPSP response to subtilisin perfusion. 
 
Preincubation with triton and VAMP-1 antibodies did not change the fEPSP response to 
subtilisin (40.69 ± 8.39%, N=4) when compared with slices incubated in aCSF alone 
(34.18 ± 9.41%, N=4)(P = 0.631). Arrows a, b & c indicate time points at which sample 
fEPSPs were taken, as shown below. 	  	  	  	  	  	  Subtilisin	  	  	  	  	  	  	  	  Triton	  +	  	  VAMP-­‐1	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  +	  subtilisin	  	  	  	  
a b c 
a b c 
Subtilisin	  
	   90	  
Effect of hippocampal slice preincubation with 0.01% Triton, 
1:5000 VAMP-1 antibody on subtilisin-related protein degradation
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Figure 4.2b Effect of preincubating hippocampal slices with 0.01% triton and 1:5000 
VAMP-1 antibodies on protein expression in response to subtilisin. 
No significant differences were observed in protein expression between the two treatment 
groups. N = 4, P > 0.05 for all proteins in antibody preincubation and untreated groups. 
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4.1.2.3 Effect of 1:500 VAMP-1 antibody preincubation on subtilisin 
 
Preincubation of slices with 1:5000 VAMP-1 antibodies had no effect on subtilisin-
mediated LTD, or protein degradation in response to subtilisin perfusion.  The presence of 
triton in the preincubation solution likewise did not produce any noticeable change to 
either process, suggesting that the concentration of VAMP-1 antibody could be insufficient 
to make an impact on the action of subtilisin.  To test this hypothesis, further experiments 
were be conducted using a higher concentration of 1:500 VAMP-1 antibody in order to 
increase the rate of antibody-protein interactions. The antibody solution was prepared by 
addition of 4µl antibody to 20ml of aCSF, which represented the total volume of the petri 
dish.  Preincubation of hippocampal slices with VAMP-1 antibodies at a concentration of 
1:500 did not result in any significant changes (Figure 4.3a; P > 0.05, N =4) to the extent 
of subtilisin-mediated LTD when compared to control slices.  This result was also mirrored 
by data obtained immunoblotting on the same hippocampal slices, which demonstrated no 
change (Figure 4.3b) in the levels of VAMP protein expression. 	  	  
4.1.2.4 Effect of hippocampal slice preincubation with 100ng/ml streptolysin and 
1:5000 VAMP-1 antibody on the effects of subtilisin 	  
VAMP-1 antibodies, even at an increased concentration of 1:500, failed to elicit any 
changes to the progression of subtilisin-mediated LTD or the associated protein 
degradation.  The use of permeabilising agents was again considered, and since the 
permeabilising chemical triton was ineffective in preventing subtilisin action, an 
alternative was considered.  The pore-forming compound streptolysin is capable of 
forming pores large enough to allow the entry of antibodies into cells, and could therefore 
be an effective method of facilitating cellular entry of VAMP-1 antibodies for this 
experiment. (Walev et al., 2001)  For this experiment, a 5ml aCSF solution containing 
200ng streptolysin was formulated and incubated with the hippocampal slices over a period 
of 5 minutes.  A 15ml aCSF solution containing 4µl of VAMP-1 antibody was prepared 
with 15ml aCSF, and subsequently added to the slices to produce an antibody 1:500 which 
was incubated for a further 15 minutes. Results of this preincubation protocol involving a 
combination of streptolysin and VAMP-1 antibody yielded no significant changes to the 
extent of the LTD response to subtilisin (Figure 4.4a; P > 0.05, N =4).  Protein degradation 
was also not inhibited by the addition o or in protein degradation (Figure 4.4b) as a result 
of subtilisin perfusion. 
	   92	  
a b c 
	   	  	  
	   	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure 4.3a Effect of preincubating hippocampal slices with 1:100 VAMP-1 
antibodies on fEPSP response to subtilisin perfusion. 
 
Preincubation with VAMP-1 antibodies did not change the fEPSP response to subtilisin 
(21.49 ± 5.5%, N=4) when compared with slices incubated in aCSF alone (26.54 ± 6.91%, 
N=4)(P = 0.5883). Arrows a, b & c indicate time points at which sample fEPSPs were 
taken, as shown below. 	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Figure 4.3b Effect of preincubating hippocampal slices with 1:500 VAMP-1 
antibodies on protein expression in response to subtilisin. 
No significant differences in protein expression were observed between the antibody 
preincubation and untreated groups. N = 4, P > 0.05 for all proteins 
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Figure 4.4a Effect of preincubating hippocampal slices with 100ng/ml streptolysin 
and VAMP-1 antibodies on fEPSP size. 
 
Subtilisin-mediated fEPSP response to slice preincubation with 100µg streptolysin, 1:500 
VAMP-1 antibody. Preincubation with streptolysin and VAMP-1 antibodies did not 
change the fEPSP response to subtilisin (42.65 ± 6.38%, N=4) when compared with slices 
incubated in aCSF alone (42.85 ± 5.77%, N=4)(P = 0.8512). Arrows a, b & c indicate time 
points at which sample fEPSPs were taken, as shown below. 	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Figure 4.4b Effect of hippocampal slice preincubation with 100ng/ml streptolysin and 
1:500 VAMP-1 antibodies on protein expression in response to subtilisin.  
 
There were no significant differences in the pattern of protein degradation between slices 
preincubated with a mixture of streptolysin and VAMP-1 antibody and control slices 
exposed to aCSF alone. N=4, P >0.05 for all protein markers. 	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4.2 Effect of Unc5H3 antibody preincubation on the 
action of 4µM subtilisin 
 
 
4.2.1 Introduction 
 
The Unc5H3 is an established target for subtilisin action, and also acts as a regulator for 
actin via the Rho GTPases.  Since actin relatively susceptible to subtilisin degradation, 
interfering with the proteolysis of Unc5H3 could represent an effective way of preventing 
subtilisin activity.   
 
 
4.2.2 Results 
 
4.2.2.1 Effect of Unc5H3 antibodies at a concentration of 1:1000 on the action of 
subtilisin 
 
The first experiments into the effects of hippocampal slice preincubation with Unc5H3 
antibodies were conducted using an antibody concentration of 1:1000.  The antibody-aCSF 
solution was prepared by addition of 2µl Unc5H3 antibody to 20ml of aCSF, held in a petri 
dish.  Slices underwent three washes in normal aCSF before they were left to recover at 
room temperature.  Hippocampal slice preincubations using Unc5H3 antibodies at a 
concentration of 1:1000 did not result in any significant changes (P > 0.05, N = 4 (aCSF), 
N = 5 (triton + Unc5H3 antibody), Figure 4.5a) to the extent of subtilisin-mediated LTD.  
Similar results were also obtained from immunoblots of the hippocampal slices used for 
recordings, demonstrating no significant differences in protein degradation between slices 
preincubated in Unc5H3 antibodies, and those preincubated with aCSF alone  (P > 0.05, 
Figure 4.5b). 	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4.2.2.2 Effect of hippocampal slice preincubation with 0.01% triton and 1:1000 
Unc5H3 antibody on the effects of subtilisin 	  
Hippocampal slices were also preincubated with a mixture of 0.01% triton and 1:1000 
Unc5H3 antibodies, in an attempt to increase the intracellular concentration of antibody to 
allow greater interaction with the Unc5H3 protein.  For this study, a 5ml aCSF solution 
containing 2µl VAMP-1 antibody was incubated with the hippocampal slices over a period 
of 5 minutes.  A 15ml aCSF solution containing 2µl triton was prepared, and subsequently 
added to the slices to yield a total triton concentration of 0.01% and incubated for a further 
15 minutes.  Hippocampal slice preincubation with triton + Unc5H3 antibodies did not 
result in any significant changes to the progression of subtilisin-mediated LTD (P > 0.05, 
N = 4, Figure 4.6a).  The protein expression levels of Unc5H3 differed very significantly 
(P = 0.0063) in slices preincubated with triton and Unc5H3, however, no other significant 
changes were found in the other protein markers measured (P > 0.05, N =3, Figure 4.6b) 	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Figure 4.5a Effect of preincubating hippocampal slices with 1:1000 Unc5H3 
antibodies on fEPSP response to subtilisin perfusion. 
 
Subtilisin-mediated fEPSP response to slice preincubation with 1:1000 Unc5H3 antibodies. 
Preincubation with streptolysin and Unc5H3 antibodies did not change the fEPSP response 
to subtilisin (38.44 ± 5.91%, N=4) when compared with slices incubated in aCSF alone 
(33.44 ± 6.54%, N=4)(P = 0.5907). Arrows a, b & c indicate time points at which sample 
fEPSPs were taken, as shown below.    	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Figure 4.5b Effect of preincubating hippocampal slices with 1:1000 Unc5H3 
antibodies on protein expression response to subtilisin perfusion. 
 
No significant differences in the pattern of protein degradation was observed between 
slices preincubated with Unc5H3 antibody and control slices exposed to aCSF alone N=3, 
P > 0.05 for all proteins 
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Figure 4.6a Effect of preincubating hippocampal slices with 0.01% triton, 1:1000 
Unc5H3 antibodies on fEPSP response to subtilisin perfusion. 
 
Preincubation with triton and Unc5H3 antibodies did not change the fEPSP response to 
subtilisin (13.13 ± 2.33%, N=5) when compared with slices incubated in aCSF alone 
(25.78 ± 11.01%, N=4)(P = 0.2476).  Arrows a, b & c indicate time points at which sample 
fEPSPs were taken, as shown below. 	  	  	  	  	  
Subtilisin 
 
 
 
 
 
 
 
Triton, 
Unc5H3  
Antibody  
subtilisin 	  	  	  
0
20
40
60
80
100
120
0 10 20 30 40 50 60
Time (minutes)
%
 fE
P
S
P
 s
pi
ke
 a
m
pl
itu
de
Subtilisin
Triton, Unc5H3 antibody preincubation + subtilisin
a b c 
0.5mV 
5ms 
0.2mV 
5ms 
a b c 
Subtilisin	  
	   101	  
Unc5H3 
Synaptotagmin 
RhoA 
VAMP-1 
Actin 
Unc5H1 
Effect of hippocampal slice preincubation with 0.01% triton, 
1:1000 Unc5H3 antibody on subtilisin-related protein degradation
O
pt
ica
l D
en
sit
y
0
20
40
60
80
100
120
aCSF
0.01% Triton, 1:1000 Unc5H3 antibody preincubation
Unc5H1      SynT        RhoA       RhoB      VAMP-1     Actin
Protein
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure 4.6b Effect of preincubating hippocampal slices with 0.01% triton and 1:1000 
Unc5H3 antibodies on protein expression response to subtilisin.  
 
There were no significant differences in the pattern of protein degradation between slices 
preincubated with a mixture of streptolysin and Unc5H3 antibody and control slices 
exposed to aCSF alone. N=3, P > 0.05 for all protein markers. 
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4.2.2.3 Effect of 1:100 Unc5H3 antibody preincubation on subtilisin 	  
Preincubation with 1:1000 Unc5H3 antibodies was ineffective in preventing subtilisin 
action, and the addition of triton to the preincubation solution also failed to elicit any 
changes in the hippocampal response to subtilisin.  In an attempt to increase the number of 
antibody-protein interactions, further experiments were conducted using a higher 
concentration of 1:100 Unc5H3 antibody.  Preincubation of hippocampal slices with 
Unc5H3 antibodies at a concentration of 1:100 did not produce significant changes (P > 
0.05, N = 3, Figure 5.7a) to the LTD effect in response to subtilisin perfusion.  The 
ineffectiveness of triton + Unc5H3 antibody preincubation in preventing subtilisin action 
was also reflected in the pattern of protein degradation, which did not differ significantly 
between slices preincubated with triton and Unc5H3, and slices preincubated with aCSF 
alone (P > 0.05, Figure 4.7b).  
 
 
4.2.2.4 Effect of hippocampal slice preincubation with 100ng/ml streptolysin and 
1:100 Unc5H3 antibodies on the effects of subtilisin 	  
Preincubation of hippocampal slices with 1:100 Unc5H3 antibodies alone did not cause 
any noticeable change to the effects of subtilisin on the hippocampal slice.  Because of the 
lack of change in either LTD effect or the pattern of proteolysis with the preincubation of 
Unc5H3 antibodies alone, an experiment was attempted using a combination of 100ng 
streptolysin and 1:100 Unc5H3 antibody.  This would likely increase the amount of 
antibodies penetrating into the neurons by facilitating transport via membrane pores. For 
this experiment, the protocol followed was identical to the one used during experiments 
with streptolysin and VAMP-1 antibodies, with the major exception being the use of 
antibodies against Unc5H3 rather than VAMP-1.  Preincubation of hippocampal slices 
using a mixture of streptolysin and Unc5H3 antibodies failed to prevent LTD in response 
to subtilisin perfusion (P > 0.05, N = 4, Figure 4.8a) and the associated protein degradation 
(P > 0.05, Figure 4.8b)  	  	  	  	  	  
	   103	  
0.2mV 
5ms 
0.2mV 
5ms 
a b c 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure 4.7a Effect of preincubating hippocampal slices with 1:100 Unc5H3 antibodies 
on fEPSP response to subtilisin perfusion.  
 
No significant differences were detected in the fEPSP response to subtilisin perfusion 
between slices preincubated with Unc5H3 antibody (16.92 ± 9.18%, N=3), and control 
slices exposed to aCSF alone (16.39 ± 7.54%, N=3; P = 0.9667).  Arrows a, b & c indicate 
time points at which sample fEPSPs were taken, as shown below. 	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Figure 4.7b Effect of preincubating hippocampal slices with 1:100 Unc5H3 antibodies 
on protein expression response to perfusion of subtilisin. 
 
The pattern of protein degradation did not differ between slices preincubated with Unc5H3 
antibody and control slices exposed to aCSF alone.  N=3, P > 0.05 for all proteins 
measured 
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Figure 4.8a Effect of hippocampal slice preincubation with 100ng/ml streptolysin, 
1:100 Unc5H3 antibodies on fEPSP response to subtilisin perfusion.  
 
The fEPSP response to subtilisin perfusion was not significantly different between slices 
preincubated with streptolysin and Unc5H3 antibody (35.06 ± 4.38%, N=4), and control 
slices exposed to aCSF alone (27.78 ± 2.80%, N=4)(P = 0.211).  Arrows a, b & c indicate 
time points at which sample fEPSPs were taken, as shown below. 	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Effect of 100ng streptolysin 1:100 Unc5H3 antibody slice 
precinubation on subtilisin-mediated protein degradation
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Figure 4.8b Effect of hippocampal slice preincubation with 100ng/ml streptolysin and 
1:100 Unc5H3 antibodies on protein expression response to subtilisin.  
 
No significant differences in the pattern of protein degradation were observed between 
slices preincubated with a mixture of streptolysin and Unc5H3 antibody and control slices 
exposed to aCSF alone. N=6, P >0.05 for all protein markers. 
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4.3 Validation of the effects of triton and streptolysin 
 
 
4.3.1 Introduction 
 
As permeabilising and pore-forming compounds respectively, triton and streptolysin alone 
have the potential to influence the action of subtilisin. In order to eliminate this possibility, 
experiments were carried out with each compound alone to determine they could affect the 
results obtained with antibody preincubations.  
 
 
4.3.2 Results 
 
4.3.2.1 Effect of 0.01% triton on subtilisin response 	  
This investigation was carried out to determine whether the permeabilising effects of triton 
alone would cause a change in the way the hippocampal slices responded to subtilisin.  For 
this experiment a modified version of the previous antibody preincubation protocol was 
used.  Hippocampal slices were exposed to 0.01% triton over a period of 20 minutes, 
followed by 3 washes in aCSF and a 30-minute recovery period. Preincubation of triton did 
not have any adverse effects on progression of subtilisin-mediated LTD, and values for 
triton preincubation did not differ significantly from those attained with aCSF alone (P > 
0.05, N = 4, Figure 4.9a).  The decrease in expression of selected proteins were likewise 
unaffected by slice preincubation in triton (P >0.05 for all proteins, Figure 4.9b) 	  
4.3.2.2 Effect of 100ng/ml streptolysin on subtilisin response 	  
Investigations were also carried out to determine whether the use of streptolysin would 
impact on the actions of subtilisin.  Hippocampal slices were preincubated with 100µg 
streptolysin over a 20-minute period, followed by 3 washes in aCSF and a 30-minute 
recovery period prior to use.  Streptolysin preincubation alone did not alter the decrease in 
fEPSP after subtilisin perfusion (P > 0.05, N =4, Figure 4.10a); in addition, it did not 
change the pattern of protein degradation after the addition of subtilisin (P > 0.05 for all 
proteins, Figure 4.10b).  	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Figure 4.9a Effect of preincubating hippocampal slices with 0.01% triton alone on 
fEPSP response to subtilisin.  
 
Preincubation with triton antibodies alone did not demonstrate a change to the fEPSP 
response to subtilisin (31.54 ± 5.07%, N=4) compared with slices incubated in aCSF alone 
(26.38 ± 6.09%, N=4; P = 0.5388).  Arrows a, b & c indicate time points at which sample 
fEPSPs were taken, as shown below. 	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Figure 4.9b Effect of preincubating hippocampal slices with triton alone on protein 
expression in response to subtilisin.  
No significant differences in the pattern of protein degradation were observed between 
slices preincubated with triton and control slices exposed to aCSF alone. N = 4, P >0.05 for 
all protein markers. 
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Figure 4.10a Effect of preincubating hippocampal slices with 100ng streptolysin alone 
on fEPSP response to subtilisin.  
 
Preincubation with streptolysin antibodies did not change the fEPSP response to subtilisin 
(37.28 ± 6.54%, N=4) compared with slices incubated in aCSF alone (41.53 ± 4.47%, 
N=4)(P = 0.222).  Arrows a, b & c indicate time points at which sample fEPSPs were 
taken, as shown below. 	  	  	  	  Subtilisin	  	  	  	  	  	  	  	  	  Streptolysin	  	  preincubation	  +	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Figure 4.10b Effect of preincubating hippocampal slices with 100ng/ml streptolysin 
on protein expression in response to subtilisin.  
 
No significant differences in the pattern of protein degradation were observed between 
slices preincubated with 100µg streptolysin and control slices exposed to aCSF alone. N = 
4, P >0.05 for all protein markers. 	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4.4 Discussion 	  
Protein-specific antibodies represent an accurate method of identifying a protein of interest 
amongst a heterogeneous group of other proteins. In addition, recent studies have also 
shown that antibodies provide an effective way of altering the protein structure, without 
changing the original amino acids present within the protein.  This mechanism can also be 
used to block the cleavage sites on a protein and interfering with the function of several 
proteases.   
In this study, antibodies against VAMP-1 and Unc5H3 proteins were used in an attempt to 
block their proteolysis by subtilisin.  Initial experiments were conducted on the synaptic 
protein VAMP-1, as a disruption of the synaptic site would produce the most obvious 
change in synaptic signalling. The first experiments utilised VAMP-1 antibodies at a 
concentration of 1:5000, but were unsuccessful in producing an inhibitory effect on 
subtilisin action.  Addition of 0.01% triton to the VAMP-1 antibody solution used for 
hippocampal slice preincubation was also ineffective in modulating the subtilisin response. 
VAMP-1 antibodies at a higher concentration of 1:500 were used in the next set of 
experiments in an attempt to increase the potential for antibody-protein interactions.  
However, even at this concentration VAMP-1 antibodies were still unable to elicit any 
noticeable changes to the activity of subtilisin.  The presence of 100ng/ml streptolysin, 
which caused the formation of pores large enough to allow antibody entry, was unable to 
facilitate the entry of VAMP-2 antibodies into the cells.   
Experiments were also conducted using antibodies against the Unc5H3 proteins, which 
was also one of the proteins most susceptible to subtilisin degradation.  There was a 
possibility that VAMP-1, being an intracellular protein, was less sensitive to the antibodies 
used in vitro.  In comparison, the Unc5H family of receptors, including Unc5H3, are 
transmembrane receptors, and therefore could be more readily bound by antibodies. 
However, use of Unc5H3 antibodies at concentrations of 1:5000 and 1:500 alone failed to 
have any impact on the progression of LTD or proteolysis in response to subtilisin.  
Addition of either triton or streptolysin to the antibody solution also failed to produce any 
changes to the decrease in fEPSP and protein degradation after perfusion of subtilisin. 
These experiments suggest that antibodies may be an ineffective method of inhibiting 
subtilisin action, unlike the activity of tetanus toxin, which was decreased in the presence 
of antibodies against VAMP-1 (Poulain et al., 1993).  However, several variables may 
have influenced the results obtained in these experiments.  The hippocampal slices were 
only incubated with the antibody solution over a period of 20 minutes, even in the presence 
	   113	  
of pore-forming chemicals.  The length of this incubation period may be insufficient for 
allowing successful antibody penetration into the cells, or the formation of stable antibody-
protein complexes. Furthermore, during the incubation period hippocampal slices were 
kept within a static incubation chamber, which could limit the interaction of antibodies 
with the target protein.  Additionally, this could lead to high levels of antibodies localised 
at several different locations, which might not correspond to the regions from which 
fEPSPs were elicited during electrophysiological recordings.   
The use of antibodies more suited to immunoblotting may also have a role in the low 
impact of these antibodies in the hippocampal slices, as this could decrease the efficiency 
of their protein binding and reduce the likelihood of antibody penetration.  Use of the 
permeabilising agent triton-X may not have been effective due to the relatively low 
concentration (0.01%) utilised for these experiments. Previous experiments in fixed cells 
utilised triton at a concentration of 0.1% to cause membrane permeabilisation and allow 
antibody entry (Appleby et al., 2011), although these experiments require the use of live 
tissue for electrophysiology, and therefore may require a lower triton concentration.  In a 
similar manner, a concentration of 100ng/ml streptolysin may have been insufficient for 
forming enough pores to allow effective antibody entry.  This initial concentration was 
based on results of cell studies in literature, which utilised 20-40ng/ml streptolysin to 
permeabilise cells (Ogino et al., 2009).  However, as hippocampal slices are much thicker 
and require a greater diffusion time, therefore a streptolysin concentration of many 
magnitudes higher may be necessary.  Experiments involving hippocampal slice 
preincubation in either triton or streptolysin alone did not result in significant changes to 
subtilisin-mediated LTD, suggesting that these chemicals did not have an impact on LTD 
or protein degradation mediated through subtilisin.   Use of these permeabilising agents is 
also likely to have non-specific effects on the hippocampal slice, or the neurons within.  
Triton-X, as a detergent, is capable of causing irreversible cell damage due to the cell 
membrane, leading to a high level of cell death.  However, at the concentration used during 
the current experiments, this is unlikely to occur as cell membranes would be capable of 
recovering after a wash-out period (Koley & Bard, 2010).  Of greater concern is the 
potential for uncontrolled entry and exit of molecules, which may change the intracellular 
balance of ions.   Similarly, previous literature on the use of streptolysin-O indicates that 
these toxins are capable of inhibiting the uptake of certain amino acids, namely 
phenylalanine and alanine, affecting the rate of protein synthesis, and have causing a 
change to the progression of long-term synaptic changes.  In addition, streptolysin also 
causes a clustering of membrane cholesterol, and reducing the fluidity of the lipid 
membrane.  This can in turn lead to a decrease in receptor turnover on the neuronal 
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surface, reducing synaptic signalling and potentially causing a reduction in the number of 
active synaptic connections. 
Future experiments into the importance of these proteins might involve the use of 
antibodies raised specifically to detect proteins in hippocampal slices, which should 
provide a much more accurate result.  Alterations to the protocol used in these experiments 
could involve the use of a shaker to produce a better distribution of antibodies within the 
preincubation solution.  This could however damage the neuronal network by disrupting 
synaptic connections, and therefore has to be closely monitored.  The incubation time for 
hippocampal slices may also need to be increased, although the use of acute hippocampal 
slices will limit the amount of time available.  The use of fluorescent tags on the antibodies 
may also allow better visualisation and optimisation of antibody entry into neurons.  	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4.5 Investigations into the effects of an actin stabiliser, 
Jasplakinolide, on subtilisin-mediated neuronal effects 
and protein expression. 	  	  	  
4.5.1 Introduction 	  
In addition to the degradation of Unc5H3 and VAMP-1, subtilisin also selectively targets 
actin, a structural protein essential for maintaining both cytoskeletal integrity and 
preserving the functionality of neurons.  Loss of this protein has been proven to cause a 
disruptive effect to neuronal signalling by through the loss of synaptic function.  Therefore, 
it is plausible that the long-term depression caused by subtilisin is due to a selective 
degradation of the actin cytoskeleton, leading to a prolonged period of disrupted synaptic 
signalling.  In addition, actin is a downstream effector protein for Unc5H3 signalling, and 
these investigations could shed new light into the role of Unc5H3 proteins in subtilisin 
action.  In order to determine the relative importance of actin to the actions of subtilisin, an 
attempt was made to prevent the depolymerisation of actin using the actin stabiliser 
jasplakinolide.   
Jasplakinolide is a compound that promotes actin stabilisation in vitro by increasing the 
rate of actin nucleation, and preventing their depolymerisation.   It is ideally suited to use 
with in vitro preparations as their use with in vivo preparations can result in cytotoxic 
effects due to uncontrolled actin polymerisation (Bubb et al., 1994; Bubb et al., 2000)  In 
the nervous system, jasplakinolide can act to increase the duration of long-term 
potentiation in rat hippocampal slices when perfused throughout the stimulus period and 
for a period following LTP induction (Messaoudi et al., 2007). 	  	  
4.5.2 Results 	  
In this experiment 100µM Jasplakinolide was perfused over the hippocampal slice for a 10-
minute period before subtilisin perfusion, throughout the perfusion period and 10 minutes 
after subtilisin perfusion ceased.  
Addition of jasplakinolide did not decrease the extent subtilisin-mediated LTD (Figure 
4.11a), also did not prevent the degradation of proteins after subtilisin perfusion (Figure 
4.11b). 	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Figure 4.11a Effect of 100µM Jasplakinolide on fEPSP response to subtilisin action.  
Addition of Jasplakinolide did not change the fEPSP response to subtilisin (17.90 ± 4.22%, 
N=4) when compared with slices incubated in aCSF alone (17.36 ± 5.12%, N=4)(P = 
0.9375). Arrows a, b & c indicate time points at which sample fEPSPs were taken, as 
shown below. 	  	  	  	  	  	  	  	  Subtilisin	  	  	  	  	  	  	  	  Jasplakinolide	  	  +	  subtilisin	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Effect of Jasplakinolide perfusion on subtilisin-related protein degradation
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Figure 4.11b Effect Jasplakinolide perfusion on protein expression in response to 
subtilisin.  
 
No significant differences in the pattern of protein degradation were observed between 
slices perfused with jasplakinolide and control slices perfused with aCSF alone during the 
administration of subtilisin. N = 4, P >0.05 for all protein markers. 	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4.5.3 Discussion 	  
The degradation of actin by subtilisin represents a potentially significant mechanism of 
inhibition, as actin is involved in a wide range of cellular activities.  The main function of 
this protein is to maintain the cell structure via the actin cytoskeleton and to facilitate the 
intracellular trafficking of vesicles (Pollard & Cooper, 2009) Disruption of either functions 
has major implications for cell-cell signalling, including at synaptic junctions. A disruption 
of actin could potentially affect the integrity of synapses by producing alterations to the 
surrounding cytoskeleton; preventing or interfering with vesicle re-uptake due to the loss 
of f-actin fibres, and interfere with the transport of neurotransmitter vesicles to the synapse 
(Yarar et al, 2005).  Stabilising or even reversing the effects of actin degradation could 
represent an effective way of preventing decreases to synaptic signalling.   
For this experiment, the actin stabiliser Jasplakinolide was used to promote actin 
polymerisation and ensure the stability of existing actin fibres.  However, this did not 
appear to have the desired effect in preventing subtilisin-mediated changes to fEPSP, and 
analysis of protein degradation indicated that Jasplakinolide was unable to prevent the 
degradation of actin.  Other proteins were similarly degraded by subtilisin even in the 
presence of jasplakinolide, suggesting that actin may not have such an essential role in the 
action of subtilisin as was initially believed.  One possible explanation is that the 
jasplakinolide was unable to penetrate the cells of the hippocampal slices, and therefore 
could not cause a change to the intracellular actin molecules within the neurons. An 
alternative explanation is that jasplakinolide molecules were not given sufficient time to 
bind to actin due to the high perfusion rate used during the experiment.  The concentration 
of jasplakinolide used for these experiments were scaled up from the concentrations used 
for neurons, although an even higher concentration may be required to in order to have an 
effect on hippocampal slices (Jaworski et al., 2009). Despite these results, further 
experiments could explore the use of other factors regulating actin, due to the importance 
of actin to the function of many cellular processes.  	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Chapter 5 - Comparison of the effects of subtilisin 
and other forms of LTD 
 
 
5.1 Introduction 
	  
In order to establish whether subtilisin-mediated LTD was a novel form of LTD, the 
characteristics of this form of LTD was compared to other more established methods of 
eliciting LTD.  Of particular interest was whether protein degradation had a role in other 
types of LTD, as selective proteolytic degradation of proteins appears to be the process that 
characterised subtilisin-mediated LTD.  One well-studied type of LTD is dependent on the 
action of mGluRs, and can be elicited chemically using the mGluR agonist DHPG (Huber 
et al., 2000).  For these experiments, the effect of 17µM DHPG was compared against the 
effects of subtilisin-mediated LTD.  This was tested by a substitution of subtilisin-
containing aCSF for one that contained DHPG, which was perfused over a 10-minute 
period in a similar manner to subtilisin. 	  	  
5.2 Results 	  
5.2.1 Comparison of the effects of 17µM DHPG against 4µM 
subtilisin 
 
At a concentration of 17µM, DHPG was expected to generate an mGLuR-mediated LTD.  
However, over the course the study, none of the hippocampal slices perfused with DHPG 
produced an LTD, and therefore could not be compared to the LTD generated by subtilisin 
(Figure 5.1a).  Immunoblotting of hippocampal slices was also carried out to determine 
whether DHPG alone could cause protein degradation, but due to the failure of DHPG to 
produce LTD, this hypothesis remained unproven (Figure 5.1b).  Perfusion of DHPG 
alone, without the generation of LTD, did not result in any notable protein degradation. 
 
 
 	  
	   120	  
a b c Subtilisin/	  DHPG	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1a Comparison of DHPG and subtilisin effects on fEPSP size.  
 
Perfusion of DHPG at a concentration of 17µM did not elicit LTD in comparison to the 
perfusion of 4µM subtilisin. Arrows a, b & c indicate time points at which sample fEPSPs 
were taken, as shown below. 
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Comparison of the effects of DHPG and subtilisin on protein degradation
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Figure	  5.1b	  Comparison	  of	  17μM	  DHPG	  and	  4μM	  subtilisin	  perfusions	  on	  
protein	  expression.	  	  Perfusion	  of	  subtilisin	  caused	  a	  significant	  decrease	  in	  protein	  expression	  compared	  with	  controls.	  	  	  In	  comparison,	  slices	  perfused	  with	  DHPG	  exhibited	  protein	  levels	  comparable	  with	  control	  slices.	  A	  significant	  difference	  in	  Unc5H1	  expression	  was	  observed	  between	  slices	  perfused	  with	  subtilisin	  and	  DHPG	  (P	  =	  0.0263,	  *).	  	  In	  addition,	  perfusion	  of	  subtilisin	  caused	  extremely	  significant	  decreases	  in	  expression	  of	  both	  VAMP-­‐1	  (P	  <	  0.0001,	  ***)	  and	  actin	  (P	  =	  0.0001,	  ***)	  in	  comparison	  to	  slices	  treated	  with	  DHPG.	  	  	  
aCSF	  +	  17μM	  DHPG	  Control	   aCSF	  +	  subtilisin	  
*	   ***	   ***	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5.2.2 Comparison of the neuronal effects of EDA and subtilisin 
 
Another compound capable of causing LTD is the GABA mimetic ethylenediamine 
(EDA).  The ability of EDA to generate LTD was accidentally discovered in a study to 
investigate the pharmacological attributes of EDA, and to assess their impact in vivo.  
Perfusion of EDA in the study resulted in the generation of an LTD effect in a portion of 
the hippocampal slices.  The mechanisms involved however are unclear, as no other 
GABA mimetic compounds are known to generate such an effect.  It was suggested that 
the LTD-inducing effects of EDA was a result of modifications to receptors such as 
mGluRs, resulting in an mGluR-dependent LTD effect (Stone et al., 2011).  The aim of the 
following experiment was therefore to provide a comparison between subtilisin, a bacterial 
protease, and the inhibitory compound EDA, in its role as an inducer of LTD.    
Experiments were conducted using 1mM EDA as a replacement for subtilisin during the 
10-minute perfusion period.  Any LTD effects generated by EDA perfusion were then 
compared with those caused by subtilisin.  Perfusion of EDA elicited a much weaker LTD, 
as reflected by a decrease in fEPSP amplitude of around 20%.  In comparison, subtilisin-
mediated LTD typically reduced the amplitude to around 70-80% of the original fEPSP 
size (Figure 5.2a, P > 0.0001).  EDA-LTD did not appear to depend on proteolytic action, 
as none of the proteins measured were significantly degraded in the presence of EDA, in 
sharp contrast to subtilisin-mediated LTD (Figure 5.2b)  
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5.3 Discussion 
 
These experiments were conducted primarily to compare the characteristics of subtilisin-
mediated LTD with LTD mediated through other mechanisms.   In particular, subtilisin-
mediated LTD is characterised by the selective degradation of several proteins, and it 
would be of great interest to determine whether this also occurs in other types of LTD.   
Comparison of the effects of subtilisin with DHPG, an mGLuR agonist was not successful, 
as DHPG did not generate an LTD effect.  There is a possibility that the failure of DHPG 
to elicit LTD was a result of the concentration of DHPG being too low to elicit such an 
effect, as many previous experiments have utilised DHPG at a concentration of 20µM or 
higher (Rush et al., 2002).  A test concentration of 100µM DHPG was also applied to a 
small number of slices, however, this was also ineffective in generating LTD.  The failure 
of DHPG to elicit LTD at this concentration suggests that the protocol used in these 
experiments may have been at fault, and a longer period of DHPG perfusion may be 
necessary to elicit an LTD effect.  A second attempt at comparing the effects of LTD 
utilising MGluR-mechanisms was made using the GABA mimetic compound EDA.  
Previous experiments have indicated that perfusion of EDA is capable of generating LTD 
(Stone et al., 2011), and this was proven during the experiment, where EDA almost always 
caused LTD induction.  Furthermore, the generation of LTD by EDA was not accompanied 
by protein degradation, indicating that protein degradation was likely restricted to LTD 
generated by subtilisin alone.   
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Figure 5.2a Comparison of the effects of EDA and subtilisin perfusion on end fEPSP 
size. 
  
Perfusion of Ethylenediamine (EDA) at a concentration of 1mM produced a LTD effect of 
(82.49 ± 3.53% baseline, N = 4), which was substantially less than the LTD effect caused 
by perfusion of 4µM subtilisin (26.97 ± 1.87% baseline, N = 4, P < 0.0001).  Arrows a, b 
& c indicate time points at which sample fEPSPs were taken, as shown below. 
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Figure 5.2b Comparison of 1mM EDA and 4µM subtilisin perfusions on protein 
expression. 
Perfusion of subtilisin caused a significant decrease in protein expression compared with 
controls.   In comparison, slices perfused with EDA exhibited protein levels comparable 
with control slices.   Significant differences in protein expression were observed between 
slices treated with subtilisin alone and those perfused with EDA, however, when compared 
to controls only those exposed to subtilisin differed significantly (Subtilisin vs. EDA P > 
0.05; N = 4). 
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Chapter 6 - Investigations into the activities of the 
subtilisin-like serine protease, chymotrypsin 
 
 
6.1 Comparison of chymotrypsin and subtilisin potency 
 
6.1.1 Introduction 
 
Most studies on serine protease mediated LTD to date have been performed using 
subtilisin as the inducing agent.  However, past studies have demonstrated other members 
of the S8A group of serine proteases can also elicit LTD, including the serine protease α-
chymotrypsin (MacGregor et al., 2007).  However, the potency of chymotrypsin is several 
magnitudes less than subtilisin, and therefore higher concentrations of chymotrypsin were 
needed to produce the same effect.   The optimal concentration of chymotrypsin for use in 
these experiments was determined through an evaluation of chymotrypsin activity at 
different concentrations.  
 
 
6.1.2 Results 
 
6.1.2.1 Comparison of 4µM chymotrypsin and 4µM subtilisin action 
 
All previous experiments in this study involved the use of subtilisin at a concentration of 
4μM.   Chymotrypsin was therefore perfused at a concentration of 4μM to provide an 
accurate comparison between the activities of these two serine proteases within the current 
experimental protocol.  
Perfusion of chymotrypsin produced a decrease in fEPSP size which was significantly 
lower than those produced by subtilisin (Figure 6.1a, P = 0.0032).   The higher potency of 
subtilisin in comparison to chymotrypsin was also reflected in the assessment of protein 
expression levels.  Hippocampal slices treated with subtilisin expressed significantly lower 
levels of proteins in all markers when compared to slices treated with chymotrypsin. 
(Figure 6.1b, P < 0.05 for all proteins) 	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6.1.2.2 Comparison of the effects of 6µM chymotrypsin and 4µM subtilisin 	  
Chymotrypsin at a concentration of 4µM was less potent than 4µM subtilisin, and as a 
result, a higher concentration of chymotrypsin was required to produce a comparable LTD 
effect.  Chymotrypsin was therefore tested at the higher concentration of 6µM 
chymotrypsin in an attempt to produce a similar LTD size.   
Despite this increase in concentration, there was still a significant difference (P = 0.0073, 
Figure 6.2a) in the end LTD size between slices perfused with chymotrypsin and those 
perfused with subtilisin.  Perfusion of 6µM chymotrypsin was still insufficient to cause the 
same level of LTD as 4µM subtilisin perfusion.  However, the difference in end fEPSP 
between chymotrypsin and subtilisin was much reduced at this concentration.  For the 
experiment comparing 4µM chymotrypsin against 4µM subtilisin, a difference in end 
fEPSP size of 37.68 ± 6.13% was observed.  In the current experiment, the difference in 
end fEPSP size between 6µM chymotrypsin and 4µM subtilisin perfusions was 21.37 ± 
5.97%.  
Analysis of protein degradation in response to either chymotrypsin or subtilisin also 
demonstrated the presence of significant differences in the expression levels of both 
synaptophysin and VAMP-1.  However, expression of both Unc5H1 and actin were similar 
between chymotrypsin and subtilisin (Figure 6.2b). 	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Figure 6.1a Comparison of the fEPSP effects of 4µM Chymotrypsin and 4µM 
subtilisin perfusion. 
 
The reduction in fEPSP after chymotrypsin perfusion (73.38 ± 6.08%, N =4) was 
significantly lower than the rate of fEPSP reduction after subtilisin perfusion (37.05 ± 
4.69%, P = 0.0032).  Arrows a, b & c indicate time points at which sample fEPSPs were 
taken, as shown below. 	  	  	  	  	  	  Subtilisin	  	  	  	  	  	  	  	  	  Chymotrypsin	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Figure 8.1b Comparison of the effects of 4µM chymotrypsin and 4µM subtilisin on 
protein degradation.  
 
Protein degradation after perfusion of 4µM chymotrypsin was significantly lower than after 
subtilisin perfusion.   P < 0.05 for all proteins, N =4) 
N = 4 for both chymotrypsin treatment and subtilisin treatment. 
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Figure 6.2a Comparison of the effects of 6µM Chymotrypsin and 4µM subtilisin on 
fEPSP size. 
 
The reduction in fEPSP after chymotrypsin perfusion (30.11 ± 5.79%, N =4) was 
significantly lower than the rate of fEPSP reduction after subtilisin perfusion (7 ± 0.65%, P 
= 0.0073).  Arrows a, b & c indicate time points at which sample fEPSPs were taken, as 
shown below.	   	  	  	  	  	  Subtilisin	  	  	  	  	  	  	  	  	  	  Chymotrypsin	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Figure 6.2b Comparison of 6µM chymotrypsin and 4µM subtilisin perfusion effects 
on protein degradation.  
 
Perfusion of 4µM chymotrypsin resulted in a significant difference in levels of 
synaptophysin (P = 0.007) and VAMP-1 (P = 0.036) expression.  Expression of Unc5H1 
and actin however did not show any significant variations.  N =4  	  	  	  	  	  
Control	   Chymotrypsin	  +	  aCSF	   Subtilisin	  +	  aCSF	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6.1.3  Discussion 
 
Previous studies have shown that chymotrypsin and subtilisin differ in their relative 
potencies in the generation of LTD (MacGregor et al., 2007), and this was further 
supported by the results obtained over these experiments.   At a concentration of 4µM, 
chymotrypsin generated an LTD of approximately 75% baseline fEPSP, in comparison to 
the LTD generated by subtilisin, which decreased fEPSP to around 35% baseline.   This 
difference was also reflected in the pattern of protein degradation caused by these serine 
proteases, with chymotrypsin perfusion having minimal effect on protein expression, even 
in proteins normally most susceptible to subtilisin degradation.  The	  effect	  of	  an	  increased	  chymotrypsin	  concentration	  of	  6μM	  was compared with the 
effects of 4µM subtilisin.  The LTD effect generated by chymotrypsin was still weaker 
than subtilisin, with chymotrypsin producing a decrease of around 30%, and subtilisin 
decreasing fEPSP size to around 7.5% baseline.  At this concentration, chymotrypsin was 
still unable to cause major changes to protein expression, in contrast to subtilisin 
perfusions, which produced a significant decrease in the expression of all protein markers.   
Despite the difference in potency between these two serine proteases, chymotrypsin at a 
concentration of 6µM was able to generate an LTD effect of a similar magnitude to those 
induced by subtilisin.   However, this effect on fEPSP was not accompanied by a similar 
level of protein degradation, leading to the possibility that mechanisms other than protein 
degradation may be responsible for this LTD effect. 
Based on these results, a chymotrypsin concentration of 6µM was selected for use in 
subsequent experiments, as this concentration produced an LTD effect of comparable size 
to 4µM subtilisin.   	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6.2 Investigations into the mechanism of chymotrypsin-
mediated LTD.  	  	  
6.2.1 Introduction 
 
Initial experiments confirmed that chymotrypsin could cause a similar LTD effect as 
subtilisin, which was also accompanied by selective protein degradation.  However, the 
potency of chymotrypsin was far lower than subtilisin, suggesting potential differences in 
their mechanisms.   Chymotrypsin-mediated LTD was therefore evaluated against other 
common types of LTD using inhibitory compounds previously tested on subtilisin.  The 
role of phosphatases was examined using the inhibitors phenylarsine oxide (PAO) and 
sodium orthovanadate, which block the activation of phosphatases essential to electrically-
stimulated LTD.  Both electrically-stimulated and mGluR-dependent LTD requires p38 
MAP kinase activity, and the contribution of this kinase to chymotrypsin-induced LTD 
was investigated using the selective inhibitor SB203580. 	  
6.2.2 Results 
 
6.2.1 Effect of 25µM PAO on the action of 6µM chymotrypsin 	  
For this set of experiments 25µM PAO was added to the aCSF and perfused over the 
hippocampal slices throughout the experimental period, up to 30 minutes of the recovery 
period after chymotrypsin perfusion.  Perfusion of PAO significantly decreased the effects 
of chymotrypsin, causing a LTD effect of 73.81 ± 3.96% of baseline values (N = 3).  In 
comparison, perfusion of chymotrypsin in aCSF alone caused an LTD decrease of 10.41 ± 
2.15% (N =4), which was extremely significant (P < 0.0001, Figure 6.3).  	  
6.2.2 Effect of 1mM sodium orthovanadate on 6µM chymotrypsin 	  
The effect of sodium orthovanadate on the action of chymotrypsin was evaluated by 
dissolving this chemical in the aCSF used for perfusing the hippocampal slices during 
electrophysiological recordings.  Sodium orthovanadate was used at a concentration of 
1mM, and slices were perfused with this modified aCSF for the duration of the experiment, 
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up to 30 minutes into the recovery period, when perfusion was switched back to ordinary 
aCSF.   
Perfusion of sodium orthovanadate did not significantly alter the LTD response in the 
hippocampal slice when compared with chymotrypsin perfusion in aCSF alone.  LTD 
generated by chymotrypsin in the presence of sodium orthovanadate caused a 77.76 ± 
3.47% (N = 4) reduction in fEPSP size; chymotrypsin in normal aCSF caused a fEPSP 
decrease of 71.82 ± 3.23 (N =5).  Therefore the perfusion of sodium orthovanadate did not 
produce a significant change to the chymotrypsin-mediated effects on fEPSP (P = 0.2525, 
Figure 6.4).  	  
6.2.3 Effect of SB203580 on 6µM chymotrypsin 	  
A final experiment was conducted to determine the effects of the p38 MAP kinase inhibitor 
SB203580 on the activity of chymotrypsin.  Over the course of the electrophysiological 
recording period, hippocampal slices were exposed to 5µM SB203580 dissolved in aCSF 
for 50 minutes, before being perfused with normal aCSF for the last 10 minutes of the 
recovery period.  Perfusion of this inhibitor did not produce a significant change to the size 
of the LTD in response to chymotrypsin perfusion (P = 0.2398, Figure 6.5). 	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Figure 6.3a Effect of perfusing 25µM phenylarsine oxide (PAO) on fEPSP response to 
6µM chymotrypsin. 
 
The reduction in fEPSP size in response to chymotrypsin perfusion was more prominent in 
slices perfused with aCSF supplemented with PAO (10.41% ± 2.15%, N = 4) than slices 
perfused with aCSF alone (73.81 ± 3.95%, N =3, P<0.0001).  Arrows a, b & c indicate 
time points at which sample fEPSPs were taken, as shown below.   	  	  	  	  	  aCSF	  	  	  	  	  	  	  	  aCSF	  +	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Figure 6.4 Effect of perfusing 1mM sodium orthovanadate (SO) on fEPSP response to 
6µM chymotrypsin. 
 
The reduction in fEPSP size in response to chymotrypsin perfusion did not differ 
significantly between slices perfused with aCSF alone (71.82 ± 3.23%, N =5) than slices 
perfused with aCSF supplemented with SO (77.76% ± 3.47%, N =4; P = 0.2525).  Arrows 
a, b & c indicate time points at which sample fEPSPs were taken, as shown below. 	  	  	  	  	  aCSF	  	  	  	  	  	  	  aCSF	  +	  sodium	  orthovanadate	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Figure 6.5 Effect of perfusing 5µM SB203580 on fEPSP response to 6µM 
chymotrypsin  
 
The reduction in fEPSP size in response to chymotrypsin perfusion was not significantly 
different in slices perfused with aCSF supplemented with SB203580 (99.01 ± 19.27%, N = 
4) than slices perfused with aCSF alone (65.65 ± 16.81%, N =4, P = 0.2398).  Arrows a, b 
& c indicate time points at which sample fEPSPs were taken, as shown below. 	  	  	  	  aCSF	  	  	  	  	  	  	  	  aCSF	  +	  Sb203580112	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6.3 Discussion 	  	  
Previous experiments on serine protease-mediated LTD was mainly focussed on the action 
of subtilisin.  However, it is known that other members of the S8A serine protease 
subfamily, to which subtilisin belongs, also possess LTD-inducing properties (MacGregor 
et al., 2007).  These other serine proteases vary in their potency and most are less effective 
in generating LTD when compared to subtilisin.  However, at a sufficiently high 
concentration, these other serine proteases can produce an LTD of similar amplitude to 
those generated by subtilisin.  In order to investigate the action of these other serine 
proteases, experiments were conducted on α-chymotrypsin, a serine protease that possesses 
a similar structure as subtilisin.  In addition, its role as an endogenous serine protease can 
also make these experiments more relevant to a physiological context.  Initial experiments 
involved optimising the concentration of chymotrypsin to produce an LTD of a similar size 
to subtilisin by testing the effect of 4µM and 6µM chymotrypsin.  Results suggested that 
chymotrypsin at concentration of 6µM was able to produce an LTD of around 70% 
baseline fEPSP, which was comparable to LTD generated by subtilisin.  This chymotrypsin 
concentration was therefore used for all subsequent experiments to enable a comparison to 
be made with subtilisin action.   
Past studies on subtilisin-mediated LTD have demonstrated that new form of LTD may 
utilise some of the mechanisms involved with electrically-induced or mGLuR-induced 
LTD.   Evaluating of the contribution these mechanisms make in the action of 
chymotrypsin would provide a clearer understanding of processes underlying serine 
protease induced LTD.  The contribution of protein phosphatases involved in electrically-
induced LTD was assessed using the protein phosphatase inhibitors PAO and sodium 
orthovanadate.  The involvement of p38 MAP kinases, which contribute to mGluR-
mediated LTD, was assessed using the inhibitory compound SB203580 which prevents the 
activity of this kinase.  The addition of SB203580 had no effect on chymotrypsin action, 
suggesting that mGLuR activity does not have a major role in this new LTD mechanism.  
In contrast, experiments with sodium orthovanadate and PAO were less conclusive.  The 
size of the chymotrypsin-mediated LTD was reduced in the presence of PAO, but sodium 
orthovanadate had no measurable effect on chymotrypsin activity.  As a consequence of 
these contradictory results, it is unclear if protein phosphatases are a factor in the 
generation of chymotrypsin-dependent LTD.   
Comparison of these results with those attained with subtilisin suggests that chymotrypsin-
mediated LTD is dependent on slightly different mechanisms.   
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Further experiments using different inhibitors may provide a better understanding of 
whether these mechanisms are utilised by chymotrypsin, and help determine the exact 
mechanisms used by this serine protease to generate LTD.   Immunoblotting could also be 
performed on these hippocampal slices to determine whether the protein phosphatase or 
MAP kinase inhibitors could have an impact on chymotrypsin-mediated protein 
degradation.  	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Chapter 7 - General Discussion 
 
 
7.1 Contribution of serine and metalloprotease 
mechanisms to subtilisin-mediated LTD 
 
 
7.1.1 Metalloprotease mechanisms and subtilisin action 
 
The possibility that subtilisin could act via metalloprotease mechanisms was based on the 
observation that subtilisin selectively cleaved the synaptic protein VAMP-1.  The VAMP 
proteins are known to be major targets for botulinum and tetanus toxins, both of which are 
zinc-dependent metalloproteases.   The possibility that subtilisin could utilise these 
mechanisms was explored using three different experimental protocols.  Initial experiments 
were conducted by addition of 50µM zinc to the aCSF perfused throughout the experiment 
in order to enhance the activity of zinc-dependent metalloproteases.  These experiments 
failed to produce any changes to the progression of subtilisin-mediated LTD, and did not 
decrease protein degradation in response to subtilisin perfusion.  Furthermore, the use of 
100µM captopril, a potent inhibitor of zinc metalloproteases, failed to elicit any change to 
the action of subtilisin.  The contribution of other metalloproteases was also examined by 
addition of the general metal chelator 20µM EDTA to aCSF in order to inhibit 
metalloprotease activity.  Experiments were also conducted to compare the action of 
subtilisin directly with tetanus toxin; however, the use of tetanus toxin in the experimental 
protocol did not produce any protein degradation, even on their target protein, VAMP-1.   
These experiments suggest that subtilisin action is not dependent on metalloproteases; 
however, there were also several shortcomings in the protocol which could have influenced 
these results.   The concentration of zinc was in the range of several micromolar, but the 
aCSF itself contains buffer chemicals in molar concentrations.  There is therefore a 
possibility that these buffer chemicals could chelate most exogenous zinc ions added to the 
aCSF, leaving a very small number of ions to interact with the hippocampal slice.  
Similarly, the use of EDTA at a micromolar concentration may not be sufficient to chelate 
zinc ions, as other metal ions are present at molar concentrations.  These concentrations 
would therefore need to be increased to provide a more reliable measurement of the 
contribution of metal ion to subtilisin action.  This could potentially in major changes to 
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aCSF composition, leading the further difficulties in comparisons between slices in normal 
aCSF and altered aCSF.  The experimental protocol used for comparing tetanus toxin and 
subtilisin action in this study was not effective, as the lack of protein degradation by 
tetanus toxin suggests that it was inactive during the administration period. As such, 
another protocol will be necessary to provide a proper comparison between these 
proteases, possibly involving a higher concentration of tetanus toxin, as concentrations of 
up to 100µM are known to cause changes to evoked potentials in hippocampal slices 
(Calabresi et al., 1989). 
 
 
7.1.2 Role of serine protease mechanisms in subtilisin-mediated 
LTD 
 
Subtilisin itself possesses inherent proteolytic capabilities as a serine protease, and the 
contribution of these mechanisms were analysed through the use of the general serine 
protease inhibitor PMSF.  These experiments were conducted in an attempt to separate the 
proteolytic and LTD-inducing effects of subtilisin, and explore the relative importance of 
each proteolytic target of subtilisin.  The use of PMSF would prevent the proteolytic action 
of subtilisin, and could determine whether LTD was closely-related to protein degradation, 
as suggested by previous data.  The results of the current experiments support this view, as 
addition of PMSF was able to prevent both protein degradation, and the generation of 
LTD.  However, these experiments failed to distinguish between each protein, and was 
therefore of limited value.   Further experiments with other serine protease inhibitors may 
be more selective and produce a partial inhibition of subtilisin activity, which would allow 
better quantification of their effects on both neuronal signalling and protein expression.   
 
 
7.2 Importance of VAMP-1, Unc5H3 and actin degradation 
for subtilisin-mediated LTD 
 
 
These three proteins are most susceptible to subtilisin proteolysis, and their degradation 
may have an important part in the progression of subtilisin-mediated LTD.   
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7.2.1 Effect of Unc5H3 and VAMP-1 antibodies on subtilisin action 
 
The importance of either VAMP-1 or Unc5H3 was tested using protein-specific antibodies 
to target these particular proteins.   Preincubation of hippocampal slices with antibodies 
failed to prevent the action of subtilisin, even in the presence of pore-forming chemicals 
such as triton or streptolysin.  This indicates that VAMP-1 and Unc5H3 may not cause 
subtilisin-mediated LTD, but could be an indication of subtilisin activity.  However, other 
explanations for these results are also possible, as there are a number of variables in the 
protocol used for these experiments.  The antibodies used for these experiments were 
optimised for molecular studies, and not for use with in-vitro preparations of hippocampal 
slices.  There is therefore a possibility that the antibodies themselves could not penetrate 
the hippocampal slices sufficiently to produce an effect.  In addition, there was no method 
of visualising or measuring the amount of antibody that had penetrated the hippocampal 
slice, which could potentially be remediated through the use of fluorescent-tagged 
antibodies.   The location of subtilisin action is also unclear, and it is possible that the 
antibodies binding site was sufficiently distant from the cleavage site that they had no 
impact on proteolytic cleavage.   The duration of the preincubation period could also be a 
cause for these negative results, as antibody penetration of cells requires a lengthy period 
of time, and an extended preincubation period may help facilitate an increased number of 
antibody-protein interactions.  However, a balance had to be struck between preincubation 
time, and slice viability, due to the use of acute hippocampal slices which decrease in 
function over time.  A preincubation period several hours long may not provide sufficient 
time for accurate electrophysiological recordings to be made from these slices.   
The aim of these experiments using antibodies against either Unc5H3 or VAMP-1 was to 
determine the relative importance of these proteins to subtilisin-mediated LTD.  Other 
methods should be explored to specifically target these proteins, such as the use of RNAi 
to silence the appropriate genes encoding these proteins.   
 
7.2.2 Impact of the actin stabiliser Jasplakinolide on subtilisin 
action 
 
Addition of jasplakinolide to the aCSF perfused over the hippocampal slice during 
recordings did not have an impact on subtilisin-mediated LTD or protein degradation.  In 
particular, it did not affect the levels of actin within the hippocampal slice, leading to the 
possibility that it did not interact with actin, or at such a low level that it could not have an 
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overall impact on actin.   A higher concentration of jasplakinolide might provide a better 
indication of the role of actin in subtilisin-mediated LTD and provide a measurable change 
to actin polymerisation.  Alternatively, addition of exogenous actin at a sufficiently high 
concentration may compensate for the degradation by subtilisin and give a better 
understanding of the actin dynamics underlying subtilisin action. 
 
 
7.3 Comparison of DHPG and EDA-mediated LTD with 
subtilisin-mediated LTD 
 
 
A comparison was made between subtilisin-mediated LTD and LTD generated by other 
means, in order to establish whether differences existed between these types.  One of the 
major forms of LTD is dependent on the action of mGluRs, which can be elicited by the 
mGluR agonist DHPG (Palmer et al., 1997).  A comparison was made between the effects 
of perfusing subtilisin and DHPG on hippocampal slices, with the aim of providing a direct 
comparison between these two types.  However, perfusion of DHPG did not result in the 
generation of an LTD effect, preventing a comparison using this compound.  A second 
experiment was conducted using ethylenediamine, a GABA mimetic previously known to 
be capable of generating LTD (Stone et al., 2011).  Perfusion of EDA produced an LTD 
effect that was smaller in magnitude than the LTD generated by subtilisin.  Furthermore, it 
was not accompanied by protein degradation, unlike subtilisin-mediated LTD, supporting 
the previous view that this was a new form of LTD closely associated with protein 
degradation.  Additional confirmation of these results will require a repeat of the DHPG 
experiments, as EDA is not well-studied as an inducer of LTD in comparison to DHPG or 
MCPG, which are well-attested as LTD inducers in literature. 
 
 
7.4 Comparison of subtilisin and chymotrypsin-mediated 
LTD 
 
 
Previous studies have shown that serine proteases related to subtilisin, such as α-
chymotrypsin, are also capable of producing LTD effects.  This serine protease is 
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structurally similar to subtilisin, but is less potent in causing LTD.   Initial experiments to 
optimise the use of chymotrypsin supports this view, as 6µM chymotrypsin was required to 
produce a similar LTD effect as 4µM subtilisin.   
Experiments were also conducted to evaluate the contribution of protein phosphatases and 
protein kinases to chymotrypsin action, which were previously tested on subtilisin-
mediated actions (Forrest et al., 2011).  These results suggest that chymotrypsin action 
involve elements of other LTD mechanisms, in a similar manner to subtilisin, which also 
utilises mechanisms from other types of LTD.  An interesting finding from these 
experiments is that chymotrypsin-LTD is less dependent on protein degradation than 
subtilisin.  Chymotrypsin-mediated LTD at 6µM was similar in to those generated by 
subtilisin at 4µM; however, protein degradation at this chymotrypsin concentration 
occurred at a much lower rate.  This suggests that chymotrypsin may be a better model for 
studying the relationship between serine protease-induced LTD and protein degradation. 
 
 
7.5 Issues on the interpretation of western blots 
 
 
Western blotting is a useful tool for measuring the presence of proteins, however, it is also 
semi-quantitative, as the final measurements can be influenced by a number of different 
variables.  For these experiments, calculations were made to load 10-12µg of protein into 
each gel lane, but without the presence of an accurate loading control, this could not be 
definitively verified.   An effective housekeeping protein would increase the reliability of 
the current results, but due to the proteolytic nature of subtilisin action against a wide range 
of proteins, this was not feasible. 
The effectiveness of the protein transfer process may also vary between each blot, as there 
was no protocol in place to measure the amount of proteins being transferred.  The 
Ponceau staining used for these experiments only provided a qualitative measurement of 
the protein transfer, which if successful would allow the next stage of the protocol to be 
performed.  
In experiments carried out over a number of blots, these variables may be even more 
prominent, as the response of each blot to blocking, antibody preincubation and 
chemiluminescence processes will be different.  The strength of each protein band is also 
very subjective, and is dependent on the exposure time of each film, with longer periods 
providing a stronger signal.  If samples are spread over several blots, this may prevent the 
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detection of small changes to protein expression.  An additional issue is that some proteins 
respond too strongly to the ECL solution, causing a high chemiluminescence value that 
causes individual protein bands to merge.  This complicates the quantification process, as 
measurements may no longer reflect the size of a single protein band, but instead 
incorporate signals from neighbouring lanes. 
 
The reliability of the results obtained using immunoblotting could also be improved by the 
use of additional controls.  Protein levels in experiments involving the addition of 
chemicals to aCSF, such as EDTA, or antibody preincubations agents were not measured 
in the absence of subtilisin. Therefore the current results may be influenced by the 
treatments themselves, and not accurately reflect the impact of subtilisin on these slices.   
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Chapter 8 - Summary 
 
8.1 Main Findings 
   
1) The action of subtilisin was unaffected by either the addition of zinc, which potentiates 
the action of zinc-dependent metalloproteases, or the addition of the zinc-specific chelator 
captopril.  These results indicate that although subtilisin and the zinc metalloprotease share 
the same proteolytic target in VAMP-1, their mechanism of action is likely different. 
 
2)  Addition of EDTA to the perfusion medium did not attenuate the action of subtilisin.  
This result suggests that not only is subtilisin not associated with zinc metalloproteases, 
other metalloproteases do not participate in the mechanisms utilised by subtilisin. 
 3)	  Inhibition	  of	  the	  serine	  protease	  action	  of	  subtilisin	  via	  PMSF	  also	  abolished	  the	  LTD-­‐inducing	  action	  of	  subtilisin.	  	  This	  suggests	  that	  these	  two	  properties	  of	  subtilisin	  may	  be	  linked	  in	  some	  way.	  	  4)	  	  VAMP-­‐1	  and	  Unc5H3	  antibodies	  were	  intended	  to	  selectively	  block	  subtilisin	  action	  on	  their	  respective	  proteins.	  This	  did	  not	  occur	  and	  the	  presence	  of	  antibody	  alone	  did	  not	  make	  an	  impact	  on	  the	  action	  of	  subtilisin.	  	  5)	  	  Jasplakinolide	  was	  unable	  to	  prevent	  actin	  degradation	  by	  subtilisin,	  although	  this	  may	  have	  been	  due	  to	  a	  general	  failure	  of	  action,	  as	  there	  was	  no	  sign	  of	  actin	  polymerisation	  in	  the	  slices	  treated	  with	  this	  actin	  stabiliser.	  	  6)	  Comparing	  LTD	  between	  the	  mGLuR	  agonist	  and	  subtilisin	  was	  not	  possible	  as	  DHPG	  did	  not	  elicit	  an	  LTD	  in	  all	  slices	  tested.	  	  However,	  subtilisin-­‐mediated	  LTD	  was	  compared	  to	  the	  LTD	  generated	  by	  a	  GABA-­‐mimetic	  compound,	  ethylenediamine.	  	  The	  LTD	  generated	  by	  subtilisin	  was	  significantly	  bigger	  in	  magnitude	  than	  the	  one	  generated	  by	  EDA;	  furthermore,	  EDA-­‐mediated	  LTD	  did	  not	  demonstrate	  any	  significant	  proteolytic	  activities	  against	  the	  proteins	  analysed,	  further	  supporting	  the	  view	  that	  subtilisin-­‐mediated	  LTD	  represents	  a	  novel	  form	  of	  LTD.	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7) Comparing the effects of subtilisin and α-chymotrypsin, subtilisin appeared to be more 
potent, requiring only a concentration of 4µM to cause a decrease in fEPSP size of 
around 70-80%.  Similar values were only attained by α-chymotrypsin at a 
concentration of 6µM. 
 
8) Subtilisin and chymotrypsin appear to share a similar mechanism of action, which is not 
dependent on the mechanisms used to generate electrical LTD or mGluR-dependent 
LTD.  However, whilst subtilisin was completely unaffected by the activity of both 
sodium orthovanadate and PAO, LTD induced by α-chymotrypsin was significantly 
reduced by the presence of PAO in the perfusion medium. 
 
 
8.2 Future work 
 
Due to the failure of several of these experiments to work as intended, some, such as the 
experiments conducted with VAMP-1 and Unc5H3 antibodies may be worth revisiting, but 
using antibodies raised specifically for the task.  In addition, the effect of subtilisin on actin 
has not yet been elucidated despite the attempts made during this investigation.  As actin is 
such a crucial protein to the normal function of cells and neurons, it would be advisable to 
repeat these experiments, but with optimised concentrations of jasplakinolide.  The 
research presented here is only an overview of some of the molecular elements of subtilisin 
action, and indeed effects of serine proteases on the aspects of neuronal signalling.  The 
similarity in action between subtilisin and chymotrypsin also lends itself to the possibility 
that other unknown serine proteases may also possess these same attributes.   The ability of 
α-chymotrypsin to induce LTD is of great interest, as unlike subtilisin, a bacterial protease, 
α-chymotrypsin is an endogenous serine protease, which could be a more attractive option 
considering their natural presence in the body.  The finding that the effects of subtilisin 
could be duplicated with chymotrypsin, albeit at a slightly higher concentration, also make 
this an attractive model for supporting evidence gathered from experiments on subtilisin, 
and may even represent a good replacement for subtilisin.  In light of the results obtained 
both in this investigation and in previous studies, it may be worth examining other 
endogenous serine proteases such as neuropsin to determine whether they have the 
potential to cause the same LTD effects or disruption to memory as subtilisin. Subtilisin 
alone is also known to impair the consolidation of memory formation in mice, when 
injected into their dorsal hippocampi.  Other behavioural tests would help to expand on the 
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current knowledge of subtilisin’s physiological roles.  Finally, serine proteases have a role 
in a number of neurological disorders such as Parkinson’s disease and dementia, and 
subtilisin, or its associated proteases such as α-chymotrypsin, may become important 
models for studying these diseases. 
 
 
8.3 Conclusions 
 
The initial discovery of serine protease-mediated LTD stemmed from a study which 
discovered a new serine protease, cadeprin, which belonged to the S8A group of small 
serine proteases.  As part of an evaluation into its activities, cadeprin was found to cause a 
novel form of LTD, which was associated with degradation of proteins, a characteristic not 
found in other forms of LTD.   Comparison of cadeprin with other members of the S8A 
group and the related S1A group of serine proteases indicated that other serine proteases, 
such as subtilisin and chymotrypsin, could also generate a similar LTD effect (MacGregor 
et al., 2007).  Further studies into this new type of LTD, using subtilisin as a model, 
indicates that subtilisin-mediated LTD is accompanied by a selective degradation of 
proteins, with the most affected being the synaptic protein VAMP-1, the netrin receptor 
Unc5H3 and the cytoskeletal protein actin (Forrest et al.,2011).  Based on these previous 
studies, the current experiments were conducted to determine the relative importance of 
these proteins to the action of subtilisin, and also to learn more about the mechanisms 
underlying this LTD effect.  Results presented in this study indicate that the proteolytic 
action of subtilisin does not utilise metalloprotease mechanisms, but is dependent on its 
inherent serine protease mechanism.  Furthermore, these results confirmed the close 
association of protein degradation with the LTD effect generated by subtilisin, although 
this effect is not dependent on the proteolysis of VAMP-1, Unc5H3 or actin alone.  These 
results also confirm the differences between subtilisin-mediated LTD and LTD induced by 
mGluR mechanisms, although more experiments would be needed to improve the 
reliability of this result.  Comparison of the effects of chymotrypsin and subtilisin also 
indicate that these two serine proteases utilise similar mechanisms for producing LTD, as 
evidenced by the susceptibility of Unc5H3, VAMP-1 and actin to degradation by both 
proteases.  Both the proteolytic and LTD-inducing effects of chymotrypsin were weaker 
than subtilisin, in keeping with previous data on the relative potencies of these two 
proteases (MacGregor et al., 2007).  However, unlike subtilisin, chymotrypsin action was 
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affected by the presence of PAO, suggesting a possible explanation for the differences in 
activity between these two serine proteases. 
Long-term depression is known to have major roles in the acquisition and retention of 
memories, and interference with this process is the cause of several major degenerative 
diseases.  In both Alzheimer’s disease and Parkinson’s disease, pathological progression 
involves an initial loss of short-term memory deficits, followed by more severe symptoms 
such as bradykinesia (for Parkinson’s disease) or speech impairment and the loss of long 
term memory (in Alzheimer’s).   Subtilisin, or serine protease-mediated LTD, have 
previously been shown to affect the consolidation of short-term memories in mice.  Direct 
injection of subtilisin into the mouse hippocampus after a training session, resulted in an 
impairment of their response to foot-shock stimuli (Kornisiuk et al., 2010).  It is therefore 
possible for serine protease-mediated LTD to be used as a model for the early stage 
symptoms of both AD and PD.  In addition, a trypsin-like serine protease neurosin, is 
known to be localised within amyloid plaques of patients suffering from Alzheimer’s 
disease (Ogawa et al., 2000).  This suggests that serine proteases can be an important 
factor in the progression of this disease, and the possibility that subtilisin or related serine 
proteases such as chymotrypsin may become useful tools for investigating these disorders. 
The results obtained in this study have helped to provide a more detailed view of the LTD 
mediated through subtilisin, as they have indicated that the actions of this serine protease is 
unlikely to occur via metalloprotease mechanisms.  These experiments also prove that 
other serine proteases such as chymotrypsin are capable of generating LTD with similar 
characteristics, opening the possibility that endogenous serine proteases with important 
roles in physiology and pathological conditions may also display this synaptic effect.  
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